,Start Date,Start Price,End Date,End Price,Weekly Returns,Bin Label,News,Basics
0,2024-11-03,100.20526885986328,2024-11-10,101.2281723022461,0.01020808041354937,U2,"[{""date"": ""20241104043500"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Merck & Co. Inc. stock outperforms competitors despite losses on the day""}, {""date"": ""20241104102250"", ""headline"": ""Stocks to watch if Kamala Harris wins the US election"", ""summary"": ""What could a Kamala Harris victory mean for sectors and stocks?""}, {""date"": ""20241104120000"", ""headline"": ""Investing Groups Digest: Mag 7 In The Market Spotlight"", ""summary"": ""Seeking Alpha's Investing Group leaders presented their earnings assessments from Mag 7 tech giants. Click here to read what investors need to know.""}, {""date"": ""20241104234140"", ""headline"": ""Is Merck & Co., Inc. (MRK) the Best Pharma Stock to Buy Right Now?"", ""summary"": ""We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other pharma stocks. Healthcare takes the concept of \u2018defensive\u2019 further than almost any industry, encompassing many companies that provide patient care, [\u2026]""}, {""date"": ""20241105043500"", ""headline"": ""Merck & Co. Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Merck & Co. Inc. stock underperforms Tuesday when compared to competitors""}, {""date"": ""20241105112943"", ""headline"": ""Vir Biotechnology's Refocused Pipeline: Hepatitis And Oncology Could Still Pay Off"", ""summary"": ""VIR's HDV and HBV treatments remain Vir's primary value drivers, with upcoming catalysts in Q4 2024 and 2025. Find out why VIR stock is a Buy.""}, {""date"": ""20241105120020"", ""headline"": ""Merck Insiders Sold US$11m Of Shares Suggesting Hesitancy"", ""summary"": ""In the last year, many Merck & Co., Inc. ( NYSE:MRK ) insiders sold a substantial stake in the company which may have...""}, {""date"": ""20241105234400"", ""headline"": ""Why most healthcare stocks are falling with Trump\u2019s win, with some exceptions"", ""summary"": ""Why most healthcare stocks are falling with Trump\u2019s win, with some exceptions""}, {""date"": ""20241106060319"", ""headline"": ""Post-Election Day Trade List: 10 S&P 500 Stocks At Risk"", ""summary"": ""Current market conditions suggest caution for some top S&P 500 stocks. Market's collective wisdom often reveals insights missed by fundamental analysis. Read more here.""}, {""date"": ""20241106114500"", ""headline"": ""Merck to Participate in the UBS Global Healthcare Conference"", ""summary"": ""RAHWAY, N.J., November 06, 2024--Merck to Participate in the UBS Global Healthcare Conference""}, {""date"": ""20241106144555"", ""headline"": ""QLV: Better Low-Volume ETF Than Quality ETF"", ""summary"": ""FlexShares US Quality Low Volatility Index Fund ETF reduces volatility but lags in returns. See why QLV ETF beats competitors but trails quality-focused ETFs.""}, {""date"": ""20241106163500"", ""headline"": ""Merck & Co. Inc. stock underperforms Wednesday when compared to competitors"", ""summary"": ""Merck & Co. Inc. stock underperforms Wednesday when compared to competitors""}, {""date"": ""20241106165300"", ""headline"": ""With Trump\u2019s Victory, Robert F. Kennedy Jr. Brings Major Uncertainties to Healthcare System"", ""summary"": ""With Trump\u2019s Victory, Robert F. Kennedy Jr. Brings Major Uncertainties to Healthcare System""}, {""date"": ""20241107085148"", ""headline"": ""Merck: An Undervalued Dividend Machine"", ""summary"": ""Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment appeal. Find out why MRK stock is a Buy.""}, {""date"": ""20241107130149"", ""headline"": ""Geron: A Post Earnings And Funding Announcement Assessment"", ""summary"": ""Geron Corporation's Rytelo gains FDA approval for MDS treatment, with promising sales and positive analyst outlook. Click here for this update of GERN stock prospects.""}, {""date"": ""20241107153644"", ""headline"": ""Merck & Co., Inc. (MRK) Makes It On UBS\u2019 List Of Stocks For The AI, Growth & Low Rates Era"", ""summary"": ""We recently made a list of UBS\u2019 Best Stocks In The AI, Growth & Low Rates Era: Top 29 US Stocks. In this piece, we will take a look at where Merck & Co., Inc. (NYSE:MRK) ranks on the list of the top UBS AI and growth era. The stock market at the tail end [\u2026]""}, {""date"": ""20241107163500"", ""headline"": ""Merck & Co. Inc. stock rises Thursday, still underperforms market"", ""summary"": ""Merck & Co. Inc. stock rises Thursday, still underperforms market""}, {""date"": ""20241108140017"", ""headline"": ""Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock"", ""summary"": ""Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.""}, {""date"": ""20241108153313"", ""headline"": ""Merck Says Winrevair Recommended for Reimbursement in Canada"", ""summary"": ""By Stephen Nakrosis Merck & Co. said Friday that Canada's Drug Agency recommended the company's Winrevair for reimbursement as a treatment for adults with pulmonary arterial hypertension. The...""}, {""date"": ""20241108154227"", ""headline"": ""Stocks to watch next week: Burberry, SSE, Disney, Alibaba and AstraZeneca"", ""summary"": ""Earnings preview of key companies reporting next week and what to look out for.""}, {""date"": ""20241108162323"", ""headline"": ""Why WEC Energy, Merck And Regions Financial Are Winners For Passive Income"", ""summary"": ""Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors. WEC Energy, Merck and Regions Financial have rewarded shareholders for decades and recently announced dividend increases. ...""}, {""date"": ""20241108194700"", ""headline"": ""Canada's Drug Agency Recommends WINREVAIR\u00ae (sotatercept) for Reimbursement"", ""summary"": ""Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that Canada's Drug Agency (CDA) has recommended WINREVAIR\u00ae (sotatercept) for reimbursement in combination with standard pulmonary arterial hypertension (PAH) therapy, for the treatment of adults with World Health Organization [WHO] Group 1 PAH and Functional Class (FC) II or III.""}, {""date"": ""20241109090000"", ""headline"": ""5 Relatively Secure And Cheap Dividend Stocks - November 2024: Yields Up To 9%"", ""summary"": ""Discover top dividend-paying stocks offering discounts, with yields ranging from 3.35% to 9%.""}, {""date"": ""20241109154134"", ""headline"": ""Merck & Co., Inc. (MRK): Among the Best Low Volatility Stocks to Invest In Now"", ""summary"": ""We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other low volatility stocks. We will also discuss the latest updates around the market and political situation of the US. [\u2026]""}, {""date"": ""20241110090000"", ""headline"": ""What To Expect From October's 2024 Inflation Report"", ""summary"": ""The upcoming October CPI report is expected to show a modest rise in inflation. Read why investors should monitor news-driven sell-offs in the drug sector.""}]",{}
1,2024-11-10,101.2281723022461,2024-11-17,94.7268295288086,-0.06422463851294136,D5+,"[{""date"": ""20241110090000"", ""headline"": ""What To Expect From October's 2024 Inflation Report"", ""summary"": ""The upcoming October CPI report is expected to show a modest rise in inflation. Read why investors should monitor news-driven sell-offs in the drug sector.""}, {""date"": ""20241111163500"", ""headline"": ""Merck & Co. Inc. stock underperforms Monday when compared to competitors"", ""summary"": ""Merck & Co. Inc. stock underperforms Monday when compared to competitors""}, {""date"": ""20241112080000"", ""headline"": ""Merck to Present New Data From GARDASIL\u00ae9 Studies Reinforcing the Importance of Gender-Neutral HPV Vaccination in Adults Up to Age 45 at the International Papillomavirus Conference (IPVC) 2024"", ""summary"": ""RAHWAY, N.J., November 12, 2024--Merck to Present New Data From GARDASIL\u00ae9 Studies Reinforcing the Importance of Gender-Neutral HPV Vaccination in Adults Up to Age 45 at IPVC 2024.""}, {""date"": ""20241112111631"", ""headline"": ""Merck: new data on HPV vaccine"", ""summary"": ""Merck announces that new clinical and real-world data on its 9-valent human papillomavirus vaccine, 'Gardasil 9', will be presented at the International Papillomavirus Conference 2024 in Edinburgh....""}, {""date"": ""20241112112412"", ""headline"": ""Merck: promising results from Koselugo study"", ""summary"": ""Alexion, AstraZeneca's rare disease company, and Merck announce positive results from the Phase 3 clinical trial of Koselugo in adult patients with neurofibromatosis type 1 with symptomatic...""}, {""date"": ""20241112114500"", ""headline"": ""KOSELUGO\u00ae (selumetinib) Showed Significant and Clinically Meaningful Improvement in Objective Response Rate Versus Placebo in Adults With Neurofibromatosis Type 1 who Have Symptomatic, Inoperable Plexiform Neurofibromas in Global Phase 3 KOMET Trial"", ""summary"": ""RAHWAY, N.J., November 12, 2024--KOSELUGO Showed Significant and Clinically Meaningful Improvement in ORR Versus Placebo in Adults With NF1 who Have Symptomatic, Inoperable PNs""}, {""date"": ""20241112120014"", ""headline"": ""With 79% ownership, Merck & Co., Inc. (NYSE:MRK) boasts of strong institutional backing"", ""summary"": ""Key Insights Given the large stake in the stock by institutions, Merck's stock price might be vulnerable to their...""}, {""date"": ""20241112145213"", ""headline"": ""Merck trial shows Koselugo effective in treating adults"", ""summary"": ""Merck & Co Inc and AstraZeneca PLC - Pharmaceutical companies based in Rahway, New Jersey and Cambridge, England, respectively - Phase 3 Komet trial shows statistically significant and clinically...""}, {""date"": ""20241112152600"", ""headline"": ""Dow's 300-point fall led by losses in shares of Amgen, 3M"", ""summary"": ""Dow's 300-point fall led by losses in shares of Amgen, 3M""}, {""date"": ""20241112163500"", ""headline"": ""Merck & Co. Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Merck & Co. Inc. stock underperforms Tuesday when compared to competitors""}, {""date"": ""20241113025000"", ""headline"": ""Shelton Equity Income Strategy Q3 2024 Commentary"", ""summary"": ""Following a rocky start to the quarter, the market found its footing and rallied to new record highs to finish the quarter strong. Click here to read the full letter. ""}, {""date"": ""20241113083000"", ""headline"": ""Organon: Certainly A Risky Bet, But Looks Increasingly Compelling (Upgrade)"", ""summary"": ""Organon reported solid Q3 2024 results with 4% revenue growth, driven by strong volume growth. Check out why I upgraded OGN stock to buy from hold.""}, {""date"": ""20241113101839"", ""headline"": ""Merck to Present New Data From GARDASIL9 Studies Reinforcing the Importance of Gender-Neutral HPV Vaccination in Adults Up to Age 45 at the International Papillomavirus Conference 2024"", ""summary"": ""RAHWAY - Merck , known as MSD outside of the United States and Canada, today announced that new clinical and real-world data for the company's 9-valent Human Papillomavirus vaccine, GARDASIL 9 ,...""}, {""date"": ""20241113101842"", ""headline"": ""Merck & Co., Inc. - KOSELUGO Showed Significant and Clinically Meaningful Improvement in Objective Response Rate Versus Placebo in Adults with Neurofibromatosis Type 1"", ""summary"": ""RAHWAY - Alexion, AstraZeneca Rare Disease and Merck , known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 KOMET trial, which is the...""}, {""date"": ""20241113102601"", ""headline"": ""MSD and AstraZeneca report positive topline data from Koselugo trial for NF1"", ""summary"": ""Participants were enrolled from 13 countries across Australia, Asia, South America, Europe, and the US.""}, {""date"": ""20241113115620"", ""headline"": ""Merck and AstraZeneca announce results of Koselugo in neurofibromatosis trial"", ""summary"": ""AstraZeneca (AZN) Rare Disease, Alexion and Merck (MRK) announced positive topline results from the Phase 3 KOMET trial, a Phase 3 trial in adults with neurofibromatosis type 1 \u2013 NF1 \u2013 who have symptomatic, inoperable plexiform neurofibromas, or PN. Topline results showed that Koselugo demonstrated a statistically significant and clinically meaningful improvement in objective response rate, the study\u2019s primary endpoint, versus placebo, in these adult patients. Neurofibromatosis type 1 is a rare,""}, {""date"": ""20241113160307"", ""headline"": ""Merck & Co., Inc. (MRK) UBS Global Healthcare Conference (Transcript)"", ""summary"": ""Merck &amp; Co., Inc. (NYSE:MRK) UBS Global Healthcare Conference November 13, 2024 12:30 PM ETCompany ParticipantsJannie Oosthuizen - President of Human...""}, {""date"": ""20241113163500"", ""headline"": ""Merck & Co. Inc. stock underperforms Wednesday when compared to competitors"", ""summary"": ""Merck & Co. Inc. stock underperforms Wednesday when compared to competitors""}, {""date"": ""20241113184055"", ""headline"": ""Tracking Jeremy Grantham's GMO Capital Portfolio - Q3 2024 Update"", ""summary"": ""GMO\u00e2\u0080\u0099s 13F portfolio increased to $31.91B in Q3 2024. Click here to read more about the holdings and trades of GMO Capital Portfolio.""}, {""date"": ""20241114075715"", ""headline"": ""Merck in Cancer Licensing Pact With LaNova Medicines"", ""summary"": ""By Colin Kellaher Merck & Co. has struck a licensing deal with LaNova Medicines that is potentially worth more than $3 billion to the clinical-stage biotechnology company. Merck on Thursday...""}, {""date"": ""20241114091000"", ""headline"": ""Immutep ADRs Climb on Positive Efti Trial Results"", ""summary"": ""Immutep ADRs Climb on Positive Efti Trial Results""}, {""date"": ""20241114091704"", ""headline"": ""Merck: Keytruda's Sales Projections Outweigh Competitive And Patent Risks"", ""summary"": ""Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite recent volatility.""}, {""date"": ""20241114101615"", ""headline"": ""Merck: acquires exclusive license from LaNova Medicines"", ""summary"": ""Merck announces that it has acquired an exclusive license from LaNova Medicines to develop, manufacture and commercialize LM-299, a bispecific antibody from LaNova.This agreement enhances our growing...""}, {""date"": ""20241114103900"", ""headline"": ""Merck, facing threat to Keytruda, buys into new kind of cancer immunotherapy"", ""summary"": ""The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that recently bested Keytruda in a clinical trial.""}, {""date"": ""20241114114500"", ""headline"": ""Merck Enters into Exclusive Global License for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody from LaNova Medicines Ltd."", ""summary"": ""RAHWAY, N.J., November 14, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately held clinical-stage biotechnology company, today announced that Merck has entered into an exclusive global license to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova.""}, {""date"": ""20241114121500"", ""headline"": ""Merck to Participate in the Jefferies London Healthcare Conference"", ""summary"": ""RAHWAY, N.J., November 14, 2024--Merck to Participate in the Jefferies London Healthcare Conference""}, {""date"": ""20241114125500"", ""headline"": ""Fidelity Growth Company Fund Q3 2024 Review"", ""summary"": ""For the third quarter, Fidelity Growth Company Fund's Retail Class shares gained 1.34%, lagging \nthe 3.42% advance of the benchmark. Click here to read more.""}, {""date"": ""20241114163500"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Merck & Co. Inc. stock outperforms competitors despite losses on the day""}, {""date"": ""20241114165456"", ""headline"": ""Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics"", ""summary"": ""Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics""}, {""date"": ""20241114171639"", ""headline"": ""United Therapeutics: One To Believe In Despite Competitive Threats"", ""summary"": ""United Therapeutics' pipeline and Tyvaso DPI drive strong growth. Read why UTHR stock offers substantial upside with promising treatments and cash reserves.""}, {""date"": ""20241114185421"", ""headline"": ""100 November Sustainable Dividend Dogs: 50 'Safer' And 2 Ideal Buys"", ""summary"": ""Calvert Research and Management ranked the 100 most sustainable companies based on over 230 ESG indicators. Read here for our picks.""}, {""date"": ""20241115081014"", ""headline"": ""Merck Gets CHMP Backing of Keytruda in Malignant Pleural Mesothelioma"", ""summary"": ""By Colin Kellaher Merck & Co. said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanded approval of its blockbuster cancer drug Keytruda in certain...""}, {""date"": ""20241115090716"", ""headline"": ""Merck: CHMP gives green light for Keytruda in pleural mesothelioma"", ""summary"": ""Merck announces that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion for the approval of Keytruda , in combination with pemetrexed...""}, {""date"": ""20241115094500"", ""headline"": ""Merck, Amgen share losses lead Dow's 168-point drop"", ""summary"": ""Merck, Amgen share losses lead Dow's 168-point drop""}, {""date"": ""20241115095738"", ""headline"": ""How To Invest $100,000 In Large Cap Stocks: A Tax-Efficient Advisor-Less Strategy"", ""summary"": ""This DIY market index strategy blends large-cap stocks and ETFs, plus tax loss harvesting. Read how you can save on fees and manage your own portfolio.""}, {""date"": ""20241115104600"", ""headline"": ""Amgen, Amazon.com Inc. share losses lead Dow's 288-point drop"", ""summary"": ""Amgen, Amazon.com Inc. share losses lead Dow's 288-point drop""}, {""date"": ""20241115105833"", ""headline"": ""Wolfe Research Initiates Coverage of Merck (MRK) with Peer Perform Recommendation"", ""summary"": """"}, {""date"": ""20241115121500"", ""headline"": ""Merck Receives Positive EU CHMP Opinion for KEYTRUDA\u00ae (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Non-Epithelioid Malignant Pleural Mesothelioma (MPM)"", ""summary"": ""RAHWAY, N.J., November 15, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency\u2019s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of KEYTRUDA\u00ae (pembrolizumab), Merck\u2019s anti-PD-1 therapy, in combination with pemetrexed and platinum chemotherapy, for the first-line treatment of adult patients with unresectable non-epithelioid malignant pleural mesothelioma (MPM).""}, {""date"": ""20241115144351"", ""headline"": ""Analysts think Wall Street's reaction to the RFK Jr. news is 'overdone.' Sort of."", ""summary"": ""President-elect Donald Trump taps Robert F. Kennedy Jr. to lead U.S. Health and Human Services Department (HHS). Vaccine stocks slide on the news.""}, {""date"": ""20241115163500"", ""headline"": ""Merck & Co. Inc. stock underperforms Friday when compared to competitors"", ""summary"": ""Merck & Co. Inc. stock underperforms Friday when compared to competitors""}, {""date"": ""20241115184737"", ""headline"": ""The Strong Earnings Posted By Merck (NYSE:MRK) Are A Good Indication Of The Strength Of The Business"", ""summary"": ""Even though Merck & Co., Inc.'s ( NYSE:MRK ) recent earnings release was robust, the market didn't seem to notice. Our...""}, {""date"": ""20241115193800"", ""headline"": ""Merck Inks $3.3B Licensing Deal With Chinese Biotech for Cancer Therapy"", ""summary"": ""MRK in-licenses a bispecific antibody, based on the same mechanism as SMMT's lead drug, which outperformed its blockbuster drug, Keytruda, in a lung cancer study.""}, {""date"": ""20241115211851"", ""headline"": ""How analysts are reacting to RFK Jr. as Trump's HHS pick"", ""summary"": ""President-elect Donald Trump has selected Robert F. Kennedy Jr. for the position of Secretary of Health & Human Services (HHS). The appointment has drawn significant attention due to Kennedy Jr.'s controversial stance on vaccines, including his designation as one of the \""Disinformation Dozen\"" during the COVID-19 pandemic. Following the announcement, vaccine-related stocks experienced a notable decline. Yahoo Finance Senior Health Reporter Anjalee Khemlani analyzes the implications of this appointment and shares reactions from market analysts regarding its potential impact on the healthcare sector. To watch more expert insights and analysis on the latest market action, check out more Market Domination\u00a0here. This post was written by Angel Smith""}, {""date"": ""20241117114714"", ""headline"": ""Bristol-Myers Squibb: Buy This Bargain Before It's Gone"", ""summary"": ""Discover why Bristol-Myers Squibb's stock price has risen 25% in six months and why it's rated a 'Buy' with a 4% dividend yield.""}]",{}
2,2024-11-17,94.7268295288086,2024-11-24,97.5496597290039,0.029799690480898366,U3,"[{""date"": ""20241117114714"", ""headline"": ""Bristol-Myers Squibb: Buy This Bargain Before It's Gone"", ""summary"": ""Discover why Bristol-Myers Squibb's stock price has risen 25% in six months and why it's rated a 'Buy' with a 4% dividend yield.""}, {""date"": ""20241118022314"", ""headline"": ""Merck Among 10 Companies To Announce Annual Dividend Increases In Second Half Of November"", ""summary"": ""I expect 10 companies to announce their annual increases in the second half of November. Click here for a detailed analysis.""}, {""date"": ""20241118041612"", ""headline"": ""Zoetis: This Beautifully Boring, Slow-Growing Compounder Is A Buy"", ""summary"": ""Zoetis, a leading animal health company, has shown impressive growth with a 17.55% CAGR since its IPO. Read why I rate ZTS stock a Buy now.""}, {""date"": ""20241118070409"", ""headline"": ""Merck Receives Positive EU CHMP Opinion for KEYTRUDA plus Chemotherapy as First-Line Treatment for Adult Patients with Unresectable Non-Epithelioid Malignant Pleural Mesothelioma"", ""summary"": ""RAHWAY - Merck , known as MSD outside of the United States and Canada, today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion...""}, {""date"": ""20241118075358"", ""headline"": ""Why Merck rolled the dice on an \u2018unbelievable\u2019 early-stage brain cancer drug"", ""summary"": ""Merck\u2019s acquisition of Modifi Biosciences bucks common M&A trends in pharma.""}, {""date"": ""20241118144924"", ""headline"": ""Is Merck & Co., Inc. (MRK) the Best Immunotherapy Stock to Buy Now?"", ""summary"": ""We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other immunotherapy stocks. The global immunotherapy drugs market is rapidly expanding, with projections to grow from $240 billion in 2023 to $1.3 [\u2026]""}, {""date"": ""20241118163500"", ""headline"": ""Merck & Co. Inc. stock rises Monday, still underperforms market"", ""summary"": ""Merck & Co. Inc. stock rises Monday, still underperforms market""}, {""date"": ""20241118230002"", ""headline"": ""Jim Cramer Says Merck & Co., Inc. (MRK) Is \u2018Just Way Too Hated\u2019"", ""summary"": ""We recently compiled a list of the Jim Cramer Talked About These 11 Stocks Recently. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other stocks Jim Cramer recently talked about. On Thursday, Jim Cramer, host of Mad Money, discussed the current state of the [\u2026]""}, {""date"": ""20241119075400"", ""headline"": ""Merck says blockbuster cancer drug met main goals in trial of new under-the-skin formulation"", ""summary"": ""Merck says blockbuster cancer drug met main goals in trial of new under-the-skin formulation""}, {""date"": ""20241119083519"", ""headline"": ""Merck: success of a subcutaneous version of Keytruda"", ""summary"": ""On Tuesday, Merck announced the success of a Phase III trial involving subcutaneous administration of its flagship immunotherapy Keytrud, in the treatment of a form of bronchial cancer.The study,...""}, {""date"": ""20241119091500"", ""headline"": ""IXJ: Healthcare Sector\u00a0Dashboard For November"", ""summary"": ""November dashboard shows the healthcare sector is overvalued by 18% relative to 11-yr averages; pharma/biotech and healthcare equipment, the most overpriced.""}, {""date"": ""20241119104900"", ""headline"": ""Merck\u2019s Cancer Shot Works. Its Post-Keytruda Plans Are Shaping Up Again."", ""summary"": ""Merck\u2019s Cancer Shot Works. Its Post-Keytruda Plans Are Shaping Up Again.""}, {""date"": ""20241119112803"", ""headline"": ""Merck: Seriously Undervalued At Peak Pessimism (Rating Upgrade)"", ""summary"": ""Merck's Keytruda sales rose 17.2% YoY to $7.43 billion. Find out why MRK stock's strong fundamentals and high dividend yield support a strong buy upgrade.""}, {""date"": ""20241119114500"", ""headline"": ""Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints"", ""summary"": ""RAHWAY, N.J., November 19, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the pivotal Phase 3 MK-3475A-D77 trial. The trial is evaluating the noninferiority of subcutaneous administration of pembrolizumab, Merck\u2019s anti-PD-1 therapy, available for intravenous use as KEYTRUDA\u00ae, together with berahyaluronidase alfa, a hyaluronidase variant developed and manufactured by Alteogen Inc. (MK-3475A; \""subcutaneous pembrolizumab\""""}, {""date"": ""20241119114700"", ""headline"": ""Under-the-skin Keytruda comparable to infused version in Phase 3 study, Merck says"", ""summary"": ""Merck plans to discuss the data with regulators as it lags rivals Roche and Bristol Myers in bringing forward a subcutaneous form of its cancer drug.""}, {""date"": ""20241119123445"", ""headline"": ""How I Repurposed My Late Father's Trust Account"", ""summary"": ""I restructured my father's Trust for better diversification and risk reduction. See why I reduced Health Care and Consumer stocks and shifted to new sectors.""}, {""date"": ""20241119124709"", ""headline"": ""Merck & Co. Raises Quarterly Dividend by 5.2%"", ""summary"": ""By Colin Kellaher Merck & Co.'s board has raised the drugmaker's quarterly dividend by 5.2%, to 81 cents a share from 77 cents. The new payout, equal to $3.24 a year, represents an annual...""}, {""date"": ""20241119131114"", ""headline"": ""Biotech: 3 Reasons The Recent Selloff Is A Buying Opportunity For XBI (Upgrade)"", ""summary"": ""SPDR\u00c2\u00ae S&P Biotech ETF had its worst week since 2020, but the sector remains undervalued. Read why XBI is a strong buy for patient investors.""}, {""date"": ""20241119133235"", ""headline"": ""Inhibikase: Potential To Improve Current Treatment Options For PAH Patients"", ""summary"": ""News on Inhibikase's promising treatments for PAH and Parkinson's Disease, supported by FDA approval and substantial funding. Click here to read my analysis.""}, {""date"": ""20241119163500"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Merck & Co. Inc. stock outperforms competitors despite losses on the day""}, {""date"": ""20241119172200"", ""headline"": ""Merck Announces First-Quarter 2025 Dividend"", ""summary"": ""RAHWAY, N.J., November 19, 2024--Merck Announces First-Quarter 2025 Dividend""}, {""date"": ""20241119181735"", ""headline"": ""Merck's Multi-Billion Dollar Drug Keytruda's Investigational Under The Skin Injection At Par With Intravenous Formulation In Untreated Lung Cancer Patients"", ""summary"": ""On Tuesday, Merck & Co Inc (NYSE:MRK) revealed topline results from the pivotal Phase 3 MK-3475A-D77 trial evaluating the noninferiority of subcutaneous administration of pembrolizumab together with berahyaluronidase alfa, administered with chemotherapy versus intravenous (IV) Keytruda administered with chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC). Pembrolizumab is available for intravenous use as Keytruda, Berahyaluronidase alfa""}, {""date"": ""20241120090800"", ""headline"": ""XLV: Healthcare Stocks In Critical Condition (Rating Downgrade)"", ""summary"": ""We advise selling healthcare stocks due to political uncertainty and unfavorable market conditions, prioritizing low-risk investments. See more on XLV ETF here.""}, {""date"": ""20241120144506"", ""headline"": ""Merck : Foundation Heightens Focus on Advancing Equity in Cardiac Care Across the U.S. - Merck.com"", ""summary"": ""November 20, 2024 2:37 pm ET RAHWAY, N.J., Nov. 20, 2024 - The Merck Foundation , a private charitable organization funded by Merck , known as MSD outside of the United States and...""}, {""date"": ""20241120152544"", ""headline"": ""Absci Corporation: Struggling To Live Up To Its AI Promise"", ""summary"": ""Absci Corporation has secured key partnerships but lacks advanced assets. Find out why ABSI stock is still a speculative investment despite its AI potential.""}, {""date"": ""20241120153500"", ""headline"": ""UnitedHealth, Amgen share gains lead Dow's 114-point climb"", ""summary"": ""UnitedHealth, Amgen share gains lead Dow's 114-point climb""}, {""date"": ""20241120191451"", ""headline"": ""Merck & Co., Inc. (MRK)\u2019s Blockbuster Drugs: A Key Player in Ken Griffin\u2019s Portfolio"", ""summary"": ""We recently published a list of Ken Griffin Stock Portfolio: 10 Stocks to Buy. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other Ken Griffin\u2019s portfolio stocks to buy. One of Wall Street\u2019s Greatest Ken Griffin, the visionary founder of Citadel Investment Group, launched his [\u2026]""}, {""date"": ""20241120201000"", ""headline"": ""Merck Foundation Announces $17 Million U.S. Initiative To Expand Access to High-Quality Cardiac Care"", ""summary"": ""RAHWAY, NJ / ACCESSWIRE / November 20, 2024 / The Merck Foundation (Foundation) has announced a new initiative to help advance equitable access to high-quality, culturally responsive care for people with heart conditions in underserved U.S. communities-the ...""}, {""date"": ""20241121071257"", ""headline"": ""Keytruda represents almost half of Merck\u2019s sales, and a new formulation could fend off rivals"", ""summary"": ""A subcutaneous version of Merck\u2019s Keytruda was as effective as the infused version in a late-stage study, but the company won\u2019t be the first to market.""}, {""date"": ""20241121090415"", ""headline"": ""Merck: to present its advances in hematology at ASH"", ""summary"": ""Merck announces the presentation of more than 20 abstracts on both approved and investigational drugs at the annual meeting of the American Society of Hematology , to be held December 7-10 in San...""}, {""date"": ""20241121112624"", ""headline"": ""Merck & Co., Inc. (MRK) Jefferies London Healthcare Conference"", ""summary"": ""Merck &amp; Co., Inc. (NYSE:MRK) Jefferies London Healthcare Conference November 21, 2024 6:30 AM ETCorporate ParticipantsJoe Romanelli - President, Human...""}, {""date"": ""20241121114500"", ""headline"": ""Merck Data at the ASH 2024 Annual Meeting Highlights Promising Hematology Pipeline With Diverse Range of Investigational Assets and Novel Modalities"", ""summary"": ""RAHWAY, N.J., November 21, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new data for approved and investigational medicines across multiple hematologic malignancies will be presented at the American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego from Dec. 7-10. Data being shared at the meeting will showcase the company\u2019s continued progress in advancing clinical research for Merck\u2019s expanding and diverse pipeline of in""}, {""date"": ""20241121114800"", ""headline"": ""Franklin Corefolio Allocation Fund Q3 2024 Commentary"", ""summary"": ""Franklin Corefolio Allocation Fund seeks capital appreciation through a diversified, multidisciplined approach. Read more here.""}, {""date"": ""20241121163500"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Merck & Co. Inc. stock outperforms competitors on strong trading day""}, {""date"": ""20241121214900"", ""headline"": ""Top Analyst Reports for Broadcom, Merck & Qualcomm"", ""summary"": ""Today's Research Daily features new research reports on 16 major stocks, including Broadcom Inc. (AVGO), Merck & Co. (MRK) and Qualcomm (QCOM), as well as a micro-cap stock, Natural Health Trends Corp. (NHTC).""}, {""date"": ""20241122073000"", ""headline"": ""Not A Banana: 2 (Special) Dividend Stocks Offering Ultra-Deep Value"", ""summary"": ""Read more on the real value in high-yield dividend stocks that provide consistent returns and build wealth over time, without getting caught up in market hype.""}, {""date"": ""20241122081300"", ""headline"": ""The Zacks Analyst Blog Highlights Broadcom, Merck, Qualcomm and Natural Health"", ""summary"": ""Broadcom, Merck, Qualcomm and Natural Health are included in this Analyst Blog.""}, {""date"": ""20241122084321"", ""headline"": ""Merck: green light for Welireg in China for VHL disease"", ""summary"": ""Merck announces that the National Medical Products Administration in China has approved Welireg for the treatment of adults with von Hippel-Lindau disease presenting with clear cell renal cell...""}, {""date"": ""20241122090019"", ""headline"": ""Merck: Emerson Electric CEO to join board"", ""summary"": ""Merck announced today that Surendralal L. 'Lal' Karsanbhai, Managing Director of Emerson Electric Co. will join its Board of Directors effective January 1, 2025. He will be elected by the company's...""}, {""date"": ""20241122094000"", ""headline"": ""Franklin Mutual Shares Fund Q3 2024 Commentary"", ""summary"": ""US equities, as measured by the Russell 1000 Index, rose in the third quarter of 2024. Read more here.""}, {""date"": ""20241122110348"", ""headline"": ""Exclusive-US FDA finds widely used asthma drug impacts the brain"", ""summary"": ""U.S. government researchers have found that a widely prescribed asthma drug originally sold by Merck & Co may be linked to serious mental health problems for some patients, according to a scientific presentation reviewed by Reuters.  The researchers found that the drug, sold under the brand name Singulair and generically as montelukast, attaches to multiple brain receptors critical to psychiatric functioning.  Singulair was a blockbuster product for Merck after its launch in 1998, offering relief in a pill as an alternative to an inhaler.""}, {""date"": ""20241122110402"", ""headline"": ""Top US Dividend Stocks To Consider In November 2024"", ""summary"": ""As the U.S. stock market continues its upward trajectory, with the S&P 500 extending its winning streak and major indices nearing record highs, investors are increasingly looking for stable income sources amidst this bullish environment. In such times, dividend stocks can provide a reliable stream of income while potentially benefiting from capital appreciation, making them an attractive option for investors seeking to balance growth with stability in their portfolios.""}, {""date"": ""20241122110703"", ""headline"": ""Moderna's Fresh Blow As RFK Heads To HHS - A Tough 2025 May Be In Store"", ""summary"": ""Moderna, Inc.'s stock plummets as challenges mount, including vaccine skepticism, competitive pressures, and the RFK appointment. Click for my MRNA stock update.""}, {""date"": ""20241122111951"", ""headline"": ""Goldman Sachs: Merck & Co., Inc. (MRK) Is A Top Growth Investor Stock"", ""summary"": ""We recently made a list of Goldman Sachs\u2019 Top Growth Investors: 34 Stocks With The Highest Investment For Growth. In this piece, we will look at where Merck & Co., Inc. (NYSE:MRK) ranks on the list. With the 2024 US Presidential Election having come to a close, Wall Street can now focus on the future [\u2026]""}, {""date"": ""20241122113000"", ""headline"": ""Surendralal Karsanbhai Elected to Merck Board of Directors"", ""summary"": ""RAHWAY, N.J., November 22, 2024--Surendralal Karsanbhai Elected to Merck Board of Directors""}, {""date"": ""20241122114500"", ""headline"": ""Merck\u2019s WELIREG\u00ae (belzutifan) Approved in China for the Treatment of Adult Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors"", ""summary"": ""RAHWAY, N.J., November 22, 2024--Merck\u2019s WELIREG Approved in China for the Treatment of Adult Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors""}, {""date"": ""20241122121500"", ""headline"": ""Merck to Participate in the 7th Annual Evercore ISI HealthCONx Conference"", ""summary"": ""RAHWAY, N.J., November 22, 2024--Merck to Participate in the 7th Annual Evercore ISI HealthCONx Conference""}, {""date"": ""20241122140017"", ""headline"": ""Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know"", ""summary"": ""Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.""}, {""date"": ""20241122143205"", ""headline"": ""Merck : Surendralal Karsanbhai Elected to Merck Board of Directors Form 8 K"", ""summary"": ""Surendralal Karsanbhai Elected to Merck Board of Directors RAHWAY, N.J., Nov. 22, 2024 - Merck , known as MSD outside of the United States and Canada, today announced that Surendralal...""}, {""date"": ""20241122151043"", ""headline"": ""AbbVie: Upgrading To 'Strong Buy' After Pullback"", ""summary"": ""AbbVie\u00e2\u0080\u0099s high dividend yield and leadership with Skyrizi and Rinvoq make it a top pick. Learn why ABBV stock is a strong buy for long-term growth.""}, {""date"": ""20241122161803"", ""headline"": ""Merck Recommends Rejection of TRC Capital\u2019s \u201cMini-Tender\u201d Offer"", ""summary"": ""Merck , known as MSD outside the United States and Canada, has been notified that TRC Capital Investment Corporation has commenced an unsolicited \u201cmini-tender\u201d offer, dated November 12, 2024, to...""}, {""date"": ""20241122163500"", ""headline"": ""Merck & Co. Inc. stock underperforms Friday when compared to competitors"", ""summary"": ""Merck & Co. Inc. stock underperforms Friday when compared to competitors""}, {""date"": ""20241122211700"", ""headline"": ""Merck Recommends Rejection of TRC Capital\u2019s \""Mini-Tender\"" Offer"", ""summary"": ""RAHWAY, N.J., November 22, 2024--Merck Recommends Rejection of TRC Capital\u2019s \""Mini-Tender\"" Offer""}, {""date"": ""20241123004924"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of November 24"", ""summary"": ""Stay informed on dividend activity with a weekly summary for Dividend Champions, Contenders, and Challengers, including changes and upcoming dates.""}, {""date"": ""20241123113057"", ""headline"": ""U.S. FDA found asthma drug Singular, montelukast impacts the brain, Reuters says"", ""summary"": ""U.S. government researchers found a widely prescribed asthama drug originally sold by Merck & Co (MRK) may be linked to serious mental health problems, Dan Levine and Sheila Dang of Reuters reports, citing a scientific presentation. The researchers found that the drug, sold under brand name Singulair and generically as montelukast, attaches to multiple brain receptors critical to psychiatric functioning. Published first on TheFly \u2013 the ultimate source for real-time, market-moving breaking financ""}, {""date"": ""20241123151802"", ""headline"": ""Hedge Funds Bet Big On Merck & Co. (MRK): Top Healthcare Stock to Watch"", ""summary"": ""We recently published a list of 8 Most Promising Healthcare Stocks According to Hedge Funds. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other most promising healthcare stocks according to hedge funds. The Healthcare Sector: Growth, Innovation, and the Impact of AI The healthcare [\u2026]""}, {""date"": ""20241124051300"", ""headline"": ""Franklin Income SMA Q3 2024 Commentary"", ""summary"": ""US equities collectively advanced during the third quarter of 2024. The S&P 500 and Dow Jones Industrial Average both reached new highs multiple times in September.""}]",{}
3,2024-11-24,97.5496597290039,2024-12-01,99.9692153930664,0.024803322438890163,U3,"[{""date"": ""20241124051300"", ""headline"": ""Franklin Income SMA Q3 2024 Commentary"", ""summary"": ""US equities collectively advanced during the third quarter of 2024. The S&P 500 and Dow Jones Industrial Average both reached new highs multiple times in September.""}, {""date"": ""20241125080035"", ""headline"": ""Nvidia's Profit Ruled Last Quarter \u2014 Now It's These 8 Stocks' Turn"", ""summary"": ""Nvidia's Profit Ruled Last Quarter \u2014 Now It's These 8 Stocks' Turn""}, {""date"": ""20241125080716"", ""headline"": ""Merck: successful study in arterial hypertension"", ""summary"": ""Merck announced on Monday that a Phase III clinical trial had met its primary endpoint in patients with pulmonary arterial hypertension.The pharmaceutical group explains that the study involved...""}, {""date"": ""20241125092259"", ""headline"": ""Merck & Co., Inc. (MRK): Among the Most Promising Cancer Stocks According to Hedge Funds"", ""summary"": ""We recently compiled a list of the 10 Most Promising Cancer Stocks According to Hedge Funds. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other promising cancer stocks. According to the World Health Organization (WHO), cancer remains one of the leading causes of death [\u2026]""}, {""date"": ""20241125094500"", ""headline"": ""Dow's 482-point rally led by gains for Boeing, Amazon.com Inc. stocks"", ""summary"": ""Dow's 482-point rally led by gains for Boeing, Amazon.com Inc. stocks""}, {""date"": ""20241125114500"", ""headline"": ""Merck Announces Pivotal Phase 3 ZENITH Trial Evaluating WINREVAIR\u2122 (sotatercept-csrk) Met Primary Endpoint at Interim Analysis"", ""summary"": ""RAHWAY, N.J., November 25, 2024--Merck Announces Pivotal Phase 3 ZENITH Trial Evaluating WINREVAIR\u2122 (sotatercept-csrk) Met Primary Endpoint at Interim Analysis""}, {""date"": ""20241125115700"", ""headline"": ""New data could help Merck expand use of cardiovascular drug"", ""summary"": ""Positive results from a study of Winrevair could help the drugmaker achieve sales growth past top-seller Keytruda\u2019s upcoming patent expirations this decade.""}, {""date"": ""20241125122900"", ""headline"": ""Nike, Sherwin-Williams Co. share gains lead Dow's nearly 250-point jump"", ""summary"": ""Nike, Sherwin-Williams Co. share gains lead Dow's nearly 250-point jump""}, {""date"": ""20241125133300"", ""headline"": ""Sherwin-Williams Co., Nike share gains lead Dow's 350-point jump"", ""summary"": ""Sherwin-Williams Co., Nike share gains lead Dow's 350-point jump""}, {""date"": ""20241125163500"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Merck & Co. Inc. stock outperforms competitors on strong trading day""}, {""date"": ""20241125170223"", ""headline"": ""Why Is Merck Stock Trading Higher On Monday?"", ""summary"": ""On Monday, Merck & Co Inc (NYSE:MRK) revealed topline results from the Phase 3 ZENITH study evaluating Winrevair (sotatercept-csrk) in adults with pulmonary arterial hypertension (PAH, WHO Group 1) functional class (FC) III or IV at high risk of mortality. PAH is high blood pressure in pulmonary arteries, which carry oxygen-poor blood from the heart to the lungs. ZENITH met its primary endpoint of time to first morbidity or mortality event (all-cause death, lung transplantation, or PAH worsening""}, {""date"": ""20241126062500"", ""headline"": ""Invesco Equity And Income Fund Q3 2024 Commentary"", ""summary"": ""The fund holds high-grade bonds and convertible securities as a source of income and to help provide a measure of stability in volatile markets.""}, {""date"": ""20241126094500"", ""headline"": ""Amgen, Boeing share losses lead Dow's 200-point fall"", ""summary"": ""Amgen, Boeing share losses lead Dow's 200-point fall""}, {""date"": ""20241126114500"", ""headline"": ""Merck to Participate in the Citi 2024 Global Healthcare Conference"", ""summary"": ""RAHWAY, N.J., November 26, 2024--Merck to Participate in the Citi 2024 Global Healthcare Conference""}, {""date"": ""20241126115034"", ""headline"": ""Merck reports \u2018positive\u2019 results from Phase 3 ZENITH trial evaluating Winrevair"", ""summary"": ""Merck (MRK) announced positive topline results from the Phase 3 ZENITH study evaluating Winrevair in adults with pulmonary arterial hypertension functional class III or IV at high risk of mortality. ZENITH met its primary endpoint of time to first morbidity or mortality event. In the study, Winrevair demonstrated a statistically significant and clinically meaningful reduction in the risk of morbidity or mortality events compared to placebo, both on top of background PAH therapy. Based on the str""}, {""date"": ""20241126123700"", ""headline"": ""Invesco Health Care Fund Q3 2024 Commentary"", ""summary"": ""Invesco Health Care Fund underperformed its benchmark. Despite earlier signs of improving trends, our health care outlook is bearish. Read more here.""}, {""date"": ""20241126141148"", ""headline"": ""Merck & Co. (MRK) Fell As It Faced Some Demand Headwinds In China"", ""summary"": ""Columbia Threadneedle Investments, an investment management company released its \u201cColumbia Dividend Opportunity Fund\u201d third quarter 2024 investor letter. A copy of the letter can be downloaded here. Equity markets rose again in the third quarter, helping most major indices finish near record levels in September. The fund\u2019s investments rose across all sectors except energy, where [\u2026]""}, {""date"": ""20241126210000"", ""headline"": ""A Scientist\u2019s Final Quest Is to Find New Schizophrenia Drugs. Will He Live to See Them?"", ""summary"": ""A Scientist\u2019s Final Quest Is to Find New Schizophrenia Drugs. Will He Live to See Them?""}, {""date"": ""20241127054000"", ""headline"": ""Invesco Dividend Income Fund Q3 2024 Commentary"", ""summary"": ""The Invesco Dividend Income Fund delivered a solid positive return for the quarter but underperformed the Russell 1000 Value Index. Click here to read the full commentary. ""}, {""date"": ""20241127061000"", ""headline"": ""Invesco Main Street Fund Q3 2024 Commentary"", ""summary"": ""Underperformance mainly resulted from stock selection in the consumer discretionary, financials and industrials sectors.""}, {""date"": ""20241127061647"", ""headline"": ""High-Quality Dividend Growth Stocks Near 52-Week Lows: Pfizer Is Fun"", ""summary"": ""Pfizer's high initial dividend yield, solid ratings, and promising pipeline make it a potentially undervalued investment. See why PFE stock is a Buy.""}, {""date"": ""20241128085500"", ""headline"": ""Janus Henderson Global Life Sciences Fund Q3 2024 Commentary"", ""summary"": ""Janus Henderson Global Life Sciences Fund returned 5.39% and the MSCI World Health Care IndexSM returned 5.70%. Read more here.""}, {""date"": ""20241129005000"", ""headline"": ""Janus Henderson Global Life Sciences Diversified ADR Managed Account Q3 2024 Commentary"", ""summary"": ""The Janus Henderson Global Life Sciences Diversified ADR Managed Account\u00c2\u00a0Portfolio returned 5.74% (gross) for Q3 2024. Click here to read the full commentary.""}, {""date"": ""20241129163500"", ""headline"": ""Merck & Co. Inc. stock underperforms Friday when compared to competitors"", ""summary"": ""Merck & Co. Inc. stock underperforms Friday when compared to competitors""}, {""date"": ""20241129222000"", ""headline"": ""The London Company Income Equity Q3 2024 Portfolio Commentary"", ""summary"": ""The London Company Income Equity portfolio gained 10.5% (10.4% net) during the quarter vs. a 9.4% increase in the Russell 1000 Value Index.""}, {""date"": ""20241130100000"", ""headline"": ""Salesforce, Marvell Technology, And Kroger Report As Earnings Season Slowing To A Crawl"", ""summary"": ""Stay informed on key events in the market with Seeking Alpha's Wall Street Week Ahead newsletter.""}, {""date"": ""20241201050026"", ""headline"": ""Instil Bio's Strategic Shift To SYN-2510: A Speculative 'Buy' Opportunity"", ""summary"": ""Instil Bio is a clinical-stage biotech focusing on personalized immunotherapy. Check out my recommendation for TIL stock.""}, {""date"": ""20241201090000"", ""headline"": ""BeiGene: Nearing Profitability On TEVIMBRA Approval In The EU And US"", ""summary"": ""BeiGene's TEVIMBRA was just approved by the European Commission. Find out what makes BGNE a compelling aggressive growth stock with substantial upside potential.""}, {""date"": ""20241201211235"", ""headline"": ""Mastercard, Broadcom, Pfizer Among Two Dozen Companies To Announce Dividend Increases In December"", ""summary"": ""It\u00e2\u0080\u0099ll be a busy December for dividend growth investors, with 25 companies announcing their annual increases. Check out the companies with dividend increases.""}]",{}
4,2024-12-01,99.9692153930664,2024-12-08,101.39537811279297,0.014266018935119806,U2,"[{""date"": ""20241201050026"", ""headline"": ""Instil Bio's Strategic Shift To SYN-2510: A Speculative 'Buy' Opportunity"", ""summary"": ""Instil Bio is a clinical-stage biotech focusing on personalized immunotherapy. Check out my recommendation for TIL stock.""}, {""date"": ""20241201090000"", ""headline"": ""BeiGene: Nearing Profitability On TEVIMBRA Approval In The EU And US"", ""summary"": ""BeiGene's TEVIMBRA was just approved by the European Commission. Find out what makes BGNE a compelling aggressive growth stock with substantial upside potential.""}, {""date"": ""20241201211235"", ""headline"": ""Mastercard, Broadcom, Pfizer Among Two Dozen Companies To Announce Dividend Increases In December"", ""summary"": ""It\u00e2\u0080\u0099ll be a busy December for dividend growth investors, with 25 companies announcing their annual increases. Check out the companies with dividend increases.""}, {""date"": ""20241202034635"", ""headline"": ""Tracking Ray Dalio's Bridgewater Associates 13F Portfolio - Q3 2024 Update"", ""summary"": ""Bridgewater Associates' 13F portfolio decreased to ~$17.66B. Read more to see the portfolio's Q3, 2024 update.""}, {""date"": ""20241202121307"", ""headline"": ""Why Is Merck & Co., Inc. (MRK) Among the Stocks Ray Dalio\u2019s Bridgewater Is Crazy About?"", ""summary"": ""We recently compiled a list of the Billionaire Ray Dalio\u2019s Bridgewater Is Crazy About These 15 Stocks. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other stocks Ray Dalio\u2019s Bridgewater is crazy about. Ray Dalio, a seasoned global macro investor with over 50 years [\u2026]""}, {""date"": ""20241202124300"", ""headline"": ""TCW Relative Value Large Cap Fund Q3 2024 Commentary"", ""summary"": ""TCW Relative Value Large Cap Fund portfolio\u00e2\u0080\u0099s top 10 average-weighted names returned 12.9%, on average, better than the portfolio and benchmark index led by robust gains from IBM.""}, {""date"": ""20241202141007"", ""headline"": ""Summit Therapeutics Stock Set To Soar By Mid-2025 On HARMONi Phase 3 Trial"", ""summary"": """"}, {""date"": ""20241202163500"", ""headline"": ""Merck & Co. Inc. stock underperforms Monday when compared to competitors"", ""summary"": ""Merck & Co. Inc. stock underperforms Monday when compared to competitors""}, {""date"": ""20241203084814"", ""headline"": ""Merck: 'therapeutic breakthrough' for antibody-conjugate"", ""summary"": ""Merck announced on Tuesday that the FDA had granted breakthrough therapy status to its antibody-conjugate project for the treatment of a specific form of bronchial cancer.The pharmaceutical group...""}, {""date"": ""20241203114500"", ""headline"": ""FDA Grants Breakthrough Therapy Designation to Sacituzumab Tirumotecan (sac-TMT) for the Treatment of Certain Patients With Previously Treated Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer With EGFR Mutations"", ""summary"": ""RAHWAY, N.J., December 03, 2024--FDA Grants Breakthrough Therapy Designation to sac-TMT for Certain Patients With Advanced or Metastatic Nonsquamous NSCLC With EGFR Mutations""}, {""date"": ""20241203174108"", ""headline"": ""Merck & Co., Inc. (MRK) 7th Annual Evercore ISI HealthCONx Conference (Transcript)"", ""summary"": ""Merck &amp; Co., Inc. (NYSE:MRK) 7th Annual Evercore ISI HealthCONx Conference December 3, 2024 1:20 PM ETCompany ParticipantsPeter Dannenbaum - SVP,...""}, {""date"": ""20241203201038"", ""headline"": ""Merck Receives FDA Breakthrough Therapy Designation for Investigational Lung Cancer Treatment"", ""summary"": ""Merck is advancing the global development of sac-TMT through multiple ongoing Phase 3 trials.""}, {""date"": ""20241204011307"", ""headline"": ""Cyber Insurance Update: Recent Decisions Addressing Coverage For Cyber Losses"", ""summary"": ""New Jersey Appellate Court Refuses to Apply Exclusion for 'Hostile/Warlike Action' to NotPetya CyberattackThe start of this year saw an anticlimactic resolution of an insurance coverage dispute over...""}, {""date"": ""20241204115012"", ""headline"": ""Merck: FDA grants Breakthrough Therapy designation to sacituzumab tirumotecan"", ""summary"": ""Merck (MRK) announced that the U.S. FDA has granted Breakthrough Therapy designation to sacituzumab tirumotecan for the treatment of patients with advanced or metastatic nonsquamous non-small cell lung cancer with epidermal growth factor receptor mutations whose disease progressed on or after tyrosine kinase inhibitor and platinum-based chemotherapy. Sac-TMT is an investigational trophoblast cell-surface antigen 2-directed antibody drug conjugate being developed in collaboration with Kelun-Biote""}, {""date"": ""20241204142554"", ""headline"": ""HSBC upgrades Merck stock to Buy on 2025 opportunities"", ""summary"": ""Investing.com -- HSBC analysts raised their rating on Merck &Company Inc (NYSE:MRK) shares to Buy from Hold while maintaining a price target of $130.""}, {""date"": ""20241204163500"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Merck & Co. Inc. stock outperforms competitors despite losses on the day""}, {""date"": ""20241204173718"", ""headline"": ""Dow 30 December Dogs Show 28 Pay Dividends And 1 \""Safer\"" Buy"", ""summary"": ""While most of this collection of Dow Industrials is too pricey and reveals only skinny dividends, one of the ten lowest priced Dogs of the Dow is ready to buy. Read on to find out which one.""}, {""date"": ""20241204223000"", ""headline"": ""Columbia Dividend Income Fund Q3 2024 Commentary"", ""summary"": ""Institutional Class shares of Columbia Dividend Income Fund returned 8.12% for the \nquarter ending September 30, 2024. Click here to read the full commentary. ""}, {""date"": ""20241205001500"", ""headline"": ""Columbia Dividend Opportunity Fund Q3 2024 Commentary"", ""summary"": ""Institutional Class shares of Columbia Dividend Opportunity Fund returned 9.51% for the \nthird quarter. Click here to read the full commentary. \n""}, {""date"": ""20241205012000"", ""headline"": ""Columbia Flexible Capital Income Fund Q3 2024 Commentary"", ""summary"": ""Columbia Flexible Capital Income Fund Institutional Class shares returned 8.25% in the \nthird quarter ending September 30, 2024. Click here to read the full commentary. ""}, {""date"": ""20241205082416"", ""headline"": ""Merck: Phase III trial of Covid-19 begins"", ""summary"": ""Merck announced on Thursday the start of a Phase 3 study to assess the efficacy of its Lavegrio tablet in the treatment of Covid-19 in patients at risk of disease progression.The double-blind,...""}, {""date"": ""20241205104511"", ""headline"": ""Merck Earns Top Spot on Newsweek's List of America's Most Responsible Companies 2025"", ""summary"": ""RAHWAY, N.J. /3BL/ - Merck , known as MSD outside of the United States and Canada, has ranked No. 1 on Newsweek's annual list of America's Most Responsible Companies for the second year in a row.We...""}, {""date"": ""20241205105906"", ""headline"": ""Merck & Co. Inc. (MRK) Citi's 2024 Global Healthcare Conference (Transcript)"", ""summary"": ""Merck &amp; Co. Inc.""}, {""date"": ""20241205114500"", ""headline"": ""Merck and Ridgeback Biotherapeutics Announce Initiation of Phase 3 Study (MOVe-NOW) Evaluating LAGEVRIO\u2122 (molnupiravir) for the Treatment of COVID-19 in High-Risk Adults"", ""summary"": ""RAHWAY, N.J. & MIAMI, December 05, 2024--Merck and Ridgeback Biotherapeutics Announce Initiation of Phase 3 Study Evaluating LAGEVRIO for the Treatment of COVID-19 in High-Risk Adults""}, {""date"": ""20241205115604"", ""headline"": ""Merck : Earns Top Spot on Newsweek\u2019s List of America\u2019s Most Responsible Companies 2025"", ""summary"": ""December 5, 2024 11:53 am ET RAHWAY, N.J., Dec. 5, 2024 - Merck , known as MSD outside of the United States and Canada, has ranked No. 1 on Newsweek's annual list of America's Most...""}, {""date"": ""20241205124828"", ""headline"": ""Here\u2019s What is Powering Merck & Co.\u2019s (MRK) Earnings Growth"", ""summary"": ""GreensKeeper Asset Management, an investment management company, released its third quarter investor letter. A copy of the letter can be downloaded here. The Value Fund appreciated +4.7% (net) in the third quarter, +16.7% year to date and +24.4% over the past twelve months, however, the US dollar lowered returns by about -1.1% in Q3. The [\u2026]""}, {""date"": ""20241205140017"", ""headline"": ""Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It"", ""summary"": ""Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.""}, {""date"": ""20241205163500"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Merck & Co. Inc. stock outperforms competitors on strong trading day""}, {""date"": ""20241205183452"", ""headline"": ""Merck (NYSE:MRK) Will Pay A Larger Dividend Than Last Year At $0.81"", ""summary"": ""Merck & Co., Inc. ( NYSE:MRK ) will increase its dividend from last year's comparable payment on the 8th of January to...""}, {""date"": ""20241206093500"", ""headline"": ""Columbia Pyrford International Stock Fund Q3 2024 Commentary"", ""summary"": ""Columbia Pyrford International Stock Fund Institutional Class shares returned 11.12% for Q3 2024. Click here to read the full commentary. ""}, {""date"": ""20241206105000"", ""headline"": ""Columbia Select Large Cap Equity Fund Q3 2024 Commentary"", ""summary"": ""Columbia Select Large Cap Equity Fund Institutional Class shares returned 3.08% for Q3 2024. Click here to read the full commentary. ""}, {""date"": ""20241206163500"", ""headline"": ""Merck & Co. Inc. stock underperforms Friday when compared to competitors"", ""summary"": ""Merck & Co. Inc. stock underperforms Friday when compared to competitors""}, {""date"": ""20241206182958"", ""headline"": ""Why Merck & Co. (MRK) Is Among the Best Affordable Stocks to Buy Right Now"", ""summary"": ""We recently published a list of 12 Best Affordable Stocks To Buy Right Now. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other best affordable stocks to buy. Economic and Market Outlook 2025 There has been a growing debate regarding whether the economy of [\u2026]""}, {""date"": ""20241207003735"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of December 8"", ""summary"": ""Stay updated on dividend activity with a weekly summary for Dividend Champions, Contenders, and Challengers, including changes and upcoming dates.""}, {""date"": ""20241207090000"", ""headline"": ""5 Relatively Secure And Cheap Dividend Stocks For December 2024: Yields Up To 9%"", ""summary"": ""Discover 15 dividend-paying stocks to consider for your portfolio, including safe picks with discounts and yields ranging from 3.28% to 9%. Click for the picks.""}, {""date"": ""20241208200000"", ""headline"": ""Merck\u2019s Investigational Zilovertamab Vedotin in Combination With R-CHP Demonstrates Complete Response Rate of 100% at 1.75 mg/kg Dose in Phase 2 Trial of Previously Untreated Patients With Diffuse Large B-Cell Lymphoma"", ""summary"": ""RAHWAY, N.J., December 08, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of data from the Phase 2 waveLINE-007 trial evaluating zilovertamab vedotin, Merck\u2019s investigational antibody drug conjugate (ADC) that targets receptor tyrosine kinase-like orphan receptor 1 (ROR1), in combination with cyclophosphamide, doxorubicin and prednisone plus rituximab (R-CHP) for the treatment of patients with previously untreated diffuse lar""}]",{}
5,2024-12-08,101.39537811279297,2024-12-15,100.32330322265625,-0.010573212606832416,D2,"[{""date"": ""20241208200000"", ""headline"": ""Merck\u2019s Investigational Zilovertamab Vedotin in Combination With R-CHP Demonstrates Complete Response Rate of 100% at 1.75 mg/kg Dose in Phase 2 Trial of Previously Untreated Patients With Diffuse Large B-Cell Lymphoma"", ""summary"": ""RAHWAY, N.J., December 08, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of data from the Phase 2 waveLINE-007 trial evaluating zilovertamab vedotin, Merck\u2019s investigational antibody drug conjugate (ADC) that targets receptor tyrosine kinase-like orphan receptor 1 (ROR1), in combination with cyclophosphamide, doxorubicin and prednisone plus rituximab (R-CHP) for the treatment of patients with previously untreated diffuse lar""}, {""date"": ""20241209061704"", ""headline"": ""Why Merck & Co. (MRK) Is the Best Beginner Stock to Invest in Now?"", ""summary"": ""We recently published a list of 11 Best Beginner Stocks To Invest In Now. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other best beginner stocks to invest in now. The Downsides to Stocks Rallying Higher Stocks in the United States are rallying high, [\u2026]""}, {""date"": ""20241209070416"", ""headline"": ""Merck: encouraging results in diffuse lymphoma"", ""summary"": ""Merck announces the results of a Phase II study evaluating zilovertamab vedotin, an investigational ADC , in combination with R-CHP to treat patients with untreated diffuse large B-cell lymphoma . In...""}, {""date"": ""20241209114500"", ""headline"": ""Merck Announces Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Advanced Epithelial Ovarian Cancer"", ""summary"": ""RAHWAY, N.J., December 09, 2024--Merck Announces Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Advanced Epithelial Ovarian Cancer""}, {""date"": ""20241209122133"", ""headline"": ""Dow Jones Stocks: Apple Rallies To New Highs; Nvidia Sells Off To Key Support Level"", ""summary"": ""Dow Jones Stocks: Apple Rallies To New Highs; Nvidia Sells Off To Key Support Level""}, {""date"": ""20241209155051"", ""headline"": ""Merck Reveals Mixed Data From Keytruda/Lynparza Regime In Ovarian Cancer"", ""summary"": ""On Monday, Merck & Co Inc (NYSE:MRK) announced topline data from the Phase 3 KEYLYNK-001 trial. The trial evaluating Keytruda (pembrolizumab) plus chemotherapy followed by maintenance with Lynparza (olaparib), with or without bevacizumab, as a first-line treatment for BRCA non-mutated advanced epithelial ovarian cancer met its primary endpoint of progression-free survival. Also Read: Merck\u2019s Multi-Billion Dollar Drug Keytruda\u2019s Investigational Under The Skin Injection At Par With Intravenous For""}, {""date"": ""20241209195514"", ""headline"": ""Tracking George Soros's 13F Portfolio - Q3 2024 Update"", ""summary"": ""George Soros' 13F portfolio value rose from $5.57B to $6.92B in Q3 2024, with 177 positions. Learn more about the trades and holdings in Q3.""}, {""date"": ""20241210062600"", ""headline"": ""BNY Mellon Concentrated International ETF Q3 2024 Commentary"", ""summary"": ""The BNY Mellon Concentrated International ETF underperformed the MSCI EAFE Index for the third quarter of 2024. Read more here.""}, {""date"": ""20241210094500"", ""headline"": ""Dow down 150 points on losses for shares of Caterpillar, 3M"", ""summary"": ""Dow down 150 points on losses for shares of Caterpillar, 3M""}, {""date"": ""20241210114200"", ""headline"": ""Moderna Stock Is Struggling. BofA Doesn\u2019t See Things Getting Better."", ""summary"": ""Moderna Stock Is Struggling. BofA Doesn\u2019t See Things Getting Better.""}, {""date"": ""20241210120014"", ""headline"": ""How Much Would It Take To Earn $100 A Month From Merck Stock"", ""summary"": ""Merck & Co. (NYSE:MRK) is a global health care company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It will report its Q4 2024 earnings on Feb. 4, 2025. Wall ...""}, {""date"": ""20241210163500"", ""headline"": ""Merck & Co. Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Merck & Co. Inc. stock underperforms Tuesday when compared to competitors""}, {""date"": ""20241210204300"", ""headline"": ""Top Analyst Reports for Alphabet, Oracle & Merck"", ""summary"": ""Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), Oracle Corporation (ORCL) and Merck & Co., Inc. (MRK), as well as two micro-cap stocks, Canterbury Park Holding Corporation (CPHC) and CompX International Inc. (CIX).""}, {""date"": ""20241211044725"", ""headline"": ""Is Merck & Co., Inc. (MRK) the Best American Dividend Stock to Buy Right Now?"", ""summary"": ""We recently compiled a list of the 8 Best American Dividend Stocks To Buy Right Now. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other American dividend stocks. The US economy expanded by 2.8% in the third quarter of 2024, as reported in the [\u2026]""}, {""date"": ""20241211071500"", ""headline"": ""The Zacks Analyst Blog Alphabet, Oracle, Merck & Co, Canterbury Park and CompX International"", ""summary"": ""Alphabet, Oracle, Merck & Co, Canterbury Park and CompX International are included in this Analyst Blog.""}, {""date"": ""20241211144211"", ""headline"": ""Merck and AstraZeneca unveil long-term Lynparza results"", ""summary"": ""Merck & Co Inc and AstraZeneca PLC - Rahway, New Jersey and Cambridge, England-based pharmaceutical firms - Report positive long-term results from phase three OlympiA trial on the use of Lynparza,...""}, {""date"": ""20241211152200"", ""headline"": ""LYNPARZA\u00ae (olaparib) Demonstrated Clinically Meaningful Prolonged Survival Benefit in Early Breast Cancer in OlympiA Phase 3 Trial"", ""summary"": ""RAHWAY, N.J., December 11, 2024--AstraZeneca and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term results from the OlympiA Phase 3 trial which showed LYNPARZA (olaparib) demonstrated sustained, clinically meaningful improvements in overall survival (OS), invasive disease-free survival (IDFS) and distant disease-free survival (DDFS) for people with germline BRCA-mutated (gBRCAm) HER2-negative high-risk early breast cancer.""}, {""date"": ""20241211163500"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Merck & Co. Inc. stock outperforms competitors despite losses on the day""}, {""date"": ""20241211191018"", ""headline"": ""AstraZeneca-Merck Partnered Lynparza Shows Long-Term Survival With Reduced Death Risk Of 28% In Breast Cancer Patients"", ""summary"": ""AstraZeneca Plc (NASDAQ:AZN) and Merck & Co Inc (NYSE:MRK), on Wednesday, announced long-term results from the OlympiA Phase 3 trial. The trial showed Lynparza (olaparib) demonstrated sustained, clinically meaningful improvements in overall survival (OS), invasive disease-free survival (IDFS), and distant disease-free survival (DDFS) for people with germline BRCA-mutated (gBRCAm) HER2-negative high-risk early breast cancer. Also Read: After Lung Cancer Approval, AstraZeneca\u2019s Imfinzi Goes Under""}, {""date"": ""20241212011605"", ""headline"": ""Bueno And More Bueno"", ""summary"": ""The last time we looked into Bueno v Merck, it was anything but bueno. Taking the position that, if there is a cause of action, there must be jurisdiction, a misguided decision had held that a branded...""}, {""date"": ""20241212073506"", ""headline"": ""2 Ideal Buys From 50 'Safer' Dividends In 100 December Sustainables"", ""summary"": ""Among 78 dividend paying sustainable companies, 8 met the Dogcatcher ideal. Read more to see 2 ideal buys.""}, {""date"": ""20241212110929"", ""headline"": ""AstraZeneca and Merck - LYNPARZA Demonstrated Clinically Meaningful Prolonged Survival Benefit in Early Breast Cancer in OlympiA Phase 3 Trial"", ""summary"": ""RAHWAY - AstraZeneca and Merck , known as MSD outside of the United States and Canada, today announced long-term results from the OlympiA Phase 3 trial which showed LYNPARZA demonstrated sustained,...""}, {""date"": ""20241212112732"", ""headline"": ""Spyre Therapeutics: Different Name, Same Tune"", ""summary"": ""Spyre Therapeutics, Inc. has promising assets in early-stage development, including SPY001, SPY002, and SPY003. Learn more about SYRE stock here.""}, {""date"": ""20241212113546"", ""headline"": ""14 Upcoming Dividend Increases"", ""summary"": ""Discover top dividend growth stocks like PHM and LDOS, outperforming ETF benchmarks.""}, {""date"": ""20241212140023"", ""headline"": ""Possible Bearish Signals With Merck Insiders Disposing Stock"", ""summary"": ""In the last year, many Merck & Co., Inc. ( NYSE:MRK ) insiders sold a substantial stake in the company which may have...""}, {""date"": ""20241212200014"", ""headline"": ""How HP, Merck And Virtus Investment Partners Can Put Cash In Your Pocket"", ""summary"": ""Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors. HP, Merck and Virtus Investment Partners have rewarded shareholders for decades and recently announced dividend increases. ...""}, {""date"": ""20241213074612"", ""headline"": ""Merck & Co. Gets Key European Backing for Welireg in Two Uses"", ""summary"": ""By Colin Kellaher Merck & Co. said a key European regulatory committee has recommended conditional approval of its Welireg oral cancer drug in a pair of indications. Merck on Friday said the...""}, {""date"": ""20241213085612"", ""headline"": ""Merck: receives a positive opinion from the CHMP on Welireg"", ""summary"": ""Merck announces that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion for the conditional approval of Welireg , an oral HIF-2\u03b1...""}, {""date"": ""20241213120500"", ""headline"": ""Merck Receives Positive EU CHMP Opinion for WELIREG\u00ae (belzutifan) as Treatment for Adult Patients With Certain Types of Von Hippel-Lindau Disease-Associated Tumors and for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma"", ""summary"": ""RAHWAY, N.J., December 13, 2024--WELIREG CHMP Opinion for VHL & RCC""}, {""date"": ""20241213163500"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Merck & Co. Inc. stock outperforms competitors on strong trading day""}, {""date"": ""20241213235416"", ""headline"": ""Best Way To Invest $100,000: Build An 8-Stock Portfolio For Growth And Value"", ""summary"": ""Learn how to maximize returns by focusing on high-conviction stocks across diverse sectors and using proven investment strategies.""}, {""date"": ""20241214083000"", ""headline"": ""Berkshire Hathaway: Very Unlikely That Buffett Has An Acquisition In Mind For His Large Cash Hoard"", ""summary"": ""Buffett's $325 billion cash position suggests he is preparing for potential market downturns rather than targeting a specific large investment.""}, {""date"": ""20241215080700"", ""headline"": ""Pioneer International Equity Fund Q3 2024 Performance And Market Commentary"", ""summary"": ""During the quarter, Pioneer International Equity Fund Class Y shares returned 7.56% outperforming the 7.26% return of MSCI EAFE. Read more here.""}]",{}
6,2024-12-15,100.32330322265625,2024-12-22,97.21019744873047,-0.031030734375009472,D4,"[{""date"": ""20241215080700"", ""headline"": ""Pioneer International Equity Fund Q3 2024 Performance And Market Commentary"", ""summary"": ""During the quarter, Pioneer International Equity Fund Class Y shares returned 7.56% outperforming the 7.26% return of MSCI EAFE. Read more here.""}, {""date"": ""20241216003528"", ""headline"": ""Merck Has Become Very Cheap Again"", ""summary"": ""Merck has become inexpensive again and combines a good growth outlook with a nice and growing dividend. Learn why MRK stock is a Buy.""}, {""date"": ""20241216031423"", ""headline"": ""Altimmune 2025: Redefining Obesity And MASH Treatment"", ""summary"": ""Altimmune is redefining success in both obesity and MASH to position Pemvidutide in blue ocean categories. Read why I rate ALT stock a Buy now.""}, {""date"": ""20241216082424"", ""headline"": ""Merck: Keytruda indication expanded in China"", ""summary"": ""Merck announces that its Keytruda treatment has been approved by the Chinese authorities in combination with platinum-based chemotherapy for patients with resectable stage II, IIIA or IIIB non-small...""}, {""date"": ""20241216100800"", ""headline"": ""Dow's 115-point rally highlighted by gains in Honeywell, Nike shares"", ""summary"": ""Dow's 115-point rally highlighted by gains in Honeywell, Nike shares""}, {""date"": ""20241216110313"", ""headline"": ""Merck Receives Positive EU CHMP Opinion for WELIREG as Treatment for Adult Patients with Certain Types of Von Hippel-Lindau Disease-Associated Tumors and for Certain Previously Treated Adult Patients with Advanced Renal Cell Carcinoma"", ""summary"": ""RAHWAY - Merck , known as MSD outside of the United States and Canada, today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion...""}, {""date"": ""20241216114500"", ""headline"": ""Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Approved in China in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy After Surgery as Adjuvant Treatment for Patients With Resectable Stage II, IIIA or IIIB NSCLC"", ""summary"": ""RAHWAY, N.J., December 16, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced KEYTRUDA, Merck\u2019s anti-PD-1 therapy, has been approved by the National Medical Products Administration (NMPA) in China in combination with platinum-containing chemotherapy as neoadjuvant treatment and then continued as monotherapy as adjuvant treatment after surgery for patients with resectable stage II, IIIA, or IIIB non-small cell lung cancer (NSCLC).""}, {""date"": ""20241216163500"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Merck & Co. Inc. stock outperforms competitors despite losses on the day""}, {""date"": ""20241216213000"", ""headline"": ""Merck Provides Update on KeyVibe and KEYFORM Clinical Development Programs Evaluating Investigational Vibostolimab and Favezelimab Fixed-Dose Combinations with Pembrolizumab"", ""summary"": ""RAHWAY, N.J., December 16, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the discontinuation of the clinical development programs for vibostolimab, an anti-TIGIT antibody, and favezelimab, an anti-LAG-3 antibody. Vibostolimab is being evaluated as an investigational fixed-dose combination with pembrolizumab (KEYTRUDA\u00ae) in the KeyVibe program. Favezelimab is being evaluated as an investigational fixed-dose combination with pembrolizumab in the KEYF""}, {""date"": ""20241217030016"", ""headline"": ""Merck: Phase 3 trials abandoned"", ""summary"": ""Merck has announced the discontinuation of clinical development programs for vibostolimab, an anti-TIGIT antibody, and favezelimab, an anti-LAG-3 antibody for lung cancer. Vibostolimab is being...""}, {""date"": ""20241217052437"", ""headline"": ""Merck: Buy Opportunity Backed By Growth"", ""summary"": ""Merck's strong financial performance in oncology and vaccines drove a 9% sales increase earlier in Q1 of 2024. See why I rate MRK stock a strong buy.""}, {""date"": ""20241217072726"", ""headline"": ""Merck Gets FDA Review of Clesrovimab RSV Vaccine Candidate"", ""summary"": ""By Colin Kellaher Merck & Co. on Tuesday said the Food and Drug Administration has accepted its application seeking approval of its proposed clesrovimab vaccine aimed at protecting infants from...""}, {""date"": ""20241217080000"", ""headline"": ""Maternal mortality trends remain dire \u2014 and researchers face an uphill battle to solve them"", ""summary"": ""Rising maternal mortality, particularly among vulnerable populations, stems in part from a lack of research in pregnant women.""}, {""date"": ""20241217081619"", ""headline"": ""Merck: FDA to review clesrovimab in RSV"", ""summary"": ""Merck announced Tuesday that the U.S. Food and Drug Administration has agreed to review its Biologics License Application for clesrovimab for protection against respiratory syncytial virus in...""}, {""date"": ""20241217100127"", ""headline"": ""Merck's KEYTRUDA Approved in China in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy After Surgery as Adjuvant Treatment for Patients With Resectable Stage II, IIIA or IIIB NSCLC"", ""summary"": ""RAHWAY - Merck , known as MSD outside of the United States and Canada, today announced KEYTRUDA, Merck's anti-PD-1 therapy, has been approved by the National Medical Products Administration in China...""}, {""date"": ""20241217114500"", ""headline"": ""Merck Announces FDA Acceptance of Biologics License Application for Clesrovimab, an Investigational Long-Acting Monoclonal Antibody Designed to Protect Infants from RSV Disease During their First RSV Season"", ""summary"": ""RAHWAY, N.J., December 17, 2024--FDA Accepts BLA for Clesrovimab, Merck's Investigational Long-Acting MAb Designed to Protect Infants from RSV During their First RSV Season""}, {""date"": ""20241217121824"", ""headline"": ""Is Merck & Co., Inc. (MRK) the Best Weight Loss Stock to Buy Now According to Hedge Funds?"", ""summary"": ""We recently compiled a list of the 12 Best Weight Loss Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other weight loss stocks. The Revolution in Obesity Treatment: Opportunities and Challenges of GLP-1 Medications Most people have [\u2026]""}, {""date"": ""20241217125800"", ""headline"": ""Merck Gets FDA Review of Clesrovimab RSV Immunization Candidate"", ""summary"": ""Merck Gets FDA Review of Clesrovimab RSV Immunization Candidate""}, {""date"": ""20241217131411"", ""headline"": ""Correction to Merck Gets FDA Review of Clesrovimab Article"", ""summary"": ""Merck's clesrovimab is an immunization aimed at protecting infants from respiratory syncytial virus, or RSV, disease. Merck Gets FDA Review of Clesrovimab RSV Vaccine Candidate, at 7:11 a.m. ET,...""}, {""date"": ""20241217163500"", ""headline"": ""Merck & Co. Inc. stock remains steady Tuesday, still outperforms market"", ""summary"": ""Merck & Co. Inc. stock remains steady Tuesday, still outperforms market""}, {""date"": ""20241217191536"", ""headline"": ""Merck Discontinues Certain Cancer Candidate Trials After Futility Analysis"", ""summary"": ""On Monday, Merck & Co Inc (NYSE:MRK) revealed that it would discontinue the clinical development programs for vibostolimab and favezelimab. Vibostolimab is being evaluated as an investigational fixed-dose combination with Keytruda (pembrolizumab) in the KeyVibe program. Favezelimab is being evaluated as an investigational fixed-dose combination with pembrolizumab in the KEYFORM program. Merck is discontinuing the Phase 3 KeyVibe-003 and KeyVibe-007 trials, which are evaluating the fixed-dose com""}, {""date"": ""20241218074028"", ""headline"": ""Merck, Hansoh Pharma in Obesity Pill License Potentially Worth More Than $2 Billion"", ""summary"": ""By Colin Kellaher Merck & Co. is licensing a potential oral obesity drug from Hansoh Pharma in a deal potentially worth more than $2 billion to the Chinese biopharmaceutical company. Merck on...""}, {""date"": ""20241218080814"", ""headline"": ""Merck: agreement with China's Hansoh Pharma on GLP-1"", ""summary"": ""Merck announced on Wednesday the signature of a worldwide licensing agreement with Hansoh Pharma, with the aim of developing the experimental GLP-1 tablet developed by the Chinese pharmaceutical...""}, {""date"": ""20241218102500"", ""headline"": ""Merck Licenses a Weight-Loss Pill. It\u2019s Bad News for Obesity Biotechs."", ""summary"": ""Merck Licenses a Weight-Loss Pill. It\u2019s Bad News for Obesity Biotechs.""}, {""date"": ""20241218114500"", ""headline"": ""Merck Enters into Exclusive Global License Agreement with Hansoh Pharma for Investigational Oral GLP-1 Receptor Agonist"", ""summary"": ""RAHWAY, N.J., December 18, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Hansoh Pharma, a Chinese biopharmaceutical company, today announced that they have entered into an exclusive global license agreement for HS-10535, an investigational preclinical oral small molecule GLP-1 receptor agonist.""}, {""date"": ""20241218115934"", ""headline"": ""Merck moves into obesity with deal for Hansoh\u2019s GLP-1 pill"", ""summary"": ""News of Merck\u2019s licensing of Hansoh\u2019s preclinical medicine pressured shares in Viking and other obesity drug developers seen as likely buyout targets.""}, {""date"": ""20241218141419"", ""headline"": ""Strong Fundamentals And Weight Loss Entry Make Merck (MRK) A Buy"", ""summary"": ""Merck has partnered with Hansoh, a Chinese biopharmaceutical company, for a global licensing deal to develop an oral GLP-1 receptor agonist for the treatment of conditions related to metabolism and obesity. With this development, the New Jersey-based pharma company has now joined a race that has so far been dominated by the likes of Eli [\u2026]""}, {""date"": ""20241218144900"", ""headline"": ""Merck to End Development of Two Cancer Candidates: Time to Sell?"", ""summary"": ""We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider selling the same.""}, {""date"": ""20241218153126"", ""headline"": ""Viking Plummets After Merck Inks A $2.01 Billion Obesity Deal \u2014 With Someone Else"", ""summary"": ""Merck threw its hat into the obesity race on Wednesday, inking a deal worth up to $2.01 billion with Hansoh Pharma for its weight-loss drug.""}, {""date"": ""20241218153136"", ""headline"": ""Wall Street Lunch: Fed Cuts Rates"", ""summary"": ""GIS reports results; Nvidia's GB200 AI and HPC servers to reach mass production in 2025; Merck partners with Hansoh on GLP-1 receptor agonist for weight loss. Click for more.""}, {""date"": ""20241218163500"", ""headline"": ""Merck & Co. Inc. stock underperforms Wednesday when compared to competitors"", ""summary"": ""Merck & Co. Inc. stock underperforms Wednesday when compared to competitors""}, {""date"": ""20241218165247"", ""headline"": ""Elon Musk, Netflix fined, Merck's GLP-1 deal: Market Minute"", ""summary"": ""Yahoo Finance host Rachelle Akuffo eyes three of this morning's biggest market stories in today's Market Minute. Tesla (TSLA) CEO Elon Musk's net worth hits a record-breaking $500 billion as the EV maker's stock climbed following the 2024 election results. Netflix (NFLX) has been fined $4.8 million by Dutch regulators over the streaming platform's mishandling of consumer data. Merck (MRK) signed a licensing agreement with Chinese biotech company Hansoh Pharma (3692.HK) for its oral GLP-1 weigh-loss drug is valued as high as $2 billion. To watch more expert insights and analysis on the latest market action, check out more Wealth\u00a0here. This post was written by Luke Carberry Mogan.""}, {""date"": ""20241218181239"", ""headline"": ""What's Going On With Viking Therapeutics Stock On Wednesday?"", ""summary"": ""On Wednesday, Merck & Co Inc (NYSE:MRK) and Hansoh Pharma, a Chinese biopharmaceutical company, entered into an exclusive global license agreement for HS-10535, an investigational preclinical oral small molecule GLP-1 receptor agonist. Under the agreement, Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture, and commercialize HS-10535. Hansoh Pharma will receive an upfront payment of $112 million and is eligible to receive up to $1.9 billion in milestone payments""}, {""date"": ""20241219065859"", ""headline"": ""Merck's HIV treatment meets main goal of two late-stage studies"", ""summary"": ""Merck said on Thursday its experimental drug combination to treat some adults with HIV-1 infection met the main goal of two late-stage studies. ...""}, {""date"": ""20241219080000"", ""headline"": ""Merck\u2019s RSV antibody could soon paddle into the rough waters of a crowded market"", ""summary"": ""A new antibody from Merck would join a market teeming with new entries, but plenty of regulatory and financial uncertainty.""}, {""date"": ""20241219082603"", ""headline"": ""PeptiDream: Opulent Dream Now A Reality"", ""summary"": ""PeptiDream's PDPS platform offers a promising investment opportunity due to the new therapeutic class of macrocyclic peptide. Read my analysis of PPTDF stock.""}, {""date"": ""20241219083227"", ""headline"": ""Merck: Healthcare Pharma Giant: 3.2% Yield, 9.3% 5-Year Dividend Growth, Buy Time"", ""summary"": ""Merck & Co., a global pharmaceutical leader, focuses on oncology, immunology, and vaccines. Click here to check out my analysis of MRK stock.""}, {""date"": ""20241219094613"", ""headline"": ""Merck Buys $50 Million of Personalis Stock"", ""summary"": ""By Dean Seal Personalis has received a $50 million equity investment from Merck and extended a deal for Moderna to use its platform and technology. The advanced cancer genomic testing...""}, {""date"": ""20241219100417"", ""headline"": ""Merck: encouraging phase III results in HIV"", ""summary"": ""On Thursday, Merck reported encouraging Phase III results for its experimental once-daily oral drug for HIV-1 patients.The US pharmaceutical giant reports that the combination of doravirine and...""}, {""date"": ""20241219105800"", ""headline"": ""Personalis Shares Surge After Merck's $50 Million Investment"", ""summary"": ""Personalis Shares Surge After Merck's $50 Million Investment""}, {""date"": ""20241219111236"", ""headline"": ""Why Is Merck & Co., Inc. (MRK) Among the Best Dividend Stocks to Invest In?"", ""summary"": ""We recently compiled a list of the 10 Dogs of the Dow Dividend Stocks to Invest in. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other dividend stocks. Dividend-focused investors are often drawn to stocks with high yields, shaping their strategies around acquiring such [\u2026]""}, {""date"": ""20241219114500"", ""headline"": ""Merck Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) for the Treatment of Adults with Virologically Suppressed HIV-1 Infection"", ""summary"": ""RAHWAY, N.J., December 19, 2024--Merck Announces Topline Results from Phase 3 Trials Evaluating Once-Daily, Oral Doravirine/Islatravir for the Treatment of Adults with HIV-1 Infection""}, {""date"": ""20241219115542"", ""headline"": ""Viking Therapeutics: Competition Fears Are Exaggerated"", ""summary"": ""Viking Therapeutics shows promise with weight loss drug VK2735 and potential in NASH treatment, making it a potential takeover target. Read more on VKTX here.""}, {""date"": ""20241219123239"", ""headline"": ""MSD makes obesity play in up to $2bn deal for Hansoh\u2019s GLP-1RA asset"", ""summary"": ""MSD could pursue \u201ccardiometabolic benefits beyond weight reduction\u201d for Hansoh\u2019s weight loss pill.""}, {""date"": ""20241219132400"", ""headline"": ""Merck Enters Obesity Space, Buys Rights to Hansoh's Oral GLP-1 Drug"", ""summary"": ""Merck gets exclusive global rights to develop, manufacture and commercialize GLP-1 receptor agonist, HS-10535, from Hansoh Pharma.""}, {""date"": ""20241219150000"", ""headline"": ""A venture firm breathes new life into an old NGM drug"", ""summary"": ""An startup formed by KdT Ventures intends to test the drug, which was once licensed to Merck and evaluated in multiple metabolic disorders, for an unspecified rare conditon.""}, {""date"": ""20241219163500"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Merck & Co. Inc. stock outperforms competitors on strong trading day""}, {""date"": ""20241219183926"", ""headline"": ""Merck's Investigational Two-Drug Regime For HIV Meets Primary Goal In Two Late-Stage Trials"", ""summary"": ""On Thursday, Merck & Co Inc (NYSE:MRK) revealed topline results from two pivotal Phase 3 trials of a two-drug regimen of doravirine/islatravir (DOR/ISL) in adults with HIV-1 infection. The trials included patients who were virologically suppressed on different antiretroviral therapy regimens, including antiretroviral therapy regimens [baseline antiretroviral therapy (bART) and Bictegravir/\u200bEmtricitabine/\u200bTenofovir Alafenamide (BIC/\u200bFTC/\u200bTAF). DOR/ISL was demonstrated to be non-inferior to bART i""}, {""date"": ""20241220103222"", ""headline"": ""Merck: LM-299 antibody agreement finalized"", ""summary"": ""Merck announced on Friday that it had finalized a worldwide licensing agreement for the takeover of LM-299, a new antibody discovered by China's LaNova Medicines.In a press release, the US...""}, {""date"": ""20241220103452"", ""headline"": ""BMO Capital Downgrades Merck (MRK)"", ""summary"": """"}, {""date"": ""20241220114500"", ""headline"": ""Merck Closes Exclusive Global License Agreement for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody"", ""summary"": ""RAHWAY, N.J., December 20, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the closing of the exclusive global license agreement for LM-299, a novel investigational PD-1/VEGF bispecific antibody, from LaNova Medicines Ltd. As previously announced, Merck will develop, manufacture and commercialize LM-299.""}, {""date"": ""20241220121226"", ""headline"": ""Is Merck & Co. (MRK) a Cheap NYSE Stock to Invest in Now?"", ""summary"": ""We recently published a list of 10 Cheap NYSE Stocks To Invest In Now. In this article, we are going to take a look at where Merck & Co. Inc. (NYSE:MRK) stands against other cheap NYSE stocks to invest in now. The stock market appears poised for another year of impressive returns, likely extending into [\u2026]""}, {""date"": ""20241220140017"", ""headline"": ""Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know"", ""summary"": ""Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.""}, {""date"": ""20241220140028"", ""headline"": ""Investing in Merck (NYSE:MRK) three years ago would have delivered you a 43% gain"", ""summary"": ""It hasn't been the best quarter for Merck & Co., Inc. ( NYSE:MRK ) shareholders, since the share price has fallen 15...""}, {""date"": ""20241220144454"", ""headline"": ""BMO cuts rating on Merck and Biogen, on lack of near term catalyst"", ""summary"": ""Investing.com -- BMO Capital Markets downgraded Merck &Company Inc (NYSE:MRK) to \""market perform\"" from \""outperform,\"" citing concerns over its Gardasil franchise in China and uncertainty around filling the revenue gap as Keytruda faces loss of exclusivity and biosimilar competition.""}, {""date"": ""20241221093000"", ""headline"": ""If I Had To Invest $100,000 In A Dividend Growth Portfolio Right Now, Here's What I Would Buy"", ""summary"": ""The methodology uses earnings yield, dividend yield, and 5-year dividend CAGR to score and rank 55 stocks across all 11 sectors.""}, {""date"": ""20241221115035"", ""headline"": ""Merck closes exclusive global license agreement for LM-299 from LaNova Medicines"", ""summary"": ""Merck (MRK) announced the closing of the exclusive global license agreement for LM-299, a novel investigational PD-1/VEGF bispecific antibody, from LaNova Medicines. As previously announced, Merck will develop, manufacture and commercialize LM-299. Merck will record a pre-tax charge relating to the upfront payment of $588M, or approximately 18c per share, in the company\u2019s fourth quarter 2024 GAAP and non-GAAP results. LaNova is also eligible to receive up to $2.7B in milestone payments associate""}, {""date"": ""20241221123052"", ""headline"": ""Personalis price target raised to $8 from $7 at BTIG"", ""summary"": ""BTIG raised the firm\u2019s price target on Personalis (PSNL) to $8 from $7 and keeps a Buy rating on the shares. The company\u2019s $50M investment from Merck (MRK) strengthens its balance sheet with another strategic partner and represents a major derisking event, the analyst tells investors in a research note. The firm also cites Personalis having extended their contract with Moderna (MRNA), which is now a 10-year contact and has two 5-year renewable options, adding that despite the higher move in the""}]",{}
7,2024-12-22,97.21019744873047,2024-12-29,98.84606170654297,0.01682811372413129,U2,"[{""date"": ""20241223051500"", ""headline"": ""Hartford Healthcare Fund Q3 2024 Commentary"", ""summary"": ""The Hartford Healthcare Fund (I Share) underperformed the S&P Composite 1500 Health Care Index during the quarter. Read more here.""}, {""date"": ""20241223090000"", ""headline"": ""Merck: A Low-Hanging Fruit To Pick"", ""summary"": ""Merck, a leading global pharmaceutical company that produces a range of medicines, vaccines, and animal healthcare products, is now a $258 billion (by market cap) healthcare behemoth.""}, {""date"": ""20241223094600"", ""headline"": ""Hartford Equity Income Fund Q3 2024 Commentary"", ""summary"": ""Hartford Equity Income Fund (I Share) underperformed the Russell 1000 Value Index during the quarter. Read more here.""}, {""date"": ""20241223110413"", ""headline"": ""Discover US Dividend Stocks For December 2024"", ""summary"": ""As the U.S. stock market navigates through a mixed December, with encouraging inflation data providing some relief amidst recent declines, investors are keenly observing opportunities that can offer stability and income. In this context, dividend stocks stand out as attractive options for those seeking consistent returns in a volatile environment, offering potential benefits such as regular income and reduced portfolio volatility.""}, {""date"": ""20241223112646"", ""headline"": ""Merck Closes Exclusive Global License Agreement for LM-299, an Investigational Anti-PD-1/VEGF Bispecific Antibody"", ""summary"": ""RAHWAY - Merck , known as MSD outside of the United States and Canada, today announced the closing of the exclusive global license agreement for LM-299, a novel investigational PD-1/VEGF bispecific...""}, {""date"": ""20241223141700"", ""headline"": ""Wall Street Lunch: Nordstrom To Go Private"", ""summary"": ""Department store chain Nordstrom (JWN) has accepted a $6.25 billion all-cash buyout offer to end its 53-year run as a publicly traded company.""}, {""date"": ""20241223155500"", ""headline"": ""Dow rallies 117 points on gains for NVIDIA Corp., UnitedHealth stocks"", ""summary"": ""Dow rallies 117 points on gains for NVIDIA Corp., UnitedHealth stocks""}, {""date"": ""20241224013000"", ""headline"": ""Why the \u2018Dogs of the Dow\u2019 Stocks Just Might Deliver in 2025"", ""summary"": ""Why the \u2018Dogs of the Dow\u2019 Stocks Just Might Deliver in 2025""}, {""date"": ""20241224163500"", ""headline"": ""Merck & Co. Inc. stock rises Tuesday, still underperforms market"", ""summary"": ""Merck & Co. Inc. stock rises Tuesday, still underperforms market""}, {""date"": ""20241224172000"", ""headline"": ""3 biggest catalysts expected for healthcare in 2025"", ""summary"": ""After an eventful year in the pharmaceutical and biotech industries, what lies ahead for the health landscape in 2025? Yahoo Finance senior health reporter Anjalee Khemlani outlines the three biggest catalysts for change and innovation for healthcare in the new year, including GLP-1 weight-loss drugs and proposed regulations on pharmacy benefit managers (PBMs) from the second Trump administration. To watch more expert insights and analysis on the latest market action, check out more Catalysts\u00a0here. This post was written by Luke Carberry Mogan.""}, {""date"": ""20241225061000"", ""headline"": ""Carillon Eagle Growth & Income Fund Q3 2024 Commentary"", ""summary"": ""The S&P 500 Index traded higher by 5.9% during the third quarter, but the bigger story was that the benchmark index closed out the first nine months of 2024 with a whopping 22.1% advance.""}, {""date"": ""20241226093036"", ""headline"": ""PJP: Big Pharma Concentration Risks Amid Looming Confirmation Of RFK Jr."", ""summary"": ""This article discusses the risk and opportunities of six major constituents of PJP ETF: Pfizer, Amgen, Gilead, AbbVie, BMY, and Merck. Read more here.""}, {""date"": ""20241227120016"", ""headline"": ""Will Weakness in Merck & Co., Inc.'s (NYSE:MRK) Stock Prove Temporary Given Strong Fundamentals?"", ""summary"": ""With its stock down 12% over the past three months, it is easy to disregard Merck (NYSE:MRK). But if you pay close...""}, {""date"": ""20241227145132"", ""headline"": ""Merck & Co. Inc. (MRK): Billionaire D.E. Shaw Is Bullish On This Stock Right Now"", ""summary"": ""We recently compiled a list of the 10 Best Stocks to Buy According to Billionaire D.E. Shaw. In this article, we are going to take a look at where Merck & Co. Inc. (NYSE:MRK) stands against the other stocks. Equity market pricing is never perfect due to supply and demand imbalances, emotional reactions, and errors. Billionaire [\u2026]""}, {""date"": ""20241227152129"", ""headline"": ""Duvakitug And Teva's Growth: A Game Changer In Pharma"", ""summary"": ""Teva Pharmaceutical Industries continues to impress investors with strong sales growth and promising development. Click here to find out why TEVA is a Buy.""}]",{}
8,2024-12-29,98.84606170654297,2025-01-05,98.29085540771484,-0.005616878297857064,D1,"[{""date"": ""20241230223205"", ""headline"": ""Is Merck & Co., Inc. (MRK) the Best Pharma Dividend Stock to Buy In 2024?"", ""summary"": ""We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other pharma dividend stocks. The pharmaceutical industry in 2024 faced a relatively quiet year, with deal volumes similar to 2023 [\u2026]""}, {""date"": ""20241231120033"", ""headline"": ""Merck & Co., Inc. (NYSE:MRK) is a favorite amongst institutional investors who own 79%"", ""summary"": ""Key Insights Given the large stake in the stock by institutions, Merck's stock price might be vulnerable to their...""}, {""date"": ""20241231190201"", ""headline"": ""Is Merck & Co., Inc. (MRK) Among the Best Low Volatility Stocks to Buy Right Now?"", ""summary"": ""We recently published a list of 8 Best Low Volatility Stocks To Buy Right Now. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other best low volatility stocks to buy right now. The market has shown strong performance overall, with the S&P 500 up [\u2026]""}, {""date"": ""20250101120300"", ""headline"": ""The 5 worst-performing stocks on the Dow Jones Industrial Average in 2024"", ""summary"": ""The Dow's biggest losers include companies in the aerospace, biopharma, and sports apparel sectors.""}, {""date"": ""20250102052000"", ""headline"": ""Not A Year For The 2024 Dogs Of The Dow"", ""summary"": ""With the close of trading for 2024 occurring on Tuesday, it is time to look at the performance of those Dogs of the Dow. Read more here.""}, {""date"": ""20250102065312"", ""headline"": ""Wall Street Breakfast Podcast: Alibaba Sells Sun Art At $2B Loss"", ""summary"": ""Alibaba to sell stake in China's hypermarket chain Sun Art. Brand prescription drugs to rise an average 4.5% in 2025. Cybertruck blast driver identified; link to New Orleans attacker growing""}, {""date"": ""20250102122143"", ""headline"": ""January Dow Dogs: 1 'Safer' Buy, And 5 With Promise"", ""summary"": ""Get insights on top Dow Dogs like Verizon and Merck, with potential net gains forecasted by analysts. Click for the January picks.""}, {""date"": ""20250102140021"", ""headline"": ""Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It"", ""summary"": ""Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.""}, {""date"": ""20250102161532"", ""headline"": ""UK Approves Merck's Hypertension Drug Acquired Via $11 Billion Acceleron Pharma Deal"", ""summary"": ""Last Friday, the Medicines and Healthcare Products Regulatory Agency approved Merck & Co Inc\u2019s (NYSE:MRK) Winrevair (sotatercept) for adult patients with pulmonary arterial hypertension (PAH). Sotatercept is used, in combination with other medicines, to treat PAH in adults with moderate or marked physical activity limitations and improve exercise capacity. The recommended dosing schedule is one injection every three weeks via self-administration. Also Read: Big Biopharma Trails Behind The Market""}, {""date"": ""20250102163500"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Merck & Co. Inc. stock outperforms competitors despite losses on the day""}, {""date"": ""20250103032916"", ""headline"": ""Moderna: From Breakthrough COVID-19 Vaccines To Personalized Cancer Therapies"", ""summary"": ""Moderna/Merck partnership and its potential in personalised cancer therapies are good opportunities for long-term investors. See why MRNA stock is a Buy.""}, {""date"": ""20250103163500"", ""headline"": ""Merck & Co. Inc. stock underperforms Friday when compared to competitors"", ""summary"": ""Merck & Co. Inc. stock underperforms Friday when compared to competitors""}, {""date"": ""20250103234905"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of January 5"", ""summary"": ""Stay up to date on dividend activity with our weekly summary for Dividend Champions, Contenders, and Challengers, including ex-dividend and pay dates.""}, {""date"": ""20250104080000"", ""headline"": ""5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (January 2025)"", ""summary"": ""Discover top dividend-paying stocks with discounts on historical norms. Filtered from 7,500+ companies.""}, {""date"": ""20250105113108"", ""headline"": ""The Play On Summit Therapeutics"", ""summary"": ""Explore Summit Therapeutics' stock performance and financial health amid ivonescimab concerns, and learn how to strategically trade this biotech company.""}]","{""assetTurnoverTTM"": 0.5665, ""bookValue"": 46313, ""cashRatio"": 0.46593947923997187, ""currentRatio"": 1.3646, ""ebitPerShare"": 1.7056, ""eps"": 1.4754, ""ev"": 275517.16, ""fcfMargin"": 0.1608, ""fcfPerShareTTM"": 7.1593, ""grossMargin"": 0.8076, ""inventoryTurnoverTTM"": 2.2454, ""longtermDebtTotalAsset"": 0.2943, ""longtermDebtTotalCapital"": 0.4131, ""longtermDebtTotalEquity"": 0.7441, ""netDebtToTotalCapital"": 0.2861, ""netDebtToTotalEquity"": 0.5154, ""netMargin"": 0.2396, ""operatingMargin"": 0.2769, ""payoutRatioTTM"": 0.458, ""pb"": 5.4336, ""peTTM"": 14.7017, ""pfcfTTM"": 13.9063, ""pretaxMargin"": 0.2669, ""psTTM"": 3.9217, ""ptbv"": 8.4042, ""quickRatio"": 1.1496, ""receivablesTurnoverTTM"": 6.2217, ""roaTTM"": 0.1511, ""roeTTM"": 0.3918, ""roicTTM"": 0.2126, ""rotcTTM"": 0.2477, ""salesPerShare"": 6.1585, ""sgaToSale"": 0.1924, ""tangibleBookValue"": 29943, ""totalDebtToEquity"": 0.8013, ""totalDebtToTotalAsset"": 0.3169, ""totalDebtToTotalCapital"": 0.4448, ""totalRatio"": 1.6542, ""period"": ""2024-12-31""}"
9,2025-01-05,98.29085540771484,2025-01-12,98.39991760253906,0.0011095863839196696,U1,"[{""date"": ""20250105113108"", ""headline"": ""The Play On Summit Therapeutics"", ""summary"": ""Explore Summit Therapeutics' stock performance and financial health amid ivonescimab concerns, and learn how to strategically trade this biotech company.""}, {""date"": ""20250106071500"", ""headline"": ""2025 Investment Playbook: How I'm Setting Up My 6-Digit Portfolio For Outperformance"", ""summary"": ""With a 31.1% gain, 2024 has proven to be my most successful investing year. Read more to see what I expect from 2025.""}, {""date"": ""20250106074944"", ""headline"": ""China's WuXi Biologics to sell Ireland vaccine facility to Merck for $500 million"", ""summary"": ""China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to Merck for about $500 million. WuXi had previously said it was planning to sell some of its...""}, {""date"": ""20250106114500"", ""headline"": ""Merck to Participate in the 43rd Annual J.P. Morgan Healthcare Conference"", ""summary"": ""RAHWAY, N.J., January 06, 2025--Merck to Participate in the 43rd Annual J.P. Morgan Healthcare Conference""}, {""date"": ""20250106163500"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Merck & Co. Inc. stock outperforms competitors on strong trading day""}, {""date"": ""20250107063600"", ""headline"": ""WuXi Biologics to Sell Irish Vaccine Facility to Merck for $500 Million"", ""summary"": ""WuXi Biologics\u2019 move to sell the facility could strengthen the company\u2019s cash flow and margins as it navigates global uncertainties.""}, {""date"": ""20250107094500"", ""headline"": ""IBM, Walt Disney share gains lead Dow's 167-point jump"", ""summary"": ""IBM, Walt Disney share gains lead Dow's 167-point jump""}, {""date"": ""20250107113119"", ""headline"": ""Top 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5)"", ""summary"": ""Day One Biopharmaceuticals focuses on pediatric cancer treatments. Read more about the biotech's therapies and its prospects for 2025.""}, {""date"": ""20250107163500"", ""headline"": ""Merck & Co. Inc. stock underperforms Tuesday when compared to competitors despite daily gains"", ""summary"": ""Merck & Co. Inc. stock underperforms Tuesday when compared to competitors despite daily gains""}, {""date"": ""20250108080048"", ""headline"": ""8 Stocks' Huge Profit Growth Is About To Knock Your Socks Off"", ""summary"": ""8 Stocks' Huge Profit Growth Is About To Knock Your Socks Off""}, {""date"": ""20250108082428"", ""headline"": ""Merck: HPV vaccine for men approved in China"", ""summary"": ""Merck announced Wednesday that China has approved the male version of its Gardasil human papillomavirus vaccine.The U.S.-based pharmaceutical company reports that China's National Medical Products...""}, {""date"": ""20250108090000"", ""headline"": ""Latest Memo From Howard Marks: On Bubble Watch"", ""summary"": """"}, {""date"": ""20250108091655"", ""headline"": ""CURE: Analyst Estimates Point To Significant Gains In 2025"", ""summary"": ""The Direxion Daily Healthcare Bull 3X Shares ETF seeks to deliver 300% (3x) of the return of an index focused on large-cap US healthcare stocks.""}, {""date"": ""20250108095300"", ""headline"": ""Merck, Johnson & Johnson share losses lead Dow's 180-point fall"", ""summary"": ""Merck, Johnson & Johnson share losses lead Dow's 180-point fall""}, {""date"": ""20250108095700"", ""headline"": ""There\u2019s a \u2018Shadow\u2019 Over Biotech Stocks. Why It Isn\u2018t All Bad News."", ""summary"": ""There\u2019s a \u2018Shadow\u2019 Over Biotech Stocks. Why It Isn\u2018t All Bad News.""}, {""date"": ""20250108114800"", ""headline"": ""Merck\u2019s GARDASIL\u00ae Receives Expanded Approval for Males in China"", ""summary"": ""RAHWAY, N.J., January 08, 2025--Merck\u2019s GARDASIL\u00ae Receives Expanded Approval for Males in China""}, {""date"": ""20250108120014"", ""headline"": ""Merck (NYSE:MRK) Has A Pretty Healthy Balance Sheet"", ""summary"": ""Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...""}, {""date"": ""20250108120405"", ""headline"": ""Truist Securities Downgrades Merck (MRK)"", ""summary"": """"}, {""date"": ""20250108135552"", ""headline"": ""Stock Market Today: Dow Jones Slips Ahead Of Fed Minutes; Nvidia Tests Key Level As Tesla Rises (Live Coverage)"", ""summary"": ""Stock Market Today: Dow Jones Slips Ahead Of Fed Minutes; Nvidia Tests Key Level As Tesla Rises (Live Coverage)""}, {""date"": ""20250109130003"", ""headline"": ""Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts."", ""summary"": ""Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second presidency.""}, {""date"": ""20250110033813"", ""headline"": ""High Expectations And Data Disappointments Have Driven Daiichi Sankyo Lower"", ""summary"": ""Daiichi Sankyo's stock dropped 25% due to disappointing clinical data, but upcoming studies could drive a rebound for risk-tolerant investors. See more here.""}, {""date"": ""20250110163200"", ""headline"": ""Merck & Co. Inc. stock underperforms Friday when compared to competitors"", ""summary"": ""Merck & Co. Inc. stock underperforms Friday when compared to competitors""}, {""date"": ""20250110165614"", ""headline"": ""A First Take On CG Oncology"", ""summary"": ""CG Oncology's stock has dropped 40% since its IPO peak, driven by profit-taking and competitive concerns despite promising Phase 3 data for Cretostimogene. Learn more on CGON stock here.""}, {""date"": ""20250111070506"", ""headline"": ""Eli Lilly: Still Expensive As Earnings Near, But Not Worthy Of A Downgrade"", ""summary"": ""Financial writer cautious on Eli Lilly stock despite strong performance, citing high valuation and underperforming drugs.""}, {""date"": ""20250111072545"", ""headline"": ""3 Ideal Buys From 51 'Safer' Dividends In 100 January Barron's Sustainable Dogs"", ""summary"": ""Discover top sustainable companies with high dividends and growth potential for smart investing strategies in ESG-focused markets.""}]","{""assetTurnoverTTM"": 0.5665, ""bookValue"": 46313, ""cashRatio"": 0.46593947923997187, ""currentRatio"": 1.3646, ""ebitPerShare"": 1.7056, ""eps"": 1.4754, ""ev"": 275517.16, ""fcfMargin"": 0.1608, ""fcfPerShareTTM"": 7.1593, ""grossMargin"": 0.8076, ""inventoryTurnoverTTM"": 2.2454, ""longtermDebtTotalAsset"": 0.2943, ""longtermDebtTotalCapital"": 0.4131, ""longtermDebtTotalEquity"": 0.7441, ""netDebtToTotalCapital"": 0.2861, ""netDebtToTotalEquity"": 0.5154, ""netMargin"": 0.2396, ""operatingMargin"": 0.2769, ""payoutRatioTTM"": 0.458, ""pb"": 5.4336, ""peTTM"": 14.7017, ""pfcfTTM"": 13.9063, ""pretaxMargin"": 0.2669, ""psTTM"": 3.9217, ""ptbv"": 8.4042, ""quickRatio"": 1.1496, ""receivablesTurnoverTTM"": 6.2217, ""roaTTM"": 0.1511, ""roeTTM"": 0.3918, ""roicTTM"": 0.2126, ""rotcTTM"": 0.2477, ""salesPerShare"": 6.1585, ""sgaToSale"": 0.1924, ""tangibleBookValue"": 29943, ""totalDebtToEquity"": 0.8013, ""totalDebtToTotalAsset"": 0.3169, ""totalDebtToTotalCapital"": 0.4448, ""totalRatio"": 1.6542, ""period"": ""2024-12-31""}"
10,2025-01-12,98.39991760253906,2025-01-19,97.08130645751953,-0.01340053098769578,D2,"[{""date"": ""20250113055655"", ""headline"": ""SpringWorks: PDUFA Review Date Could Lead To Next Approved Pipeline Candidate"", ""summary"": ""SpringWorks has shown strong revenue growth with OGSIVEO, achieving a 23% increase from Q2 of 2024 to Q3 of 2024. See why I rate SWTX stock a strong buy.""}, {""date"": ""20250113080000"", ""headline"": ""Arcus: Excellent Pipeline And Collaborations, Cash Runway"", ""summary"": ""Invest in Arcus Biosciences for a strong buying opportunity with promising data, robust pipeline, and significant market potential, backed by Gilead's...""}, {""date"": ""20250113085100"", ""headline"": ""Moderna Stock Sinks. It Disappoints With Covid-19 Vaccine Forecast."", ""summary"": ""Moderna Stock Sinks. It Disappoints With Covid-19 Vaccine Forecast.""}, {""date"": ""20250113105703"", ""headline"": ""Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts."", ""summary"": ""Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.""}, {""date"": ""20250113125900"", ""headline"": ""UnitedHealth, Caterpillar share gains contribute to Dow's 240-point climb"", ""summary"": ""UnitedHealth, Caterpillar share gains contribute to Dow's 240-point climb""}, {""date"": ""20250113181002"", ""headline"": ""Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025"", ""summary"": ""The cancer therapeutics market is set to exceed $400 billion. Read why five pharmaceutical companies offer attractive opportunities for investors.""}, {""date"": ""20250113193000"", ""headline"": ""Transcript : Merck & Co., Inc. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-13-2025 04"", ""summary"": ""Presenter SpeechChristopher Schott Good afternoon, everybody. I'm Chris Schott from JPMorgan, and it's my pleasure to be introducing Merck today. From the company, we have Rob Davis, Chairman and""}, {""date"": ""20250114103703"", ""headline"": ""Merck & Co. Inc. (MRK) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)"", ""summary"": ""Merck &amp; Co. Inc.""}, {""date"": ""20250114113400"", ""headline"": ""Merck Speeds Up Launch of New Keytruda Version as Patent Expiration Nears"", ""summary"": ""Merck Speeds Up Launch of New Keytruda Version as Patent Expiration Nears""}, {""date"": ""20250114115700"", ""headline"": ""Boeing, NVIDIA Corp. share losses lead Dow's 113-point drop"", ""summary"": ""Boeing, NVIDIA Corp. share losses lead Dow's 113-point drop""}, {""date"": ""20250114163200"", ""headline"": ""Merck & Co. Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Merck & Co. Inc. stock underperforms Tuesday when compared to competitors""}, {""date"": ""20250115071520"", ""headline"": ""Vaxcyte Aims To Outshine Pfizer With Bold VAX-31 Strategy"", ""summary"": ""Vaxcyte's robust financial position supports its strategic flexibility and extended timelines. Read more to see why I rate PCVX stock as a buy.""}, {""date"": ""20250115083000"", ""headline"": ""Regeneron: Phase III Success In Skin Cancer For Libtayo"", ""summary"": ""Regeneron shares have been in a bearish trend since August, losing over one third of their value. Read why I am initiating REGN stock with a buy rating.""}, {""date"": ""20250116064604"", ""headline"": ""Merck to Hold Fourth-Quarter and Full-Year 2024 Sales and Earnings Conference Call Feb. 4"", ""summary"": ""Merck , known as MSD outside of the United States and Canada, will hold its fourth-quarter and full-year 2024 sales and earnings conference call with institutional investors and analysts at 9:00 a.m....""}, {""date"": ""20250117013500"", ""headline"": ""Earnings Gains Anticipated In 7 S&P 500 Sectors, Led By Communication Services"", ""summary"": ""Seven of the S&P 500's 11 sectors are expected to achieve cumulative year-over-year growth in normalized earnings per share among their constituent companies in fourth quarter 2024 earnings""}, {""date"": ""20250118093300"", ""headline"": ""Summit Therapeutics: Data Signals A Potential Paradigm Shift In NSCLC (Rating Upgrade)"", ""summary"": ""Learn why Summit Therapeutics' stock soared 888% on positive Phase 3 data for ivonescimab, with a potential value of $20.5B-$29B. Read more here.""}, {""date"": ""20250119134124"", ""headline"": ""Despite Setbacks, Moderna Sees Opportunity In Avian Flu, Merck Partnership"", ""summary"": ""Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.""}, {""date"": ""20250119165445"", ""headline"": ""Top 4 Immunology Stocks Poised For Growth In 2025"", ""summary"": ""Discover the latest trends and developments in the global immunology drugs market, along with four promising stocks to watch for potential investments.""}]","{""assetTurnoverTTM"": 0.5665, ""bookValue"": 46313, ""cashRatio"": 0.46593947923997187, ""currentRatio"": 1.3646, ""ebitPerShare"": 1.7056, ""eps"": 1.4754, ""ev"": 275517.16, ""fcfMargin"": 0.1608, ""fcfPerShareTTM"": 7.1593, ""grossMargin"": 0.8076, ""inventoryTurnoverTTM"": 2.2454, ""longtermDebtTotalAsset"": 0.2943, ""longtermDebtTotalCapital"": 0.4131, ""longtermDebtTotalEquity"": 0.7441, ""netDebtToTotalCapital"": 0.2861, ""netDebtToTotalEquity"": 0.5154, ""netMargin"": 0.2396, ""operatingMargin"": 0.2769, ""payoutRatioTTM"": 0.458, ""pb"": 5.4336, ""peTTM"": 14.7017, ""pfcfTTM"": 13.9063, ""pretaxMargin"": 0.2669, ""psTTM"": 3.9217, ""ptbv"": 8.4042, ""quickRatio"": 1.1496, ""receivablesTurnoverTTM"": 6.2217, ""roaTTM"": 0.1511, ""roeTTM"": 0.3918, ""roicTTM"": 0.2126, ""rotcTTM"": 0.2477, ""salesPerShare"": 6.1585, ""sgaToSale"": 0.1924, ""tangibleBookValue"": 29943, ""totalDebtToEquity"": 0.8013, ""totalDebtToTotalAsset"": 0.3169, ""totalDebtToTotalCapital"": 0.4448, ""totalRatio"": 1.6542, ""period"": ""2024-12-31""}"
11,2025-01-19,97.08130645751953,2025-01-26,94.73161315917969,-0.024203354735115923,D3,"[{""date"": ""20250119134124"", ""headline"": ""Despite Setbacks, Moderna Sees Opportunity In Avian Flu, Merck Partnership"", ""summary"": ""Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.""}, {""date"": ""20250119165445"", ""headline"": ""Top 4 Immunology Stocks Poised For Growth In 2025"", ""summary"": ""Discover the latest trends and developments in the global immunology drugs market, along with four promising stocks to watch for potential investments.""}, {""date"": ""20250120050608"", ""headline"": ""High-Quality Dividend Growth Stocks Near 52-Week Lows: Merck Is Magnificent"", ""summary"": ""A list of high-quality dividend-growth stocks near 52-week lows, including Merck, Nike, J&J, Pfizer, and more. Click here to find out more about dividend stocks.""}, {""date"": ""20250120054247"", ""headline"": ""IYH: Healthcare Dashboard For January"", ""summary"": ""iShares U.S. Healthcare ETF has higher fees and lower performance. See why IYH is a top choice and learn about 10 cheaper healthcare stocks this January.""}, {""date"": ""20250120083000"", ""headline"": ""Merck: 3x Pipeline And Undervaluation Make It A Buy"", ""summary"": ""Discover why Merck presents a compelling long-term investment opportunity with its discounted valuation, robust pipeline, and strong financial performance.""}, {""date"": ""20250120143458"", ""headline"": ""Viking Therapeutics: The Turning Point Is Not Here Yet"", ""summary"": ""Viking Therapeutics investors face challenges as stock plummets, cash runway helps but betting on early stage biopharma remains risky.""}, {""date"": ""20250121163300"", ""headline"": ""Merck & Co. Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Merck & Co. Inc. stock underperforms Tuesday when compared to competitors""}, {""date"": ""20250122105500"", ""headline"": ""Baron Health Care Fund Q4 2024 Shareholder Letter"", ""summary"": ""Baron Health Care Fund retreated in the fourth quarter of 2024, in line with its benchmark, the Russell 3000 Health Care Index. Read more here.""}, {""date"": ""20250122163448"", ""headline"": ""Moderna Surges After Larry Ellison Calls Out The Potential Of AI In Cancer Vaccines"", ""summary"": ""Moderna Surges After Larry Ellison Calls Out The Potential Of AI In Cancer Vaccines""}, {""date"": ""20250123133622"", ""headline"": ""AstraZeneca's Growth Potential: 6 Reasons For A Buy Rating"", ""summary"": ""AstraZeneca is a leader in cancer treatments with FDA-approved drugs. Read why AZN stock is still a 'Buy' and why the company\u00e2\u0080\u0099s future looks bright.""}, {""date"": ""20250124074809"", ""headline"": ""Merck, Eisai See Mixed Keytruda/Lenvima Results in Phase 3 Gastroesophageal Cancer Study"", ""summary"": ""By Colin Kellaher Merck & Co. and Eisai reported mixed results from a late-stage study of the cancer drugs Keytruda and Lenvima in patients with certain types of gastroesophageal cancer. ...""}, {""date"": ""20250124082013"", ""headline"": ""Merck: mixed results in esophageal adenocarcinoma"", ""summary"": ""Merck announces that the phase 3 trial evaluating the combination of Keytruda and Lenvima with chemotherapy for the first-line treatment of patients with HER2-negative advanced gastroesophageal...""}, {""date"": ""20250124114500"", ""headline"": ""Merck and Eisai Provide Update on Phase 3 LEAP-015 Trial Evaluating KEYTRUDA\u00ae (pembrolizumab) Plus LENVIMA\u00ae (lenvatinib) in Combination with Chemotherapy in Patients with Certain Types of Gastroesophageal Adenocarcinoma"", ""summary"": ""RAHWAY, N.J. & NUTLEY, N.J., January 24, 2025--Merck and Eisai Provide Update on Phase 3 LEAP-015 Trial""}, {""date"": ""20250124121212"", ""headline"": ""Why Is Billionaire Prem Watsa Bullish on Merck & Co., Inc. (MRK) Now?"", ""summary"": ""We recently compiled a list of the Billionaire Prem Watsa\u2019s Top 15 Long-Term Stock Picks. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against Prem Watsa\u2019s other long-term stock picks. Prem Watsa is a Canadian billionaire, entrepreneur, and investor often referred to as the Canadian Warren [\u2026]""}, {""date"": ""20250124163300"", ""headline"": ""Merck & Co. Inc. stock underperforms Friday when compared to competitors"", ""summary"": ""Merck & Co. Inc. stock underperforms Friday when compared to competitors""}, {""date"": ""20250125155819"", ""headline"": ""Is Merck & Co., Inc. (MRK) the Best Dow Stocks to Buy Right Now?"", ""summary"": ""We recently published a list of 12 Best Dow Stocks to Buy Right Now. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other best dow stocks to buy right now. The Dow Jones Industrial Average is among the most popular stock market indices globally. [\u2026]""}, {""date"": ""20250125181854"", ""headline"": ""Jim Cramer Says Merck & Co., Inc. (MRK) \u2018Needs To Have China Be Less Of Our Enemy\u2019"", ""summary"": ""We recently published an article titled Jim Cramer Discusses These 18 Stocks & President Trump\u2019s $500 Billion AI Plan. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other stocks Jim Cramer recently discussed. In his latest appearance on CNBC\u2019s Squawk on the Street, Jim [\u2026]""}]",{}
12,2025-01-26,94.73161315917969,2025-02-02,97.97360229492188,0.03422288534551399,U4,"[{""date"": ""20250127072615"", ""headline"": ""Merck Gets FDA Priority Review of Welireg in Rare Adrenal Tumors"", ""summary"": ""By Colin Kellaher Merck & Co. has won U.S. Food and Drug Administration priority review for its application seeking expanded use of its Welireg oral cancer drug in patients with rare tumors that...""}, {""date"": ""20250127082814"", ""headline"": ""Merck: priority review for Welireg in the USA"", ""summary"": ""Merck announced Monday that the U.S. Food and Drug Administration has granted priority review to its Welireg tablet for the treatment of advanced pheochromocytomas and...""}, {""date"": ""20250127110525"", ""headline"": ""Merck and Eisai Provide Update on Phase 3 LEAP-015 Trial Evaluating KEYTRUDA plus LENVIMA in Combination with Chemotherapy in Patients with Certain Types of Gastroesophageal Adenocarcinoma"", ""summary"": ""RAHWAY, NUTLEY - Merck , known as MSD outside of the United States and Canada, and Eisai today announced results from the Phase 3 LEAP-015 trial evaluating KEYTRUDA , Merck's anti-PD-1 therapy, plus...""}, {""date"": ""20250127114500"", ""headline"": ""FDA Grants Priority Review to Merck\u2019s Application for WELIREG\u00ae (belzutifan) for the Treatment of Patients With Advanced Pheochromocytoma and Paraganglioma (PPGL)"", ""summary"": ""RAHWAY, N.J., January 27, 2025--FDA Accepts for Priority Review Merck's Application for WELIREG for Treatment of Advanced PPGL""}, {""date"": ""20250127163300"", ""headline"": ""Merck & Co. Inc. stock underperforms Monday when compared to competitors despite daily gains"", ""summary"": ""Merck & Co. Inc. stock underperforms Monday when compared to competitors despite daily gains""}, {""date"": ""20250127200744"", ""headline"": ""Is Merck & Co.\u00a0(MRK) the Best Depressed Stock to Invest in Now?"", ""summary"": ""We recently published a list of 12 Best Depressed Stocks to Invest in Now. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other best depressed stocks to invest in now. The US stocks ended 2024 with a healthy Q4, as the equity markets were primarily [\u2026]""}, {""date"": ""20250128085910"", ""headline"": ""Merck : Issues Statement on GARDASIL\u00ae Litigation - Merck.com"", ""summary"": ""January 28, 2025 8:55 am ET RAHWAY, N.J., Jan. 28, 2025 - Merck , known as MSD outside of the United States and Canada, today reaffirmed its commitment to defending the safety and...""}, {""date"": ""20250128132800"", ""headline"": ""Merck Announces Second-Quarter 2025 Dividend, Payable on April 7, 2025"", ""summary"": ""Merck known as MSD outside of the United States and Canada, announced that the Board of Directors has declared a quarterly dividend of $0.81 per share of the company?s common stock for the second...""}, {""date"": ""20250128140112"", ""headline"": ""Merck Announces $10 Billion Share Repurchase Authorization"", ""summary"": ""By Stephen Nakrosis Merck said its board authorized an additional $10 billion share repurchase authorization, which has no time limit for completion. The maker of medicines and vaccines has a...""}, {""date"": ""20250128142400"", ""headline"": ""Merck Q4 Earnings Coming Up: Buy, Hold or Sell MRK Stock Now?"", ""summary"": ""When Merck reports fourth-quarter earnings, investors are likely to focus on the sales of its blockbuster oncology medicine, Keytruda.""}, {""date"": ""20250128150048"", ""headline"": ""Merck (MRK) Earnings Expected to Grow: Should You Buy?"", ""summary"": ""Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.""}, {""date"": ""20250128182211"", ""headline"": ""Is Merck & Co. (MRK) Among Kevin O\u2019Leary\u2019s Stock Picks for 2025?"", ""summary"": ""We recently published a list of Kevin O\u2019Leary\u2019s Stock Portfolio: 15 Stock Picks for 2025. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other Kevin O\u2019Leary\u2019s stock picks for 2025. Television personality, financier, and entrepreneur, Kevin O\u2019Leary, also known as \u2018Mr. Wonderful\u2019 is recognized [\u2026]""}, {""date"": ""20250128182800"", ""headline"": ""Merck Announces Second-Quarter 2025 Dividend and $10 Billion Share Repurchase Authorization"", ""summary"": ""RAHWAY, N.J., January 28, 2025--Merck Announces Second-Quarter 2025 Dividend and $10 Billion Share Repurchase Authorization""}, {""date"": ""20250129095100"", ""headline"": ""Moderna Stock Falls After Goldman Downgrade. Vaccine Sales Are a Worry."", ""summary"": ""Moderna Stock Falls After Goldman Downgrade. Vaccine Sales Are a Worry.""}, {""date"": ""20250129115857"", ""headline"": ""Merck & Co., Inc. (MRK): Is This Healthcare Stock A Good Buy?"", ""summary"": ""We recently compiled a list of the Retirement Stock Portfolio: 10 Healthcare Stocks to Buy. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other healthcare stocks. Healthcare stocks are widely considered a cornerstone of a retirement portfolio due to their resilience, long-term growth potential, [\u2026]""}, {""date"": ""20250129120031"", ""headline"": ""Merck & Co., Inc.'s (NYSE:MRK) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?"", ""summary"": ""With its stock down 7.0% over the past three months, it is easy to disregard Merck (NYSE:MRK). However, a closer look...""}, {""date"": ""20250129130029"", ""headline"": ""The RFK Jr. Effect: Biotech Stocks Brace For 'Games' In Senate Hearings"", ""summary"": ""Biotech stocks will need to brace for political \""games\"" Wednesday as the Senate meets to potentially confirm RFK Jr. to lead HHS.""}, {""date"": ""20250129135800"", ""headline"": ""RFK Jr. Is Grilled by Senators With HHS Nomination Under Fire"", ""summary"": ""RFK Jr. Is Grilled by Senators With HHS Nomination Under Fire""}, {""date"": ""20250129150459"", ""headline"": ""3 Prominent US Dividend Stocks Yielding Up To 4.2%"", ""summary"": ""As the U.S. stock market navigates a period of cautious anticipation ahead of the Federal Reserve's interest rate decision and major tech earnings reports, investors are keenly observing how these factors might impact broader economic trends. In this environment, dividend stocks offer a compelling option for those seeking steady income, as they can provide a buffer against market volatility while contributing to portfolio stability.""}, {""date"": ""20250129212404"", ""headline"": ""Is Merck & Co., Inc. (MRK) Among the Best Blue Chip Stocks to Buy Under $100?"", ""summary"": ""We recently compiled a list of the 12 Best Blue Chip Stocks to Buy Under $100. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other best blue chip stocks to buy under $100. Blue chip stocks have long been considered the gold standard of investments, [\u2026]""}, {""date"": ""20250130081620"", ""headline"": ""Merck: Phase III study on Winrevair halted"", ""summary"": ""Merck announced on Thursday that it had decided to discontinue a Phase III clinical trial of its Winrevair pulmonary arterial hypertension treatment in view of the positive results obtained in other...""}, {""date"": ""20250130093016"", ""headline"": ""Merck Stops Winrevair Study Early Amid Positive Results"", ""summary"": ""By Colin Kellaher Merck & Co. has ended another late-stage study of its Winrevair treatment for pulmonary arterial hypertension, or PAH, early due to strong evidence of the drug's benefit. ...""}, {""date"": ""20250130114500"", ""headline"": ""Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR\u2122 (sotatercept-csrk) Early and Move to Final Analysis"", ""summary"": ""RAHWAY, N.J., January 30, 2025--Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR\u2122 (sotatercept-csrk) Early and Move to Final Analysis""}, {""date"": ""20250130140023"", ""headline"": ""Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know"", ""summary"": ""Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.""}, {""date"": ""20250130174546"", ""headline"": ""Jim Cramer Says Merck & Co. (MRK) Has Been a One-way Stock Even Though CEO Rob Davis Has Done Some Terrific Things"", ""summary"": ""We recently compiled a list of the Jim Cramer Discussed These 12 Stocks Amidst The DeepSeek AI Selloff. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other stocks that Jim Cramer discussed. In the episode of CNBC\u2019s Squawk on the Street aired on the [\u2026]""}, {""date"": ""20250131074116"", ""headline"": ""Merck Gets Key European Regulatory Backing for Capvaxive Vaccine"", ""summary"": ""By Colin Kellaher Merck & Co. said a key European regulatory committee has recommended approval of its Capvaxive pneumococcal disease vaccine designed for adults. Merck on Friday said the...""}, {""date"": ""20250131084412"", ""headline"": ""Merck: CHMP gives positive opinion on pneumococcal vaccine"", ""summary"": ""Merck announced on Friday that it had received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use concerning the marketing authorization...""}, {""date"": ""20250131114500"", ""headline"": ""Merck Receives Positive EU CHMP Opinion for CAPVAXIVE\u2122 (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults"", ""summary"": ""RAHWAY, N.J., January 31, 2025--Merck Receives Positive EU CHMP Opinion for CAPVAXIVE\u2122 (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults""}, {""date"": ""20250131140000"", ""headline"": ""DeepSeek! More Earnings! Trump!"", ""summary"": ""DeepSeek dominating markets and AI narrative. Earnings takeaways.""}, {""date"": ""20250131155047"", ""headline"": ""AbbVie earnings: Analyst weighs in on drug pipeline, HHS hearing"", ""summary"": ""As its shares pop in Friday's session, pharmaceutical giant AbbVie Inc. (ABBV) posted a fourth quarter revenue beat and raised its long-term sales guidance for new drugs Skyrizi and Rinvoq by $4 billion. BMO Capital Markets managing director Evan Seigerman sits down with Seana Smith and Brad Smith on the Morning Brief to speak about AbbVie's drug research and product pipeline, especially as sales of immunosuppressant Humira fell dramatically by 49%. \""They talk a lot about some of their efforts in oncology, some of their efforts in neuroscience. Yes, they had some disappointing news last year with their schizophrenia drug, but they are moving forward with other assets in Parkinson's and oncology.\"" The senior biopharma research analyst also weighs in on Robert F. Kennedy Jr.'s secretary of the Department of Health and Human Services (HHS) confirmation hearing and how pharma stocks like Pfizer (PFE) and Merck (MRK) may be impacted: \""There's been a lot of rhetoric over the past couple of days with the confirmation hearings. I've always said HHS is a very complicated organization. I'm still most focused on... the head of the FDA [Food and Drug Administration], potentially Martin McElroy. That's really important because that's kind of the critical agency for the biopharma sector.\"" To watch more expert insights and analysis on the latest market action, check out more Morning Brief\u00a0here. This post was written by Luke Carberry Mogan.""}, {""date"": ""20250201090000"", ""headline"": ""5 Relatively Secure And Cheap Dividend Stocks, Yields Upto 8% (February 2025)"", ""summary"": ""See top dividend-paying stock picks offering discounts and yields ranging from 3.67% to 8% in our monthly article for conservative investors. Click for the picks.""}, {""date"": ""20250202060956"", ""headline"": ""Wall Street Week Ahead"", ""summary"": ""Stay informed with the latest financial updates! Get a daily podcast of Wall Street Breakfast on Seeking Alpha, iTunes, and Spotify by 8:00 a.m.""}]",{}
13,2025-02-02,97.97360229492188,2025-02-09,86.53244018554688,-0.11677800796723403,D5+,"[{""date"": ""20250202060956"", ""headline"": ""Wall Street Week Ahead"", ""summary"": ""Stay informed with the latest financial updates! Get a daily podcast of Wall Street Breakfast on Seeking Alpha, iTunes, and Spotify by 8:00 a.m.""}, {""date"": ""20250203090636"", ""headline"": ""Merck Receives Positive EU CHMP Opinion for CAPVAXIVE for Pneumococcal Vaccination in Adults"", ""summary"": ""RAHWAY - Merck , known as MSD outside of the United States and Canada, announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended the...""}, {""date"": ""20250203165628"", ""headline"": ""Gilead: Strong Sales Growth Remains With Veklury And Beyond"", ""summary"": ""Gilead Sciences, Inc.'s strong sales growth in Veklury, Livdelzi, and Trodelvy shows promise for long-term financial success. Click for my GILD stock update.""}, {""date"": ""20250204055510"", ""headline"": ""Alphabet results lead busy day of earnings"", ""summary"": ""Alphabet results lead busy day of earnings""}, {""date"": ""20250204063203"", ""headline"": ""Merck Announces Fourth-Quarter and Full-Year 2024 Financial Results"", ""summary"": ""Fourth-Quarter Worldwide Sales Were $15.6 Billion, an Increase of 7% From Fourth Quarter 2023; Excluding the Impact of Foreign Exchange, Growth Was 9%Fourth-Quarter GAAP EPS Was $1.48; Non-GAAP...""}, {""date"": ""20250204063810"", ""headline"": ""Merck: Q4 Earnings Snapshot"", ""summary"": ""RAHWAY, N.J. \u2014 RAHWAY, N.J. \u2014 Merck & Co. on Tuesday reported fourth-quarter net income of $3.74 billion. On a per-share basis, the Rahway, New Jersey-based company said it had profit of...""}, {""date"": ""20250204065807"", ""headline"": ""Merck 4Q Sales Increase Results in Swing to Profit"", ""summary"": ""By Denny Jacob Merck swung to a fourth-quarter profit as sales grew and even exceeded Wall Street's estimates, boosted in part by the performance of top asset Keytruda. The drug company...""}, {""date"": ""20250204073000"", ""headline"": ""S&P 500 Futures Steady in Premarket Trading; Palantir Technologies, Spotify Technology Lead"", ""summary"": ""S&P 500 Futures Steady in Premarket Trading; Palantir Technologies, Spotify Technology Lead""}, {""date"": ""20250204073415"", ""headline"": ""Merck 4Q Earnings Rise; 2025 Outlook Hits Shares -- Update"", ""summary"": ""By Denny Jacob Merck swung to a quarterly profit as sales grew to beat Wall Street's estimates, though the drug company's outlook for 2025 and a slide in sales of its HPV vaccine, Gardasil, hit...""}, {""date"": ""20250204085600"", ""headline"": ""Merck Stock Tumbles on Weak Guidance, Bad News in China for Gardasil Sales"", ""summary"": ""Merck Stock Tumbles on Weak Guidance, Bad News in China for Gardasil Sales""}, {""date"": ""20250204094734"", ""headline"": ""Merck Stock Plummets 10% As Gardasil Dynamics, 2025 Guidance Weigh On Shares"", ""summary"": ""Merck Stock Plummets 10% As Gardasil Dynamics, 2025 Guidance Weigh On Shares""}, {""date"": ""20250204095312"", ""headline"": ""Dow Jones Falls On Trump Tariff News; Palantir Surges 27% On Earnings"", ""summary"": ""Dow Jones Falls On Trump Tariff News; Palantir Surges 27% On Earnings""}, {""date"": ""20250204103800"", ""headline"": ""Merck Shares Hit After Guidance Falls Short, Gardasil Challenge"", ""summary"": ""Merck Shares Hit After Guidance Falls Short, Gardasil Challenge""}, {""date"": ""20250204104400"", ""headline"": ""Merck\u2019s struggles with HPV vaccine send stock to worst selloff in almost 17 years"", ""summary"": ""Merck\u2019s struggles with HPV vaccine send stock to worst selloff in almost 17 years""}, {""date"": ""20250204105400"", ""headline"": ""These Stocks Are Moving the Most Today: Palantir, Alphabet, Tesla, Merck, PayPal, Super Micro, Spotify, Estee Lauder, and More"", ""summary"": ""These Stocks Are Moving the Most Today: Palantir, Alphabet, Tesla, Merck, PayPal, Super Micro, Spotify, Estee Lauder, and More""}, {""date"": ""20250204125515"", ""headline"": ""Merck & Co., Inc. (MRK) Q4 2024 Earnings Call Transcript"", ""summary"": ""Merck &amp; Co., Inc. (NYSE:MRK) Q4 2024 Results Conference Call February 4, 2025 9:00 AM ETCompany ParticipantsPeter Dannenbaum - Senior Vice President,...""}, {""date"": ""20250204144420"", ""headline"": ""Big Pharma, Bigger Bargain: Why Merck Stock Is Too Cheap To Ignore (Upgrade)"", ""summary"": ""Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential. Click for this MRK earnings update.""}, {""date"": ""20250204145918"", ""headline"": ""Merck: Ideal Case Of Why I Love Option Collars (Upgrade To Buy)"", ""summary"": """"}, {""date"": ""20250204152300"", ""headline"": ""Wall Street Lunch: It's No Yolk - Egg Surcharges Are Here"", ""summary"": ""Egg prices continue to soar to unprecedented levels.""}, {""date"": ""20250204172700"", ""headline"": ""Health Care Declines Amid Mixed Earnings - Health Care Roundup"", ""summary"": ""Health Care Declines Amid Mixed Earnings - Health Care Roundup""}, {""date"": ""20250205070000"", ""headline"": ""Merck Is Suffering From a Classic Pharma Problem"", ""summary"": ""Merck Is Suffering From a Classic Pharma Problem""}, {""date"": ""20250205074500"", ""headline"": ""Regeneron Presents An Opportunity After LIBTAYO Sales Growth Bolsters Earnings"", ""summary"": ""Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for LIBTAYO in 2024. Read more here.""}, {""date"": ""20250205100300"", ""headline"": ""Dow's 140-point fall led by losses for shares of UnitedHealth, Merck"", ""summary"": ""Dow's 140-point fall led by losses for shares of UnitedHealth, Merck""}, {""date"": ""20250205172819"", ""headline"": ""Merck: Don't Fight The Tape, How Low Can It Go?"", ""summary"": ""Financial writer advises caution on investing in Merck & Co., Inc. due to negative sentiment and potential price declines. Click for more on MRK Q4 earnings.""}, {""date"": ""20250206135400"", ""headline"": ""Wall Street Lunch: U.S. Could Ban DeepSeek On Government Devices"", ""summary"": ""U.S. House lawmakers plan to introduce legislation to ban DeepSeek\u00e2\u0080\u0099s app from government-issued devices""}, {""date"": ""20250206163300"", ""headline"": ""Merck & Co. Inc. stock underperforms Thursday when compared to competitors"", ""summary"": ""Merck & Co. Inc. stock underperforms Thursday when compared to competitors""}, {""date"": ""20250207053000"", ""headline"": ""The Drug Industry Is Having Its Own DeepSeek Moment"", ""summary"": ""The Drug Industry Is Having Its Own DeepSeek Moment""}, {""date"": ""20250207080040"", ""headline"": ""15 Stocks' Profit Grows Faster Than Any Of The Magnificent Seven"", ""summary"": ""15 Stocks' Profit Grows Faster Than Any Of The Magnificent Seven""}, {""date"": ""20250207123000"", ""headline"": ""AI Earnings, Tariff Threats, And Other Bellwether Stocks"", ""summary"": ""Palantir's soaring but concerns remain. Tariff threats and bellwether earnings.""}, {""date"": ""20250208075421"", ""headline"": ""One 'Safer' Buy In 10 February Dogs Of The Dow"", ""summary"": ""Verizon's dividend yield and Merck\u00e2\u0080\u0099s growth lead the Dow Dogs. Read why they\u00e2\u0080\u0099re set for solid returns, with other top picks closely following in February 2026.""}]",{}
14,2025-02-09,86.53244018554688,2025-02-16,82.29901885986328,-0.0489229393809546,D5,"[{""date"": ""20250210163647"", ""headline"": ""Ideaya Biosciences: Potential Registration-Enabling Darovasertib Study Coming"", ""summary"": ""Explore the potential of Ideaya Biosciences, Inc.'s Darovasertib in treating uveal melanoma as a monotherapy and in combination therapy. Click for more on IDYA.""}, {""date"": ""20250211014000"", ""headline"": ""Steady M&A Deals To Begin 2025, Disappointing IPOs So Far"", ""summary"": ""A few notable health care deals along with M&A in the AI-adjacent and reshoring themes occurred in January. Read more here.""}, {""date"": ""20250212073400"", ""headline"": ""Neuphoria Therapeutics to Receive $15 Mln Payment from Merck"", ""summary"": ""Neuphoria Therapeutics to Receive $15 Mln Payment from Merck""}, {""date"": ""20250212162606"", ""headline"": ""IGA: Good Diversification And Fully-Covered Distribution (Rating Upgrade)"", ""summary"": ""Voya Global Advantage and Premium Opportunity Fund has a 10.74% yield, diversification benefits, and well-covered distributions. Click for my IGA CEF update.""}, {""date"": ""20250212163400"", ""headline"": ""Merck & Co. Inc. stock underperforms Wednesday when compared to competitors"", ""summary"": ""Merck & Co. Inc. stock underperforms Wednesday when compared to competitors""}, {""date"": ""20250213163300"", ""headline"": ""Merck & Co. Inc. stock underperforms Thursday when compared to competitors"", ""summary"": ""Merck & Co. Inc. stock underperforms Thursday when compared to competitors""}, {""date"": ""20250213194202"", ""headline"": ""Gossamer Bio Is A Good Speculative Buy On Seralutinib For PAH And PH-ILD"", ""summary"": ""Gossamer Bio's Seralutinib shows promise for PAH and PH-ILD treatment. The main event comes with its topline results in Q4 2025. Read more on GOSS stock here.""}, {""date"": ""20250213224026"", ""headline"": ""Tracking Jeremy Grantham's GMO Capital Portfolio - Q4 2024 Update"", ""summary"": ""GMO's portfolio update highlights key stock adjustments and forecasts a promising 9.6% return for International Deep Value assets. See more here.""}, {""date"": ""20250214112000"", ""headline"": ""Dow's nearly 125-point fall led by losses for Procter & Gamble, Travelers stocks"", ""summary"": ""Dow's nearly 125-point fall led by losses for Procter & Gamble, Travelers stocks""}, {""date"": ""20250216011101"", ""headline"": ""IXJ: Healthcare Sector\u00a0Dashboard For February"", ""summary"": ""The healthcare sector is currently overvalued by about 13% relative to 11-year averages. Check out the top-down analysis of the healthcare sector.""}, {""date"": ""20250216215403"", ""headline"": ""Why Regeneron's Price May Soon Break Out"", ""summary"": ""Regeneron Pharmaceuticals' fourth quarter results beat my and Wall Street analysts' expectations. See why REGN stock is a top pick for long-term investors.""}]",{}
15,2025-02-16,82.29901885986328,2025-02-23,88.73342895507812,0.07818331475094742,U5+,"[{""date"": ""20250216011101"", ""headline"": ""IXJ: Healthcare Sector\u00a0Dashboard For February"", ""summary"": ""The healthcare sector is currently overvalued by about 13% relative to 11-year averages. Check out the top-down analysis of the healthcare sector.""}, {""date"": ""20250216215403"", ""headline"": ""Why Regeneron's Price May Soon Break Out"", ""summary"": ""Regeneron Pharmaceuticals' fourth quarter results beat my and Wall Street analysts' expectations. See why REGN stock is a top pick for long-term investors.""}, {""date"": ""20250218022133"", ""headline"": ""GSK's Strong Performance: Why I'm Upgrading To 'Strong Buy'"", ""summary"": ""GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's rating from Buy to Strong Buy.""}, {""date"": ""20250218093500"", ""headline"": ""American Century Growth Fund Q4 2024 Commentary"", ""summary"": ""We seek to invest in larger U.S. companies that are demonstrating their businesses are improving, as opposed to absolute levels of growth.""}, {""date"": ""20250218095900"", ""headline"": ""UnitedHealth, Sherwin-Williams Co. share losses lead Dow's 131-point drop"", ""summary"": ""UnitedHealth, Sherwin-Williams Co. share losses lead Dow's 131-point drop""}, {""date"": ""20250218144921"", ""headline"": ""Merck vaccine case linked to HHS Secretary Kennedy delayed mid-trial"", ""summary"": ""Merck and a woman suing the drugmakeragreed to halt a trial over alleged injuries from thedrugmaker's human papillomavirus vaccine in a case with ties toU.S. Department of Health and Human Services...""}, {""date"": ""20250218145406"", ""headline"": ""MRK Purchasers Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit"", ""summary"": ""NEW YORK, Feb. 18, 2025 /PRNewswire/ --\u00a0Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Merck & Co., Inc. ...""}, {""date"": ""20250218165912"", ""headline"": ""Push UPs [Stocks] Vs Pull DOWNs [Retail Sales]"", ""summary"": ""This week's review and preview: The S&P 500 and Nasdaq showed bullish behavior, with the Dow Jones leading YTD gains at 4.7%, despite weak retail sales data. Read the full report here.""}, {""date"": ""20250219000406"", ""headline"": ""Deutsche Bank Downgrades Merck (MRK)"", ""summary"": """"}, {""date"": ""20250219114544"", ""headline"": ""Merck - WELIREG Receives First European Commission Approval for Two Indications"", ""summary"": ""RAHWAY - Merck , known as MSD outside of the United States and Canada, today announced that the European Commission has conditionally approved WELIREG , Merck's oral hypoxia-inducible factor-2 alpha ...""}, {""date"": ""20250219180756"", ""headline"": ""10 Ideal 'Safer' January Dividend Buys, Out Of 40 Choices From Readers"", ""summary"": ""Discover our top dividend-yield stocks & reader favorites for 2025! See the best performers by net gains, price upside, and yield. Click for the exclusive picks.""}, {""date"": ""20250219210103"", ""headline"": ""Securities Fraud Investigation Into Merck & Co (MRK) Announced \u2013 Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz"", ""summary"": ""The Law Offices of Frank R. Cruz announces an investigation of Merck & Co on behalf of investors concerning the Company\u2019s possible violations of federal securities laws.IF YOU ARE AN INVESTOR...""}, {""date"": ""20250219235900"", ""headline"": ""Why Novo Nordisk Is A Strong Buy Despite Market Concerns"", ""summary"": ""Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO stock a buy.""}, {""date"": ""20250220054626"", ""headline"": ""Merck & Co., Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before April 14, 2025 to Discuss Your Rights - MRK"", ""summary"": ""NEW YORK, Feb. 20, 2025 /PRNewswire/ --\u00a0The Gross Law Firm issues the following notice to shareholders of Merck & Co., Inc. . ...""}, {""date"": ""20250220105205"", ""headline"": ""MRK Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In MRK To Contact Him Directly To Discuss Their Options"", ""summary"": ""Faruqi & Faruqi, LLP Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Merck To Contact Him Directly To Discuss Their OptionsIf you suffered...""}, {""date"": ""20250220130604"", ""headline"": ""Merck & Co (MRK) Investors Who Lost Money \u2013 Contact Law Offices of Howard G. Smith About Securities Fraud Investigation"", ""summary"": ""Law Offices of Howard G. Smith announces an investigation on behalf of Merck & Co investors concerning the Company\u2019s possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO...""}, {""date"": ""20250220140000"", ""headline"": ""I'm Buying Discounted Dividend Icons Up To 6% Yield"", ""summary"": ""Great dividend stocks should offer a mix of durability, solid income generation, and growth prospects. Read more to see 2 such picks.""}, {""date"": ""20250220150103"", ""headline"": ""Securities Fraud Investigation Into Merck & Co (MRK) Announced \u2013 Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm"", ""summary"": ""Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Merck & Co investors concerning the Company\u2019s...""}, {""date"": ""20250221054626"", ""headline"": ""Merck & Co., Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - MRK"", ""summary"": ""NEW YORK, Feb. 21, 2025 /PRNewswire/ -- Levi &\u00a0Korsinsky, LLP notifies investors in Merck & Co., Inc. of a class action securities lawsuit. ...""}, {""date"": ""20250221074500"", ""headline"": ""The London Company Income Equity Vs. Russell 1000 Value Q4 2024 Commentary"", ""summary"": ""The London Company Income Equity portfolio declined 2.2% during the quarter vs. a 2.0% decrease in the Russell 1000 Value Index.""}, {""date"": ""20250221084000"", ""headline"": ""The London Company Income Equity Vs. Russell 1000 Value Full Year 2024 Commentary"", ""summary"": ""The London Company Income Equity portfolio returned 12.3% year-to-date vs. a 14.4% increase in the Russell 1000 Value Index.""}, {""date"": ""20250221120104"", ""headline"": ""Law Offices of Howard G. Smith Encourages Merck & Co (MRK) Investors To Inquire About Securities Fraud Class Action"", ""summary"": ""Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Merck & Co securities between February 3, 2022, to February 3, 2025,...""}, {""date"": ""20250221144500"", ""headline"": ""Past Week Dominated By Corporate Earnings Stories"", ""summary"": ""Past week dominated by good news and a few corporate earnings.""}, {""date"": ""20250221163400"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Merck & Co. Inc. stock outperforms competitors on strong trading day""}, {""date"": ""20250222081314"", ""headline"": ""Esperion Therapeutics: Little Upside Potential In Their Earlier Generation Drug"", ""summary"": ""Esperion Therapeutics has two approved LDL-C lowering therapies, Nexletol and Nexlizet, but lacks a strong pipeline for future growth.""}, {""date"": ""20250223115222"", ""headline"": ""Why AbbVie Remains A Strong Buy For Long-Term Investors"", ""summary"": ""Discover why AbbVie stands out for long-term investors with strong growth in Skyrizi & Qulipta sales.""}]",{}
16,2025-02-23,88.73342895507812,2025-03-02,91.45986938476562,0.030726192617528403,U4,"[{""date"": ""20250223115222"", ""headline"": ""Why AbbVie Remains A Strong Buy For Long-Term Investors"", ""summary"": ""Discover why AbbVie stands out for long-term investors with strong growth in Skyrizi & Qulipta sales.""}, {""date"": ""20250224034105"", ""headline"": ""MRK Purchasers Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit"", ""summary"": ""NEW YORK, Feb. 24, 2025 /PRNewswire/ --\u00a0Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Merck & Co., Inc. ...""}, {""date"": ""20250224053500"", ""headline"": ""Columbia Dividend Income Fund Q4 2024 Commentary"", ""summary"": ""Institutional Class shares of Columbia Dividend Income Fund returned -1.34% for Q4 2024. Click here to read the full commentary. ""}, {""date"": ""20250224054627"", ""headline"": ""The Gross Law Firm Notifies Merck & Co., Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - MRK"", ""summary"": ""NEW YORK, Feb. 24, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of\u00a0Merck & Co., Inc. . ...""}, {""date"": ""20250224064603"", ""headline"": ""Merck to Participate in the TD Cowen 45th Annual Health Care Conference"", ""summary"": ""Merck , known as MSD outside of the United States and Canada, announced today that Caroline Litchfield, executive vice president and chief financial officer, and Dr. Dean Y. Li, executive vice...""}, {""date"": ""20250224073000"", ""headline"": ""Don't Get Left Behind - The Great Rotation Into Dividend Stocks Is Here"", ""summary"": ""Dividend stocks are becoming safer bets for future returns, as highlighted by recent market analyses. Read more to see my thoughts.""}, {""date"": ""20250224083000"", ""headline"": ""The Top Dog Of The Dow Buys For 2025"", ""summary"": ""Dogs of the Dow can be described as the 10 highest yielding stocks that are within the DJI. Read more to see the best Dog of the Dow buys.""}, {""date"": ""20250224083500"", ""headline"": ""Columbia Flexible Capital Income Fund Q4 2024 Commentary"", ""summary"": ""Columbia Flexible Capital Income Fund Institutional Class shares returned -0.67% in Q4 2024. Click here to read the full commentary. ""}, {""date"": ""20250224105350"", ""headline"": ""Pfizer: What The Summit Therapeutics Deal Brings"", ""summary"": ""Pfizer partners with Summit Therapeutics to advance cancer treatments using ADCs and ivonescimab.""}, {""date"": ""20250224112000"", ""headline"": ""Nike, Travelers share gains contribute to Dow's nearly 125-point climb"", ""summary"": ""Nike, Travelers share gains contribute to Dow's nearly 125-point climb""}, {""date"": ""20250224120103"", ""headline"": ""Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages Merck & Co (MRK) Investors To Inquire About Securities Fraud Class Action"", ""summary"": ""Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise...""}, {""date"": ""20250224124500"", ""headline"": ""Dow's nearly 250-point rally highlighted by gains in shares of Nike, Travelers"", ""summary"": ""Dow's nearly 250-point rally highlighted by gains in shares of Nike, Travelers""}, {""date"": ""20250224214300"", ""headline"": ""Hartford Healthcare Fund Q4 2024 Commentary"", ""summary"": ""The Hartford Healthcare Fund (I share) underperformed the S&P Composite 1500 Health Care Index during the quarter. Read more here.""}, {""date"": ""20250224222300"", ""headline"": ""Hartford Equity Income Fund Q4 2024 Commentary"", ""summary"": ""Hartford Equity Income Fund (I share) underperformed the Russell 1000 Value Index during the quarter. Read more here.""}, {""date"": ""20250225054624"", ""headline"": ""Class Action Filed Against Merck & Co., Inc. (MRK) - April 14, 2025 Deadline to Join - Contact Levi & Korsinsky"", ""summary"": ""NEW YORK, Feb. 25, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Merck & Co., Inc. of a class action securities lawsuit. ...""}, {""date"": ""20250225064604"", ""headline"": ""FDA Grants Priority Review to Merck\u2019s Application for KEYTRUDA\u00ae (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma"", ""summary"": ""Acceptance based on results from the KEYNOTE-689 trial: the first Phase 3 trial to demonstrate significant improvement in event-free survival in the neoadjuvant and adjuvant setting for an anti-PD-1...""}, {""date"": ""20250225070704"", ""headline"": ""MRK Investors Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit with the Schall Law Firm"", ""summary"": ""LOS ANGELES, Feb. 25, 2025 /PRNewswire/ --\u00a0The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against\u00a0Merck & Co., Inc. \u00a0for violations...""}, {""date"": ""20250225073807"", ""headline"": ""Merck Gets Speedy FDA Review of Keytruda in Certain Head, Neck Cancers"", ""summary"": ""By Colin Kellaher Merck & Co. has won U.S. Food and Drug Administration priority review for its application seeking expanded use of its blockbuster cancer drug Keytruda in certain patients with...""}, {""date"": ""20250225090000"", ""headline"": ""10 Undervalued Dividend Growth Stocks: February 2025"", ""summary"": """"}, {""date"": ""20250225095400"", ""headline"": ""Hims & Hers Stumbles as GLP-1 Compounding Ends. Lilly Presses the Advantage."", ""summary"": ""Hims & Hers Stumbles as GLP-1 Compounding Ends. Lilly Presses the Advantage.""}, {""date"": ""20250225102000"", ""headline"": ""Columbia Select Large Cap Equity Fund Q4 2024 Commentary"", ""summary"": ""Columbia Select Large Cap Equity Fund Institutional Class shares returned 3.31% for\nthe three months ending 12/31/2024. Click here to read the full commentary.""}, {""date"": ""20250225120804"", ""headline"": ""Law Offices of Frank R. Cruz Encourages Merck & Co (MRK) Investors to Inquire About Securities Fraud Class Action"", ""summary"": ""The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of investors who purchased Merck & Co securities between February 3, 2022, to February 3, 2025,...""}, {""date"": ""20250225160203"", ""headline"": ""MRK Bronstein, Gewirtz & Grossman LLC Announces that Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"", ""summary"": ""Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Merck & Co., Inc. and certain of its...""}, {""date"": ""20250225165124"", ""headline"": ""Merck expects cancer therapy Keytruda to be part of government price setting in 2026"", ""summary"": ""Drugmaker Merck said onTuesday it expects its top selling cancer therapy Keytruda to beselected in 2026 for government price setting, which wouldbecome effective on January 1, 2028. ...""}, {""date"": ""20250226054110"", ""headline"": ""Merck & Co.'s Real Value: A Deep Dive Into Its Fundamentals"", ""summary"": ""While Merck reported strong financial results in recent quarters, it faces both upsides and risks in the future. Read why I'm neutral on MRK stock.""}, {""date"": ""20250226054500"", ""headline"": ""Miller-Howard Income-Equity Q4 2024 Commentary"", ""summary"": ""Both versions of Miller-Howard Income-Equity outperformed the Russell 1000 Value Index for the fourth quarter and for 2024. Click here to read the full commentary. ""}, {""date"": ""20250226091544"", ""headline"": ""Merck's Oncology Strength: Beating Wall Street Again"", ""summary"": ""Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK may work for income investors.""}, {""date"": ""20250226125600"", ""headline"": ""Dow falls 110 points on losses for Boeing, Amgen shares"", ""summary"": ""Dow falls 110 points on losses for Boeing, Amgen shares""}, {""date"": ""20250226135700"", ""headline"": ""Boeing, Apple share losses lead Dow's 289-point drop"", ""summary"": ""Boeing, Apple share losses lead Dow's 289-point drop""}, {""date"": ""20250226151300"", ""headline"": ""Apple, Amgen share losses lead Dow's 175-point drop"", ""summary"": ""Apple, Amgen share losses lead Dow's 175-point drop""}, {""date"": ""20250227054625"", ""headline"": ""Shareholders that lost money on Merck & Co., Inc.(MRK) Urged to Join Class Action - Contact The Gross Law Firm to Learn More"", ""summary"": ""NEW YORK, Feb. 27, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Merck & Co., Inc. . ...""}, {""date"": ""20250227103200"", ""headline"": ""MannKind Q4 Review: Solid Financials, But Tyvaso DPI's Market Share In Question"", ""summary"": ""MannKind\u00e2\u0080\u0099s future hinges on Tyvaso DPI's growth, R&D prospects, and financial stability despite competition and risks. Explore more details here.""}, {""date"": ""20250228054625"", ""headline"": ""MRK LAWSUIT ALERT: Levi & Korsinsky Notifies Merck & Co., Inc. Investors of a Class Action Lawsuit and Upcoming Deadline"", ""summary"": ""NEW YORK, Feb. 28, 2025 /PRNewswire/ -- Levi &\u00a0Korsinsky, LLP notifies investors in Merck & Co., Inc. of a class action securities lawsuit. ...""}, {""date"": ""20250228064500"", ""headline"": ""Rapid Micro Biosystems Shares Rise in Premarket on New Distribution Agreement with Merck"", ""summary"": ""Rapid Micro Biosystems Shares Rise in Premarket on New Distribution Agreement with Merck""}, {""date"": ""20250228163200"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Merck & Co. Inc. stock outperforms competitors on strong trading day""}, {""date"": ""20250301080000"", ""headline"": ""5 Relatively Secure And Cheap Dividend Stocks, Yields Upto 8% (March 2025)"", ""summary"": ""Discover 5 large-cap, dividend-paying stocks trading at significant discounts. Explore conservative picks plus options with yields up to 8%.""}]",{}
17,2025-03-02,91.45986938476562,2025-03-09,93.83931732177734,0.026016305872923695,U3,"[{""date"": ""20250303010414"", ""headline"": ""My Top 10 High-Yield Dividend Stocks For March 2025"", ""summary"": ""The promising start to 2025 did not last very long, as major indices declined in February. Find out my top 10 high-yield dividend stocks for March 2025.""}, {""date"": ""20250303054626"", ""headline"": ""The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Merck Lawsuit - MRK"", ""summary"": ""NEW YORK, March 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Merck & Co., Inc. . ...""}, {""date"": ""20250303080000"", ""headline"": ""Buy These Mispriced Dividend Icons For Retirement Income"", ""summary"": ""Wall Street is generally afraid of uncertainty, but with adversity also comes opportunity. Find out my 2 picks that have well-above average yields.""}, {""date"": ""20250303095506"", ""headline"": ""MRK Investors Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit with the Schall Law Firm"", ""summary"": ""LOS ANGELES, March 3, 2025 /PRNewswire/ --\u00a0The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against\u00a0Merck & Co., Inc. \u00a0for violations...""}, {""date"": ""20250303125115"", ""headline"": ""Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming Deadlines - MRK"", ""summary"": ""NEW YORK, March 3, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Merck & Co., Inc. \u00a0. Such investors are advised to contact Danielle Peyton at...""}, {""date"": ""20250303131106"", ""headline"": ""MRK Purchasers Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit"", ""summary"": ""NEW YORK, March 3, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Merck & Co., Inc. ...""}, {""date"": ""20250303191303"", ""headline"": ""Merck & Co., Inc. (MRK) Presents at TD Cowen 45th Annual Health Care Conference (Transcript)"", ""summary"": ""Start Time: 14:30 January 1, 0000 3:05 PM ETMerck &amp; Co., Inc.""}, {""date"": ""20250304054624"", ""headline"": ""Class Action Filed Against Merck & Co., Inc. (MRK) Seeking Recovery for Investors - Contact Levi & Korsinsky"", ""summary"": ""NEW YORK, March 4, 2025 /PRNewswire/ --\u00a0Levi & Korsinsky, LLP notifies investors in Merck & Co., Inc. of a class action securities lawsuit. ...""}, {""date"": ""20250304145603"", ""headline"": ""Dogs Of The Dow Chase A \""Safer\"" Buy For March"", ""summary"": ""My monthly update and commentary on the top dividend stock picks from the Dogs Of The Dow, March 2025 edition. Click here to read more about Dogs of the Dow.""}, {""date"": ""20250304162400"", ""headline"": ""$20 Billion Club: For The Largest Corporate DB Plans, Maximizing Returns Is Not The Goal"", ""summary"": ""Russell Investments expects the trend toward liability-hedging fixed income to persist as funded status inches upward. We also expect ongoing interest in alternative asset classes.""}, {""date"": ""20250305053000"", ""headline"": ""New Version of Merck\u2019s Blockbuster Cancer Drug Threatened by Patent Battle"", ""summary"": ""New Version of Merck\u2019s Blockbuster Cancer Drug Threatened by Patent Battle""}, {""date"": ""20250305205726"", ""headline"": ""Merck & Co.\u00a0(MRK): An Undervalued Wide Moat Stock to Buy According to Analysts"", ""summary"": ""We recently compiled a list of the 12 Undervalued Wide Moat Stocks to Buy According to Analysts. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other undervalued wide moat stocks. As per BlackRock, European equity gains have managed to outpace the US to start [\u2026]""}, {""date"": ""20250306054625"", ""headline"": ""Merck & Co., Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - MRK"", ""summary"": ""NEW YORK, March 6, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Merck & Co., Inc. . ...""}, {""date"": ""20250306163110"", ""headline"": ""Merck (MRK) Up 3.9% Since Last Earnings Report: Can It Continue?"", ""summary"": ""Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.""}, {""date"": ""20250306193205"", ""headline"": ""Merck & Co. (MRK): Among the Best Undervalued Stocks to Invest In Now"", ""summary"": ""We recently compiled a list of the 11 Best Undervalued Stocks to Invest in Now. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other best undervalued stocks. How Will Tariffs Affect the Market? On March 5th, BBC reported that the US stock market [\u2026]""}, {""date"": ""20250307014728"", ""headline"": ""ImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum"", ""summary"": ""ImmunityBio (IBRX) faces operational, financial, and competitive challenges, impacting its growth prospects despite Anktiva's potential. See more here.""}, {""date"": ""20250307055413"", ""headline"": ""Merck & Co., Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - MRK"", ""summary"": ""NEW YORK, March 7, 2025 /PRNewswire/ -- Levi &\u00a0Korsinsky, LLP notifies investors in Merck & Co., Inc. of a class action securities lawsuit. ...""}, {""date"": ""20250307093414"", ""headline"": ""Pfizer Vs. Johnson & Johnson: Who's The Better Bargain For Investors"", ""summary"": ""Discover the strengths & weaknesses of healthcare giants Johnson & Johnson and Pfizer. Find out which stock is more promising for long-term investors.""}, {""date"": ""20250307120109"", ""headline"": ""Merck & Co (MRK) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit"", ""summary"": ""BENSALEM, Pa., March 7, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit...""}, {""date"": ""20250308003657"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of March 9"", ""summary"": ""Read here for weekly updates on Dividend Champions, Contenders, and Challengers. Track dividend changes, ex-dividend dates, and upcoming pay dates.""}, {""date"": ""20250308081500"", ""headline"": ""Why And How To Plan For A Potential $2 Million Retirement"", ""summary"": ""$1 million may no longer be sufficient for folks in their late 40s or early 50s who are 15 years away from retirement. See here for easy-to-implement strategies.""}, {""date"": ""20250308205258"", ""headline"": ""Merck & Co., Inc. (MRK) Among The Best Cheap Dividend Stock To Buy Right Now"", ""summary"": ""We recently published a list of 13 Best Cheap Dividend Stocks To Buy Right Now. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other best cheap dividend stocks to buy right now. Value investing has remained a favored approach among investors for years, largely [\u2026]""}, {""date"": ""20250309091500"", ""headline"": ""This Is The Time For SCHD To Shine"", ""summary"": ""Schwab U.S. Dividend Equity ETF excels in market downturns with a 3.6% dividend yield. Find out why SCHD offers lower risk and better downside protection.""}, {""date"": ""20250309193505"", ""headline"": ""Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q4 2024 Update"", ""summary"": ""Discover Prem Watsa\u00e2\u0080\u0099s latest 13F portfolio updates: major stakes in Orla Mining, Occidental Petroleum, Blackberry & new positions in CVS Health.""}, {""date"": ""20250309204524"", ""headline"": ""Is Merck & Co., Inc. (MRK) the Most Undervalued High Quality Stock to Buy According to Analysts?"", ""summary"": ""We recently published a list of 10 Most Undervalued High Quality Stocks to Buy According to Analysts. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other most undervalued high quality stocks to buy according to analysts. Is a Market Rally Around The Corner? In [\u2026]""}]",{}
18,2025-03-09,93.83931732177734,2025-03-16,93.76000213623047,-0.0008452233862156211,D1,"[{""date"": ""20250309091500"", ""headline"": ""This Is The Time For SCHD To Shine"", ""summary"": ""Schwab U.S. Dividend Equity ETF excels in market downturns with a 3.6% dividend yield. Find out why SCHD offers lower risk and better downside protection.""}, {""date"": ""20250309193505"", ""headline"": ""Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q4 2024 Update"", ""summary"": ""Discover Prem Watsa\u00e2\u0080\u0099s latest 13F portfolio updates: major stakes in Orla Mining, Occidental Petroleum, Blackberry & new positions in CVS Health.""}, {""date"": ""20250309204524"", ""headline"": ""Is Merck & Co., Inc. (MRK) the Most Undervalued High Quality Stock to Buy According to Analysts?"", ""summary"": ""We recently published a list of 10 Most Undervalued High Quality Stocks to Buy According to Analysts. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other most undervalued high quality stocks to buy according to analysts. Is a Market Rally Around The Corner? In [\u2026]""}, {""date"": ""20250310054627"", ""headline"": ""The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Merck & Co., Inc.(MRK) Shareholders"", ""summary"": ""NEW YORK, March 10, 2025 /PRNewswire/ --\u00a0The Gross Law Firm issues the following notice to shareholders of\u00a0Merck & Co., Inc. . ...""}, {""date"": ""20250310101205"", ""headline"": ""MRK Investors Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit with the Schall Law Firm"", ""summary"": ""LOS ANGELES, March 10, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against\u00a0Merck & Co., Inc. \u00a0for violations...""}, {""date"": ""20250310124605"", ""headline"": ""MRK Purchasers Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit"", ""summary"": ""NEW YORK, March 10, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Merck & Co., Inc. ...""}, {""date"": ""20250310181712"", ""headline"": ""Stock market sell-off: Why these stocks are in the green amid the pain"", ""summary"": ""The shift to defense is on.""}, {""date"": ""20250310191900"", ""headline"": ""Safe Haven Stocks: 3 Top Picks for Navigating Volatility"", ""summary"": ""Merck and Co., Molson Coors and Deutsche Telekom all show defensive characteristics and bullish catalysts amid market turmoil""}, {""date"": ""20250310204051"", ""headline"": ""Merck & Co. (MRK): One of the Most Undervalued US Stocks to Buy According to Hedge Funds"", ""summary"": ""We recently compiled a list of the 10 Most Undervalued US Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other undervalued US stocks. On a down day for major market averages, Paul Hickey, co-founder of Bespoke Investment [\u2026]""}, {""date"": ""20250311020042"", ""headline"": ""Wall Street Analysts Think This Medical Dividend Stock Could Have Massive 82% Upside"", ""summary"": ""Imagine yourself as a passive income investor looking for a medical stock with significant share growth potential. Wall Street analysts with JP Morgan, Citi, and Evercore ISI would recommend looking at Merck & Co (NYSE: MRK), which they've all given a ...""}, {""date"": ""20250311082221"", ""headline"": ""Merck & Co.\u00a0(MRK): Hedge Funds Are Bullish On This Oversold Blue Chip Stock Now"", ""summary"": ""We recently compiled a list of the 11 Oversold Blue Chip Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other oversold blue chip stocks. The uncertainty related to the tariff announcements continues to influence Wall Street. Reuters reported that [\u2026]""}, {""date"": ""20250311104500"", ""headline"": ""Merck Unveils New Facility to Increase Vaccine Production Capacity"", ""summary"": ""DURHAM, N.C., March 11, 2025--Merck Unveils New Facility to Increase Vaccine Production Capacity""}, {""date"": ""20250311130205"", ""headline"": ""BMEZ: Recession Fears Making You Sick? Buy This High-Yield Healthcare Fund"", ""summary"": ""BlackRock Health Sciences Term Trust is a top pick for high-yield dividends in healthcare. Click here to find out why BMEZ stock is a Buy.""}, {""date"": ""20250311134214"", ""headline"": ""Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming Deadlines - MRK"", ""summary"": ""NEW YORK, March 11, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Merck & Co., Inc. \u00a0. Such investors are advised to contact Danielle\u00a0Peyton at...""}, {""date"": ""20250311135300"", ""headline"": ""Zacks Investment Ideas feature highlights: Molson Coors, Merck & Co. and Deutsche Telekom"", ""summary"": ""Molson Coors, Merck & Co. and Deutsche Telekom are part of the Zacks Investment Ideas article.""}, {""date"": ""20250311164019"", ""headline"": ""Merck prevails in Gardasil safety litigation"", ""summary"": ""A federal judge has ruled in favor of Merck in litigation accusing the drugmaker of concealing the risks of Gardasil, a vaccine to prevent cervical and other fatal cancers. The decision...""}, {""date"": ""20250311174715"", ""headline"": ""Merck (NYSE:MRK) Unveils US$1 Billion Durham Facility For Advanced Vaccine Manufacturing Expansion"", ""summary"": ""Merck (NYSE:MRK) announced the opening of a new $1 billion vaccine manufacturing facility in Durham, North Carolina, a major development aligning with the company's broader $12 billion U.S. investment initiative. This expansion could have played a pivotal role in the 9% rise in the company's share price last month, particularly as it underscores Merck's commitment to innovation and growth. The company's strategic focus on advanced technologies may also position it favorably in a volatile...""}, {""date"": ""20250312054624"", ""headline"": ""Class Action Filed Against Merck & Co., Inc. (MRK) - April 14, 2025 Deadline to Join - Contact Levi & Korsinsky"", ""summary"": ""NEW YORK, March 12, 2025 /PRNewswire/ --\u00a0 Levi & Korsinsky, LLP notifies investors in Merck & Co., Inc. of a class action securities lawsuit. ...""}, {""date"": ""20250312100100"", ""headline"": ""Fidelity Select Health Care Portfolio Q4 2024 Review"", ""summary"": ""Health care stocks returned -9.75% in the final quarter of 2024, according to the MSCI U.S. IMI Health Care 25/50 Index, widely lagging the 2.41% gain of the broad-based S&P 500\u00c2\u00ae index.""}, {""date"": ""20250312130906"", ""headline"": ""Merck Announces Positive Data From Phase 3 Trials Of Doravirine/Islatravir"", ""summary"": ""Merck & Co Inc: * MERCK ANNOUNCES POSITIVE DATA FROM PHASE 3 TRIALS THATSHOW THEINVESTIGATIONAL, ONCE-DAILY, ORAL, TWO-DRUG REGIMEN OFDORAVIRINE/ISLATRAVIR MAINTAINED HIV-1...""}, {""date"": ""20250312132907"", ""headline"": ""Caterpillar: Diversification Without Diworsification; Home Depot Looks Healthy, So Do Others"", ""summary"": ""Diversify Caterpillar holdings with tax-efficient strategies. Explore HD, LOW, and SNA for income replacement potential and strong dividend growth.""}, {""date"": ""20250312141115"", ""headline"": ""Merck & Co., Inc. (MRK): Among Dobermans of the Dow to Buy"", ""summary"": ""We recently published a list of Dobermans of the Dow: 10 Stocks to Consider. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other Dobermans of the Dow to buy. The Dobermans of the Dow strategy serves as an alternative to the well-known Dogs of [\u2026]""}, {""date"": ""20250312152600"", ""headline"": ""Merck Announces Positive Data from Phase 3 Trials that Show the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) Maintained HIV-1 Viral Suppression at Week 48"", ""summary"": ""RAHWAY, N.J., March 12, 2025--Merck Announces Data from Phase 3 Trials that Show Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir Maintained HIV-1 Viral Suppression""}, {""date"": ""20250312163200"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Merck & Co. Inc. stock outperforms competitors despite losses on the day""}, {""date"": ""20250312173037"", ""headline"": ""Merck Plans Regulatory Submission For Two-Drug Regime For HIV Infection By Mid-2025"", ""summary"": ""On Wednesday, Merck & Co Inc (NYSE:MRK) announced the presentation of results from two Phase 3 trials of doravirine/islatravir (DOR/ISL) in adults with HIV-1 infection that is virologically suppressed on bictegravir/emtricitabine/tenofovir alafenamidei (BIC/FTC/TAF) in trial MK-8591A-052) or antiretroviral therapy (bART) in trial MK-8591A-051. In both trials, DOR/ISL met the primary efficacy success criterion for non-inferiority to comparator antiretroviral therapies and primary safety objective""}, {""date"": ""20250312183220"", ""headline"": ""Why Merck & Co., Inc. (MRK) is the Best Pharma Stock to Buy According to Hedge Funds"", ""summary"": ""We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other best pharma stocks to buy according to hedge funds. Why is China the Talk of the Town [\u2026]""}, {""date"": ""20250313013000"", ""headline"": ""Merck and 8 More Healthcare Stocks for Nervous Dividend Investors"", ""summary"": ""Merck and 8 More Healthcare Stocks for Nervous Dividend Investors""}, {""date"": ""20250313053000"", ""headline"": ""They Wanted a Quick Fix for Hair Loss. Instead, These Young Men Got Sick."", ""summary"": ""They Wanted a Quick Fix for Hair Loss. Instead, These Young Men Got Sick.""}, {""date"": ""20250313054626"", ""headline"": ""Merck & Co., Inc. Class Action: The Gross Law Firm Reminds Merck Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 - MRK"", ""summary"": ""NEW YORK, March 13, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Merck & Co., Inc. . ...""}, {""date"": ""20250313110805"", ""headline"": ""Merck & Co., Inc. (NYSE:MRK) Looks Interesting, And It's About To Pay A Dividend"", ""summary"": ""Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Merck & Co...""}, {""date"": ""20250313124947"", ""headline"": ""MSD to push for approval of HIV combo after Phase III success"", ""summary"": ""MSD\u2019s HIV treatment is now back on track after an earlier hit which saw the FDA place a clinical hold on the therapy.""}, {""date"": ""20250313160612"", ""headline"": ""Merck & Co (MRK) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit"", ""summary"": ""LOS ANGELES, March 13, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Merck & Co . ...""}, {""date"": ""20250314030000"", ""headline"": ""Measles Is Back Across the U.S. What to Know About the Deadly Virus."", ""summary"": ""Measles Is Back Across the U.S. What to Know About the Deadly Virus.""}, {""date"": ""20250315110000"", ""headline"": ""Nike, FedEx To Report Results As Investors Await Fed's Latest Economic Projections"", ""summary"": ""Stay ahead with Seeking Alpha's Wall Street Week Ahead! Get key insights on upcoming events, earnings, IPOs, and market trends to make informed decisions.""}, {""date"": ""20250316134003"", ""headline"": ""Kenvue + Johnson & Johnson: I Choose To Own The Whole 'Humpty Dumpty'"", ""summary"": ""Discover why Johnson & Johnson and Kenvue offer resilient defensive stocks with high dividends.""}, {""date"": ""20250316152000"", ""headline"": ""Wall Street Brunch: Is The Force Still Strong With Nvidia?"", ""summary"": ""Bullish AI news from Nvidia\u00e2\u0080\u0099s GTC conference could lure in investors shunning risk. Fed\u00e2\u0080\u0099s Jay Powell will find it tougher to dodge tariff questions. Bill Gross weighs in on tariffs""}, {""date"": ""20250316170632"", ""headline"": ""Merck & Co., Inc. (MRK): Among Top Dividend Contenders List"", ""summary"": ""We recently published a list of Dividend Contenders List: Top 15. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other top dividend contenders. Dividend stocks have remained a popular choice among investors due to the steady income they provide, becoming even more attractive when [\u2026]""}]",{}
19,2025-03-16,93.76000213623047,2025-03-23,93.11000061035156,-0.0069326099730082635,D1,"[{""date"": ""20250316134003"", ""headline"": ""Kenvue + Johnson & Johnson: I Choose To Own The Whole 'Humpty Dumpty'"", ""summary"": ""Discover why Johnson & Johnson and Kenvue offer resilient defensive stocks with high dividends.""}, {""date"": ""20250316152000"", ""headline"": ""Wall Street Brunch: Is The Force Still Strong With Nvidia?"", ""summary"": ""Bullish AI news from Nvidia\u00e2\u0080\u0099s GTC conference could lure in investors shunning risk. Fed\u00e2\u0080\u0099s Jay Powell will find it tougher to dodge tariff questions. Bill Gross weighs in on tariffs""}, {""date"": ""20250316170632"", ""headline"": ""Merck & Co., Inc. (MRK): Among Top Dividend Contenders List"", ""summary"": ""We recently published a list of Dividend Contenders List: Top 15. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other top dividend contenders. Dividend stocks have remained a popular choice among investors due to the steady income they provide, becoming even more attractive when [\u2026]""}, {""date"": ""20250317054655"", ""headline"": ""Class Action Filed Against Merck & Co., Inc. (MRK) - April 14, 2025 Deadline to Join - Contact The Gross Law Firm"", ""summary"": ""NEW YORK, March 17, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of\u00a0Merck & Co., Inc. . ...""}, {""date"": ""20250317134214"", ""headline"": ""Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming Deadlines - MRK"", ""summary"": ""NEW YORK, March 17, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Merck & Co., Inc. \u00a0.\u00a0 Such investors are advised to contact Danielle Peyton at...""}, {""date"": ""20250317163200"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Merck & Co. Inc. stock outperforms competitors on strong trading day""}, {""date"": ""20250317185705"", ""headline"": ""MRK Purchasers Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit"", ""summary"": ""NEW YORK, March 17, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Merck & Co., Inc. ...""}, {""date"": ""20250317193228"", ""headline"": ""Is Merck & Co Inc. (NYSE:MRK) the Most Profitable Value Stock to Buy Now?"", ""summary"": ""We recently published a list of 10 Most Profitable Value Stocks to Buy Now. In this article, we are going to take a look at where Merck & Co Inc. (NYSE:MRK) stands against other profitable value stocks to buy now. Matt Powers, Managing Partner at Powers Advisory Group, joined the discussion on CNBC\u2019s \u2018Power Lunch\u2019 [\u2026]""}, {""date"": ""20250317225823"", ""headline"": ""Why Organon Is A Top Pick For Income Investors"", ""summary"": ""In mid-Feb., Organon pleasantly surprised me with its financial results for Q4 2024. Read why I believe OGN is an attractive stock for income-oriented investors.""}, {""date"": ""20250318054623"", ""headline"": ""Levi & Korsinsky Reminds Merck Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 - MRK"", ""summary"": ""NEW YORK, March 18, 2025 /PRNewswire/ --\u00a0Levi & Korsinsky, LLP notifies investors in Merck & Co., Inc. of a class action securities lawsuit. ...""}, {""date"": ""20250318124656"", ""headline"": ""Is Merck & Co Inc. (NYSE:MRK) the Most Undervalued S&P 500 Stock to Buy Now?"", ""summary"": ""We recently published a list of 10 Most Undervalued S&P 500 Stocks to Buy Now. In this article, we are going to take a look at where Merck & Co Inc. (NYSE:MRK) stands against other undervalued S&P 500 stocks to buy now. Earlier on March 13, Michael Cuggino, President and Portfolio Manager of the Permanent [\u2026]""}, {""date"": ""20250318130628"", ""headline"": ""Big pharma fears best-selling drugs in crosshairs of US-EU tariff spat"", ""summary"": ""Drugmakers are urging theTrump administration and European Union officials to excludemedical goods from expanding tariff wars, hoping to avert pricespikes on top-selling medicines made in Europe...""}, {""date"": ""20250318191853"", ""headline"": ""Merck & Co., Inc. (MRK): A Bull Case Theory"", ""summary"": ""We came across a bullish thesis on Merck & Co., Inc. (MRK) on Substack by Jimmy Investor. In this article, we will summarize the bulls\u2019 thesis on MRK. Merck & Co., Inc. (MRK)\u2019s share was trading at $94.79 as of March 17th. MRK\u2019s trailing and forward P/E were 14.06 and 10.53 respectively according to Yahoo Finance. Merck [\u2026]""}, {""date"": ""20250319071425"", ""headline"": ""Health Canada Approves KEYTRUDA For The Treatment Of Adult Patients With Primary Advanced Or Recurrent Endometrial Carcinoma, In Combination With Carboplatin And Paclitaxel And Then Continued As Monotherapy"", ""summary"": ""Merck & Co Inc: * HEALTH CANADA APPROVES KEYTRUDA\u00ae FOR THE TREATMENT OFADULTPATIENTS WITH PRIMARY ADVANCED OR RECURRENT ENDOMETRIALCARCINOMA, IN COMBINATION WITH CARBOPLATIN AND...""}, {""date"": ""20250319104500"", ""headline"": ""Merck Data at ACC.25 Highlight Innovative Advancements and Commitment to Improving Outcomes for People Living with Cardiovascular Disease"", ""summary"": ""RAHWAY, N.J., March 19, 2025--Merck Data at ACC.25 Highlight Innovative Advancements and Commitment to Improving Outcomes for People Living with Cardiovascular Disease""}, {""date"": ""20250319110000"", ""headline"": ""Health Canada Approves KEYTRUDA\u00ae for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy"", ""summary"": ""Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Health Canada approved KEYTRUDA\u00ae (pembrolizumab), Merck's anti-PD-1 therapy, in combination with carboplatin and paclitaxel, followed by KEYTRUDA\u00ae as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. The approval is based on data from the Phase 3 KEYNOTE-868 trial, also known as NRG-GY018, which demonstrated statistically significant improvemen""}, {""date"": ""20250319121132"", ""headline"": ""Actinium Pharmaceuticals launches clinical trial for Actimab-A in combination"", ""summary"": ""Actinium Pharmaceuticals (ATNM) announced a clinical program comprising of trials studying Actimab-A in combination with either Keytruda \u2013 pembrolizumab -or Opdivo \u2013 nivolumab \u2013 which are blockbuster immunotherapies known as PD-1 inhibitors which are approved in multiple solid tumor indications. Keytruda, developed and commercialized by Merck (MRK) and Opdivo developed and commercialized by Bristol Myers Squibb (BMY), collectively generated $38.8B in sales in 2024 across several solid tumor canc""}, {""date"": ""20250319140957"", ""headline"": ""FDA Approves Pembrolizumab For Her2 Positive Gastric Or Gastroesophageal Junction Adenocarcinoma Expressing Pd-L1"", ""summary"": ""FDA: * FDA: APPROVES PEMBROLIZUMAB FOR HER2 POSITIVE GASTRIC ORGASTROESOPHAGEAL JUNCTION ADENOCARCINOMA EXPRESSING PD-L1Further company coverage: ...""}, {""date"": ""20250319141100"", ""headline"": ""Merck Loses Almost $52B in 6 Months: How to Play MRK Stock"", ""summary"": ""We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider selling the same.""}, {""date"": ""20250319144500"", ""headline"": ""Managing Risk Through Market Badness With Rob Isbitts"", ""summary"": ""Rob Isbitts explains how investors should manage risk in the midst of volatile markets.""}, {""date"": ""20250319144539"", ""headline"": ""Why Merck & Co. (MRK) Is Among the Most Undervalued Biotech Stocks to Invest In"", ""summary"": ""We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other most undervalued biotech stocks to invest in. Trump\u2019s Tariffs and the Pharma Sector On February 21, Jared Holz, Mizuho [\u2026]""}, {""date"": ""20250319185303"", ""headline"": ""ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK"", ""summary"": ""WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Merck & Co., Inc. between February 3, 2022 and February 3, 2025, both dates inclusive , of the important...""}, {""date"": ""20250320050516"", ""headline"": ""Shareholders of Merck & Co., Inc. Should Contact The Gross Law Firm Before April 14, 2025 to Discuss Your Rights - MRK"", ""summary"": ""NEW YORK, March 20, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of\u00a0Merck & Co., Inc. . ...""}, {""date"": ""20250320152627"", ""headline"": ""Merck & Co., Inc. (MRK): Among Incredibly Cheap Dividend Stock to Buy Now"", ""summary"": ""We recently published a list of 12 Incredibly Cheap Dividend Stocks to Buy Now. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other incredibly cheap dividend stocks to buy now. Value investing has long been a preferred strategy among investors, largely influenced by Warren [\u2026]""}, {""date"": ""20250320173201"", ""headline"": ""Merck (NYSE:MRK) Unveils New Data On Cardiovascular Advances At ACC.25 Annual Conference"", ""summary"": ""Merck (NYSE:MRK) experienced a 13% increase in its stock price over the last month, aided by several significant developments. The company's upcoming presentations at the American College of Cardiology's Annual Scientific Session, particularly the announcement of Phase 3 results for WINREVAIR\u2122 targeting pulmonary arterial hypertension, highlight ongoing advancements in cardiovascular research. Additionally, positive Phase 3 trial results for the HIV-1 treatment DOR/ISL further underscore...""}, {""date"": ""20250321054626"", ""headline"": ""Levi & Korsinsky Notifies Merck & Co., Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - MRK"", ""summary"": ""NEW YORK, March 21, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Merck & Co., Inc. of a class action securities lawsuit. ...""}, {""date"": ""20250321072147"", ""headline"": ""Merck Vs. Bristol-Myers Squibb: Which Pharma Stock Should You Buy"", ""summary"": ""Merck and Bristol-Myers Squibb are key players in cancer treatment. Find out why MRK and BMY stocks have different prospects for long-term investment.""}, {""date"": ""20250321120109"", ""headline"": ""Merck & Co (MRK) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit"", ""summary"": ""BENSALEM, Pa., March 21, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit...""}, {""date"": ""20250321121800"", ""headline"": ""Nike, Coca-Cola share losses contribute to Dow's nearly 125-point fall"", ""summary"": ""Nike, Coca-Cola share losses contribute to Dow's nearly 125-point fall""}, {""date"": ""20250321122000"", ""headline"": ""The Davenport Value & Income Fund Q4 2024 Commentary"", ""summary"": ""The Davenport Value & Income Fund (DVIPX) generated a -4.18% total return in the fourth quarter of 2024. Click here to read the full commentary. ""}, {""date"": ""20250321133052"", ""headline"": ""3 of Goldman Sachs' best investing tips for currently volatile markets"", ""summary"": ""Volatile times in markets require precision, Goldman Sachs reminds investors.""}, {""date"": ""20250321154142"", ""headline"": ""MDPL: No Reason To Pay Those Hefty Fees For Now"", ""summary"": ""Monarch Dividend Plus ETF holds a 30-stock portfolio focused on dividend growth. Click to see whether the MDPL ETF is worth the high fees that it charges.""}, {""date"": ""20250322014000"", ""headline"": ""The Davenport Balanced Income Fund Q4 2024 Commentary"", ""summary"": ""The Davenport Balanced Income Fund (DBALX) generated a -2.93% total return in the fourth quarter of 2024. Click here to read the full commentary. ""}, {""date"": ""20250322075405"", ""headline"": ""DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co."", ""summary"": ""Faruqi & Faruqi, LLP Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Merck To Contact Him Directly To Discuss Their OptionsIf you suffered...""}, {""date"": ""20250322203525"", ""headline"": ""Merck & Co. (MRK): Among Stocks Insiders Were Piling Into Recently"", ""summary"": ""We recently published a list of Should You Buy the Dip and Follow Insiders into These 10 Stocks?. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other stocks insiders were piling into recently. After a turbulent week, stocks began recovering on Monday, with all [\u2026]""}]",{}
20,2025-03-23,93.11000061035156,2025-03-30,89.2300033569336,-0.041671111888990864,D5,"[{""date"": ""20250324054625"", ""headline"": ""MRK LAWSUIT ALERT: The Gross Law Firm Notifies Merck & Co., Inc. Investors of a Class Action Lawsuit and Upcoming Deadline"", ""summary"": ""NEW YORK, March 24, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of\u00a0Merck & Co., Inc. . ...""}, {""date"": ""20250324085700"", ""headline"": ""Chipotle and 4 More Stocks to Consider for a Volatile Market"", ""summary"": ""Chipotle and 4 More Stocks to Consider for a Volatile Market""}, {""date"": ""20250324130202"", ""headline"": ""1 Value Stock with Solid Fundamentals and 2 to Turn Down"", ""summary"": ""Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.""}, {""date"": ""20250324131026"", ""headline"": ""Is Merck & Co. (MRK) The Best Healthcare Dividend Stock to Invest in?"", ""summary"": ""We recently published a list of 13 Best Healthcare Dividend Stocks to Invest in. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other best healthcare dividend stocks to invest in. The US healthcare sector has been at the forefront since the emergence of COVID-19 [\u2026]""}, {""date"": ""20250325064916"", ""headline"": ""Merck Enters Exclusive License Agreement For HRS-5346 From Jiangsu Hengrui Pharmaceuticals"", ""summary"": ""Merck & Co Inc: * MERCK & CO- SEES TO RECORD PRE-TAX CHARGE OF $200 MILLION,ORABOUT $0.06 PER SHARE, TO BE INCLUDED IN GAAP AND NON-GAAPRESULTS IN QUARTER DEAL CLOSES *...""}, {""date"": ""20250325065508"", ""headline"": ""Hengrui Pharmaceuticals Signs Authorisation Agreement With Merck"", ""summary"": ""Jiangsu Hengrui Pharmaceuticals CoLtd: * SAYS IT SIGNS AUTHORISATION AGREEMENT WITH MERCK SHARP &DOHMEFOR HRS-5346 Source textFurther company coverage: ...""}, {""date"": ""20250325070643"", ""headline"": ""Merck signs deal with Jiangsu Hengrui worth up to $2 billion for access to heart drug"", ""summary"": ""Merck has signed alicensing deal with Jiangsu Hengrui Pharmaceuticalsworth up to $2 billion for its experimental heart disease drug,the companies said on Tuesday. Under the terms of...""}, {""date"": ""20250325070800"", ""headline"": ""Mural Oncology to Discontinue Ovarian Cancer Drug Candidate as Trial Misses Targets"", ""summary"": ""Mural Oncology to Discontinue Ovarian Cancer Drug Candidate as Trial Misses Targets""}, {""date"": ""20250325072610"", ""headline"": ""Merck, Hengrui Pharma in Lipoprotein(a) Licensing Deal"", ""summary"": ""By Colin Kellaher Merck & Co. has agreed to license an investigational oral small molecule lipoprotein inhibitor from Jiangsu Hengrui Pharmaceuticals in a deal potentially worth more than $2...""}, {""date"": ""20250325094305"", ""headline"": ""MRK Investors Have Final Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit with the Schall Law Firm"", ""summary"": ""LOS ANGELES, March 25, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against\u00a0Merck & Co., Inc. \u00a0for violations...""}, {""date"": ""20250325100136"", ""headline"": ""Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming Deadlines - MRK"", ""summary"": ""NEW YORK, March 25, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Merck & Co., Inc. . Such investors are advised to contact Danielle\u00a0Peyton at...""}, {""date"": ""20250325104500"", ""headline"": ""Merck Enters Exclusive License Agreement for HRS-5346, an Investigational Oral Lipoprotein(a) Inhibitor, for Cardiovascular Disease from Jiangsu Hengrui Pharmaceuticals Co., Ltd."", ""summary"": ""RAHWAY, N.J., March 25, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Jiangsu Hengrui Pharmaceuticals Co., Ltd. (\""Hengrui Pharma\""), a global pharmaceutical company focused on scientific and technological innovation, today announced that the companies have entered into an exclusive license agreement for HRS-5346, an investigational oral small molecule Lipoprotein(a), or Lp(a), inhibitor currently being evaluated in a Phase 2 clinical trial in China.""}, {""date"": ""20250325115900"", ""headline"": ""Merck bets $200M on a new type of heart pill"", ""summary"": ""A licensing deal with Jiangsu\u00a0Hengrui Pharmaceuticals puts Merck in a competitive race to develop a medicine that targets a genetic risk factor called lipoprotein(a).""}, {""date"": ""20250325120011"", ""headline"": ""Is Weakness In Merck & Co., Inc. (NYSE:MRK) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?"", ""summary"": ""It is hard to get excited after looking at Merck's (NYSE:MRK) recent performance, when its stock has declined 7.2% over...""}, {""date"": ""20250325120317"", ""headline"": ""Trump tariffs drive pharma manufacturing to US but risk inflation and disruption"", ""summary"": ""Pressure may grow on companies to repatriate production, raising production costs and potentially medicine prices too.""}, {""date"": ""20250325134214"", ""headline"": ""Merck Will Pay Up to $2 Billion for Chinese Heart Drug"", ""summary"": ""(Bloomberg) -- Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co.\u2019s experimental heart drug, the US drugmaker\u2019s second recent foray into China for a novel medicine.Most Read from BloombergThey Built a Secret Apartment in a Mall. Now the Mall Is Dying.Why Did the Government Declare War on My Adorable Tiny Truck?Trump Slashed International Aid. Geneva Is Feeling the Impact.Chicago Transit Faces \u2018Doomsday Scenario,\u2019 Regional Agency SaysParis Votes to Ma""}, {""date"": ""20250325141456"", ""headline"": ""S&P 500 struggles to extend its relief rally. Here are the stocks capping market upside."", ""summary"": ""S&P 500 struggles to extend its relief rally. Here are the stocks capping market upside.""}, {""date"": ""20250325160528"", ""headline"": ""Deals of the day-Mergers and acquisitions"", ""summary"": ""The following bids, mergers,acquisitions and disposals were reported by 2000 GMT on Tuesday: ** AT&T is in talks to acquire Lumen Technologies'consumer fiber operations,...""}, {""date"": ""20250325163000"", ""headline"": ""Merck & Co. Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Merck & Co. Inc. stock underperforms Tuesday when compared to competitors""}, {""date"": ""20250325190053"", ""headline"": ""Merck Bets $2B on China's Hengrui for Next Big Heart Drug"", ""summary"": ""Big Pharma taps Chinese innovation again--this time for a potential blockbuster heart treatment targeting 1.4B people.""}, {""date"": ""20250325214851"", ""headline"": ""Is Merck & Co. Inc. (MRK) The Best Defensive Stock Amid Market Volatility?"", ""summary"": ""We recently published a list of 15 Best Defensive Stocks Amid Market Volatility In this article, we are going to take a look at where Merck & Co. Inc. (NYSE:MRK) stands against other best defensive stocks amid market volatility. With ongoing inflation, economic uncertainty, and global tensions, more investors are looking for ways to protect [\u2026]""}, {""date"": ""20250326071015"", ""headline"": ""Merck Gets European Commission Approval of Capvaxive Vaccine"", ""summary"": ""By Colin Kellaher Merck & Co. has won approval from the European Commission of its Capvaxive pneumococcal disease vaccine for adults. The Rahway, N.J., drugmaker on Wednesday said the...""}, {""date"": ""20250326075122"", ""headline"": ""European Commission (EC) Approves Merck's CAPVAXIVE\u00ae (Pneumococcal 21-valent Conjugate Vaccine)"", ""summary"": ""Merck & Co Inc: * EUROPEAN COMMISSION APPROVES MERCK\u2019S CAPVAXIVE\u00ae FOR PREVENTION OFINVASIVE PNEUMOCOCCAL DISEASE AND PNEUMOCOCCAL PNEUMONIA INADULTSSource text:Further company...""}, {""date"": ""20250326091950"", ""headline"": ""Why Merck & Co. Inc. (MRK) Performed Worst On Tuesday?"", ""summary"": ""We recently published a list of Pulse of The Market: Tuesday\u2019s 10 Worst Performers. In this article, we are going to take a look at where Merck & Co. Inc. (NYSE:MRK) stands against other Tuesday\u2019s worst performers. Wall Street finished Tuesday\u2019s trading in a lackluster fashion, with all major indices ending in the green territory, [\u2026]""}, {""date"": ""20250326092805"", ""headline"": ""Merck & Co.: Looming Patent Expiries For Key Drugs Weakens Longer-Term Outlook"", ""summary"": "">40% of Merck's revenues are driven by cancer med Keytruda, which faces patent expiry by 2028. See why I rate MRK stock a hold.""}, {""date"": ""20250326095629"", ""headline"": ""Merck: pneumococcal vaccine approved in EU"", ""summary"": ""On Wednesday Merck announced that the European Commission has approved its pneumococcal vaccine Capvaxive for the prevention of invasive pneumococcal disease in adults.The authorisation granted by...""}, {""date"": ""20250326104500"", ""headline"": ""European Commission (EC) Approves Merck\u2019s CAPVAXIVE\u00ae (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults"", ""summary"": ""RAHWAY, N.J., March 26, 2025--European Commission (EC) Approves Merck\u2019s CAPVAXIVE\u00ae for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults""}, {""date"": ""20250326110000"", ""headline"": ""Forget S&P 500 And Buy These Dividend Icons Instead"", ""summary"": """"}, {""date"": ""20250326111800"", ""headline"": ""Chevron, McDonald's share gains contribute to Dow's 118-point jump"", ""summary"": ""Chevron, McDonald's share gains contribute to Dow's 118-point jump""}, {""date"": ""20250326123118"", ""headline"": ""5 Reasons To Buy Regenxbio Right Now"", ""summary"": ""Regenxbio Inc. is ranked a Strong Buy due to low EV, strong partnerships, royalty income, bullish trends, and major buyout potential. Click for more on RGNX stock.""}, {""date"": ""20250326173210"", ""headline"": ""Merck (NYSE:MRK) Gains EC Approval For CAPVAXIVE\u00ae Amid Recent 7% Share Price Dip"", ""summary"": ""Merck (NYSE:MRK) has recently achieved a significant milestone with the European Commission's approval of its pneumococcal vaccine CAPVAXIVE\u00ae, boosting its portfolio in the vaccines market. Despite this positive development, the company's share price encountered a 1.82% decline over the last month, a period marked by substantial turmoil across global markets. Influenced by concerns related to potential U.S. tariffs and the broader selloff in the technology sector, many investors were...""}, {""date"": ""20250326174513"", ""headline"": ""Jim Cramer on Merck (MRK): \u201cI Like It at This Level \u2013 But I Like Bristol-Myers Even More!\u201d"", ""summary"": ""We recently published a list of Jim Cramer Recently Put These 10 Stocks Under Spotlight. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other stocks that Jim Cramer discussed recently. On Monday, Jim Cramer, host of Mad Money, shared his thoughts on how the [\u2026]""}, {""date"": ""20250326220946"", ""headline"": ""Is Merck & Co., Inc. (MRK) the Best Consistent Dividend Stock to Buy?"", ""summary"": ""We recently published a list of 12 Best Consistent Dividend Stocks to Buy. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other best consistent dividend stocks to buy. Over the past two years, persistently high inflation has led to increased borrowing costs, creating a [\u2026]""}, {""date"": ""20250327014113"", ""headline"": ""Here is Why Jim Cramer Is Bullish About Merck (MRK)"", ""summary"": ""We recently published a list of Jim Cramer Focused On These 9 Stocks Recently. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other stocks that Jim Cramer discussed recently. Jim Cramer, host of Mad Money, expressed his frustration on March 19 about how investors [\u2026]""}, {""date"": ""20250327054624"", ""headline"": ""Class Action Filed Against Merck & Co., Inc. (MRK) - April 14, 2025 Deadline to Join - Contact The Gross Law Firm"", ""summary"": ""NEW YORK, March 27, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of\u00a0Merck & Co., Inc. . ...""}, {""date"": ""20250327110000"", ""headline"": ""Merck plans to\u00a0 launch US subcutaneous version of Keytruda on October 1"", ""summary"": ""Merck & Co saidon Thursday that it plans to launch a subcutaneously injectedversion of its blockbuster cancer immunotherapy Keytruda in theU.S. on October 1, and expects to hit peak adoption rates...""}, {""date"": ""20250327110003"", ""headline"": ""Merck Says FDA PDUFA Date For Subcutaneous Pembrolizumab Set For Sept 23"", ""summary"": ""Merck & Co Inc: * MERCK: INVESTIGATIONAL SUBCUTANEOUS PEMBROLIZUMAB WITHBERAHYALURONIDASE ALFA SHOWS NONINFERIOR PHARMACOKINETICS VERSUSIV KEYTRUDA IN 3475A-D77 TRIAL *...""}, {""date"": ""20250327120034"", ""headline"": ""China Expansion Helps Fuel This AI-Powered Cloud Stock In Rough Market"", ""summary"": ""Boosted by partnerships with Big Pharma and a push into China, Veeva continues to battle to break out in troubled market.""}, {""date"": ""20250327120109"", ""headline"": ""Merck & Co (MRK) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit"", ""summary"": ""LOS ANGELES, March 27, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Merck & Co . ...""}, {""date"": ""20250327150009"", ""headline"": ""Positive phase III data gives Merck potential boost for blockbuster Keytruda in injection form"", ""summary"": ""Merck has filed for approval for a new drug that could buoy the bottom line from headwinds in recent months.""}, {""date"": ""20250327150100"", ""headline"": ""Merck\u2019s Investigational Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Demonstrates Noninferior Pharmacokinetics Compared to Intravenous (IV) KEYTRUDA\u00ae (pembrolizumab) in Pivotal 3475A-D77 Trial"", ""summary"": ""RAHWAY, N.J., March 27, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first data presentation from the pivotal 3475A-D77 Phase 3 trial, evaluating the subcutaneous administration of pembrolizumab, together with berahyaluronidase alfa (MK-3475A; from now on referred to as \""subcutaneous pembrolizumab\""). Berahyaluronidase alfa is a variant of human hyaluronidase developed and manufactured by Alteogen Inc. These results are being presented today a""}, {""date"": ""20250327163844"", ""headline"": ""Merck's Biggest Moneymaker Could Get Even Bigger. But Will It Help Downtrodden Shares?"", ""summary"": ""The FDA is due to make an approval decision on injectable Keytruda by mid-September. The move could bolster downtrodden Merck stock.""}, {""date"": ""20250327201400"", ""headline"": ""Merck releases positive data for blockbuster cancer drug"", ""summary"": ""Merck & Co. (MRK) releases positive phase three data for its injectable-form cancer drug Keytruda. Yahoo Finance Senior Health Reporter Anjalee Khemlani joins Market Domination to break down the company's new data. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.""}, {""date"": ""20250327204750"", ""headline"": ""Tracking Cliff Asness' AQR Capital Management 13F Portfolio - Q4 2024 Update"", ""summary"": ""AQR Capital Management's portfolio grew to $77.63B with top stakes in Apple, Nvidia, Microsoft, Amazon and Alphabet. Read here for a portfolio update.""}, {""date"": ""20250327213637"", ""headline"": ""Is Merck & Co. (MRK) the Low Volatility Stock to Buy According to Billionaire Ken Fisher?"", ""summary"": ""We recently published a list of 10 Low Volatility Stocks to Buy According to Billionaire Ken Fisher. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other low volatility stocks to buy according to billionaire Ken Fisher. Billionaire Ken Fisher, a prominent money manager, renowned [\u2026]""}, {""date"": ""20250328023200"", ""headline"": ""Germany's Merck Teams Up With Abbisko for Global Sale Rights of Bone-Tumor Drug"", ""summary"": ""Germany's Merck Teams Up With Abbisko for Global Sale Rights of Bone-Tumor Drug""}, {""date"": ""20250328054622"", ""headline"": ""Lost Money on Merck & Co., Inc.(MRK)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky"", ""summary"": ""NEW YORK, March 28, 2025 /PRNewswire/ -- Levi &\u00a0Korsinsky, LLP notifies investors in Merck & Co., Inc. of a class action securities lawsuit. ...""}, {""date"": ""20250328094008"", ""headline"": ""Merck's Investigational Subcutaneous Pembrolizumab with Berahyaluronidase Alfa Demonstrates Noninferior Pharmacokinetics Compared to Intravenous KEYTRUDA in Pivotal 3475A-D77 Trial"", ""summary"": ""RAHWAY - Merck , known as MSD outside of the United States and Canada, today announced the first data presentation from the pivotal 3475A-D77 Phase 3 trial, evaluating the subcutaneous administration...""}, {""date"": ""20250328094442"", ""headline"": ""AbbVie Vs. Sanofi: Which Is The Better Investment Right Now"", ""summary"": """"}, {""date"": ""20250328152000"", ""headline"": ""FDA Accepts Merck's Filing for Subcutaneous Version of Keytruda"", ""summary"": ""The filing is based on late-stage data, which shows that treatment with the subcutaneous version of MRK's Keytruda is at least as effective as the IV version.""}, {""date"": ""20250328163300"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Merck & Co. Inc. stock outperforms competitors on strong trading day""}, {""date"": ""20250328174005"", ""headline"": ""MRK Purchasers Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit"", ""summary"": ""NEW YORK, March 28, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Merck & Co., Inc. ...""}, {""date"": ""20250329015542"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of March 30"", ""summary"": ""Stay updated on dividend trends with a weekly summary of Dividend Champions, Contenders, and Challengers.""}, {""date"": ""20250329023140"", ""headline"": ""Why Merck & Co. Inc. (MRK) Went Up On Friday?"", ""summary"": ""We recently published a list of 10 Firms End Friday Strong; 3 Reach All-Time Highs. In this article, we are going to take a look at where Merck & Co. Inc. (NYSE:MRK) stands against other firms that end Friday strong. Wall Street\u2019s main indices finished the trading week in the negative territory as investor sentiment [\u2026]""}, {""date"": ""20250330060000"", ""headline"": ""Eli Lilly Vs. Novo Nordisk: Which Is The Better Bargain For Investors"", ""summary"": ""Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain for investors.""}, {""date"": ""20250330100500"", ""headline"": ""Putnam Large Cap Growth Fund Q4 2024 Commentary"", ""summary"": ""US equities had another positive quarter, with the S&P 500 Index returning 2.41% and our primary benchmark, the Russell 1000 Growth Index, returning 7.07%.""}]",{}
